



■

# Reference Section A

Incidence of  
reported ESRD

table a.1 · 233

incident counts of reported ESRD: all patients

*by demographic characteristics & primary diagnosis*

table a.2 · 234

incident counts of reported esrd patients: U.S. only, with unknowns dropped

*by demographic characteristics & primary diagnosis, after dropping non-u.s. patients & patients of unknown age, gender, race, & ethnicity*

table a.3 · 235

incident rates of reported esrd, unadjusted

*per million population, by demographic characteristics & primary diagnosis*

table a.4 · 236

incident rates of reported esrd, adjusted

*per million population, by demographic characteristics & primary diagnosis*

table a.5 · 237

incident counts of reported esrd patients, by time period

*by age, gender, & race*

table a.6 · 238

incident rates of reported esrd, by time period

*per million population, by age, gender, & race*

table a.7 · 239

incident counts of reported esrd, by primary diagnosis

*1998-2001 combined, by age, gender, & race*

table a.8 · 243

incident rates of reported esrd, by primary diagnosis

*per ten million population, 1998-2001 combined, by age, gender, & race*

table a.9 · 246

mean age at start of esrd therapy

*by demographic characteristics & primary diagnosis*

table a.10 · 247

incidence of reported esrd: all patients, row percent

*1997-2001 combined, by detailed primary diagnosis*

table a.11 · 248

incidence of reported esrd: all patients, column percent

*1997-2001 combined, by detailed primary diagnosis*

table a.12 · 249

incidence of reported esrd: hispanics, row percent

*1997-2001 combined, by detailed primary diagnosis*

table a.13 · 250

incidence of reported esrd: hispanics, column percent

*1997-2001 combined, by detailed primary diagnosis*

table a.14 · 251

incidence of reported esrd: non-hispanics, row percent

*1997-2001 combined, by detailed primary diagnosis*

table a.15 · 252

incidence of reported esrd: non-hispanics, column percent

*1997-2001 combined, by detailed primary diagnosis*

table a.16 · 253

incident counts of reported esrd patients, by diabetic status & state/territory: all patients

table a.17 · 256

incident counts of reported esrd patients, by diabetic status & state: u.s. only, with unknowns dropped

table a.18 · 259

incident rates of reported esrd, by diabetic status & state, adjusted

*per million population*

table a.19 · 262

incident counts of reported esrd patients, by diabetic status & esrd network: all patients

table a.20 · 263

incident counts of reported esrd patients, by diabetic status & esrd network: u.s. only, with unknowns dropped

table a.21 · 264

incident rates of reported esrd, by diabetic status & esrd network, adjusted

*per million population*

Table A.1

**Incident Counts of Reported ESRD: All Patients**

by demographic characteristics &amp; primary diagnosis

	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	
0-4	28	32	40	64	98	100	105	121	119	127	140	148	139	162	150	170	151	172	190	192	177	189	213	245	
5-9	77	86	89	97	102	93	103	100	118	100	103	138	158	144	126	146	170	158	154	138	141	176	167	154	
10-14	203	182	172	185	211	207	221	202	196	213	231	231	245	247	244	251	273	292	282	286	281	317	331	326	
15-19	405	430	412	467	452	436	422	410	438	478	508	552	528	483	502	528	567	584	603	547	551	630	604	624	
20-24	623	620	615	689	740	686	763	779	752	828	906	874	915	943	1,030	999	1,101	1,085	1,049	970	1,036	994	1,001	1,064	
25-29	826	847	853	964	1,140	1,124	1,169	1,222	1,313	1,271	1,418	1,595	1,573	1,617	1,611	1,691	1,905	1,698	1,714	1,719	1,760	1,732	1,773	1,706	
30-34	844	964	1,103	1,291	1,385	1,411	1,486	1,498	1,712	1,633	1,889	2,083	2,122	2,207	2,275	2,364	2,754	2,602	2,511	2,455	2,506	2,529	2,542	2,424	
35-39	939	931	1,036	1,173	1,330	1,395	1,496	1,697	1,809	1,970	2,242	2,329	2,474	2,655	2,913	2,885	3,620	3,408	3,407	3,409	3,407	3,541	3,397	3,417	
40-44	996	1,062	1,069	1,280	1,331	1,484	1,521	1,675	1,816	2,088	2,293	2,578	2,917	3,272	3,460	3,454	4,093	4,228	4,366	4,294	4,667	4,681	4,806	4,749	
45-49	1,149	1,289	1,269	1,410	1,496	1,689	1,738	1,898	2,018	2,211	2,485	2,868	2,961	3,411	3,733	4,025	4,985	5,081	5,400	5,457	5,904	6,191	6,349	6,401	
50-54	1,498	1,613	1,676	1,893	2,093	2,108	2,125	2,308	2,432	2,624	3,056	3,261	3,464	3,717	4,273	4,489	5,733	5,660	5,856	6,417	7,029	7,708	7,955	8,517	
55-59	1,688	1,849	1,950	2,371	2,521	2,658	2,847	3,022	3,130	3,356	3,754	4,079	4,410	4,790	5,219	5,352	6,678	6,682	6,911	7,424	8,079	8,699	9,004	9,292	
60-64	1,608	1,859	2,069	2,372	2,716	3,180	3,458	3,829	3,991	4,440	4,872	5,336	5,764	6,409	6,738	6,938	8,139	8,322	8,556	8,974	9,516	9,787	10,100	10,420	
65-69	1,637	1,905	2,147	2,177	2,534	3,350	3,457	3,906	4,421	5,043	5,559	6,463	7,177	7,982	8,597	8,895	9,852	9,643	10,390	10,829	11,078	11,225	11,415	11,545	
70-74	1,152	1,401	1,565	1,672	2,103	2,895	2,907	3,447	3,795	4,303	4,712	5,472	6,159	7,260	8,093	8,533	9,664	9,678	10,753	11,248	11,648	12,005	12,276	12,367	
75-79	569	791	906	958	1,206	1,824	1,980	2,274	2,736	3,046	3,485	4,221	4,587	5,367	5,997	6,293	7,243	7,404	8,481	9,339	10,133	11,170	11,407	11,408	
80-84	173	278	331	349	455	761	811	1,013	1,209	1,437	1,673	2,065	2,386	2,754	3,228	3,427	4,051	4,290	4,959	5,725	6,125	6,785	7,349	7,477	
85+	57	86	101	103	181	261	284	368	442	499	607	813	961	1,113	1,277	1,481	1,659	1,833	2,248	2,598	3,110	3,587	3,870	4,146	
Unknown	*	*	*	*	14	17	*	17	12	12	*	*	*	*	*	*	23	*	*	*	*	*	*	43	13
0-19	713	730	713	813	863	836	851	833	871	918	982	1,069	1,070	1,036	1,022	1,095	1,161	1,206	1,229	1,163	1,150	1,312	1,315	1,349	
20-44	4,228	4,424	4,676	5,397	5,926	6,100	6,435	6,871	7,402	7,790	8,748	9,459	10,001	10,694	11,289	11,393	13,473	13,021	13,047	12,847	13,376	13,477	13,519	13,360	
45-64	5,943	6,610	6,964	8,046	8,826	9,635	10,168	11,057	11,571	12,631	14,167	15,544	16,599	18,327	19,963	20,804	25,535	25,745	26,723	28,272	30,528	32,385	33,408	34,630	
65-74	2,789	3,306	3,712	3,849	4,637	6,245	6,364	7,353	8,216	9,346	10,271	11,935	13,336	15,242	16,690	17,428	19,516	19,321	21,143	22,077	22,726	23,230	23,691	23,912	
75+	799	1,155	1,338	1,410	1,842	2,846	3,075	3,655	4,387	4,982	5,765	7,099	7,934	9,234	10,502	11,201	12,953	13,527	15,688	17,662	19,368	21,542	22,626	23,031	
Unknown	*	*	*	*	14	17	*	17	12	12	*	*	*	*	*	*	23	*	*	*	*	*	*	43	13
Male	8,051	9,010	9,733	10,821	12,205	14,117	14,861	16,213	17,777	19,349	21,600	24,446	26,469	29,263	31,534	33,048	38,178	38,400	41,579	43,653	46,377	49,135	50,584	51,828	
Female	6,423	7,215	7,671	8,698	9,901	11,556	12,036	13,571	14,682	16,326	18,336	20,659	22,475	25,271	27,935	28,873	34,459	34,420	36,252	38,371	40,773	42,812	43,980	44,453	
Unknown	.	*	.	.	*	*	*	*	.	*	*	*	*	*	*	*	24	*	*	*	*	.	.	38	14
White	9,117	10,055	10,766	12,427	14,931	16,917	17,760	19,687	21,456	23,327	25,943	29,473	32,037	35,549	38,381	39,155	44,679	44,727	47,685	52,016	54,857	58,842	60,826	61,989	
Black	4,764	5,513	5,885	6,276	6,391	7,684	7,847	8,652	9,319	10,406	11,805	13,740	14,641	16,395	17,947	19,132	22,185	22,744	24,159	24,475	26,099	26,847	26,990	27,665	
Native American	127	132	175	209	224	295	290	308	374	435	540	629	695	770	923	879	1,058	1,236	1,394	1,036	1,481	1,236	1,277	1,220	
Asian	101	127	157	226	373	535	770	879	1,012	1,186	1,223	1,017	1,271	1,421	1,638	1,878	2,389	2,547	2,784	2,717	3,134	3,383	3,329	3,448	
Other/unknown	365	399	421	381	189	248	232	260	298	325	426	252	303	406	583	886	2,350	1,573	1,811	1,784	1,583	1,639	2,180	1,973	
†Hispanic																			9,110	9,193	10,163	10,733	11,589	11,850	
†Non-Hispanic																			68,723	72,835	76,991	81,214	83,013	84,445	
Diabetes	1,428	1,658	2,272	3,670	5,079	5,981	7,166	8,310	9,563	10,701	12,048	14,671	16,518	19,242	21,421	21,412	26,052	29,233	33,110	35,567	38,034	40,060	41,924	42,813	
Hypertension	1,875	2,089	2,600	4,069	5,545	6,047	6,783	7,805	8,462	9,652	10,911	12,939	14,038	15,856	17,732	17,000	20,384	18,495	19,995	21,508	22,758	24,119	24,660	25,419	
Glomerulonephritis	1,936	2,070	2,165	3,118	3,924	4,123	4,376	4,580	4,697	4,999	5,295	5,706	6,033	6,324	6,616	6,520	7,457	7,777	8,298	8,253	8,431	8,397	8,152	7,986	
Cystic kidney	544	595	632	859	1,024	1,070	1,105	1,161	1,253	1,275	1,285	1,282	1,457	1,537	1,633	1,576	1,774	1,894	1,888	1,977	2,136	2,174	2,171	2,211	
Other urologic	210	245	275	399	414	499	499	648	644	652	718	800	846	1,142	1,180	1,053	1,178	1,345	1,588	1,509	1,562	1,676	1,623	1,590	
Other cause	1,236	1,409	1,609	2,301	3,158	3,550	3,796	4,167	4,226	4,397	4,482	4,982	4,864	5,082	5,414	5,368	6,498	8,116	8,656	9,002	9,628	10,117	10,472	10,679	
Unknown cause	1,244	1,345	1,363	1,591	1,370	1,371	1,409	1,435	1,664	1,925	1,966	1,791	1,908	2,305	2,564	2,295	2,545	2,622	3,015	3,165	3,463	3,527	3,855	3,920	
Missing disease	6,001	6,815	6,488	3,512	1,594	3,038	1,765	1,680	1,950	2,078	3,232	2,940	3,283	3,053	2,912	6,706	6,773	3,345	1,283	1,047	1,142	1,877	1,745	1,677	
U.S.	14,266	15,951	17,082	19,175	21,681	25,214	26,361	29,193	31,825	34,850	38,586	43,826	47,787	53,304	57,914	60,095	67,915	71,541	76,674	80,853	85,877	90,603	93,204	94,905	
U.S. territories	*	10	*	14	19	17	13	26	24	29	44	48	56	63	87	66	78	102	120	138	142	138	141	154	
Puerto Rico	148	167	234	240	292	302	378	385	390	427	470	561	568	643	769	740	870	852	950	966	1,049	1,121	1,114	1,150	
Foreign	*	14	*	10	*	12	11	18	12	15	24	32	47	44	56	53	72	43	42	37	49	32	42	34	
Unknown	49	84	73	80	107	134	136	164	208	358	813	644	489	487	646	976	3,726	289	47	34	37	53	101	52	
All	14,474	16,226	17,404	19,519	22,108	25,679	26,899	29,786	32,459	35,679	39,937	45,111	48,947	54,541	59,472	61,930	72,661	72,827	77,833	82,028	87,154	91,947	94,602	96,295	

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule. The age of the incident patient is determined as of the date of ESRD initiation.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank. \*Values for cells with fewer than 10 patients are suppressed. . Zero values in this cell.

Table A.2

**Incident Counts of Reported ESRD Patients: U.S. Only, with Unknowns Dropped**

by demographic characteristics &amp; primary diagnosis, after dropping non-U.S. patients &amp; patients of unknown age, gender, race, &amp; ethnicity

	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	26	28	39	64	93	99	99	114	109	119	126	135	125	158	143	160	132	155	166	171	158	178	198	217
5-9	74	83	85	94	100	88	100	96	116	97	96	120	150	134	116	137	157	152	146	132	128	160	157	141
10-14	197	174	163	175	203	198	212	191	189	201	209	206	224	237	230	240	254	275	270	266	267	307	307	301
15-19	390	419	405	457	437	423	405	397	421	438	455	510	501	470	481	498	529	554	569	517	522	607	549	582
20-24	597	599	591	669	723	665	731	744	716	783	816	828	858	895	982	950	973	1,025	995	908	984	942	918	991
25-29	791	807	815	932	1,109	1,083	1,126	1,180	1,264	1,215	1,313	1,504	1,506	1,547	1,539	1,588	1,666	1,615	1,631	1,634	1,680	1,655	1,662	1,607
30-34	814	923	1,048	1,243	1,345	1,365	1,446	1,453	1,653	1,558	1,769	1,981	2,046	2,132	2,189	2,253	2,396	2,475	2,413	2,360	2,395	2,420	2,418	2,303
35-39	888	885	996	1,123	1,300	1,351	1,440	1,651	1,759	1,877	2,105	2,225	2,380	2,569	2,818	2,751	3,147	3,269	3,282	3,292	3,296	3,419	3,268	3,259
40-44	961	1,017	1,023	1,236	1,291	1,441	1,480	1,608	1,756	2,011	2,156	2,474	2,796	3,148	3,314	3,284	3,565	4,058	4,194	4,160	4,507	4,544	4,596	4,593
45-49	1,112	1,233	1,224	1,359	1,434	1,638	1,687	1,850	1,954	2,129	2,320	2,755	2,849	3,265	3,585	3,850	4,414	4,867	5,156	5,244	5,731	5,994	6,105	6,196
50-54	1,437	1,543	1,615	1,839	2,019	2,054	2,064	2,218	2,357	2,530	2,914	3,142	3,345	3,582	4,082	4,248	5,089	5,393	5,622	6,127	6,755	7,422	7,648	8,184
55-59	1,640	1,788	1,880	2,301	2,456	2,604	2,773	2,963	3,046	3,265	3,612	3,910	4,268	4,614	4,990	5,086	5,994	6,373	6,607	7,130	7,778	8,367	8,626	8,907
60-64	1,550	1,786	1,974	2,292	2,653	3,090	3,393	3,731	3,900	4,346	4,742	5,187	5,618	6,264	6,519	6,675	7,499	8,007	8,219	8,633	9,184	9,455	9,695	10,045
65-69	1,583	1,843	2,073	2,098	2,494	3,290	3,395	3,842	4,342	4,949	5,465	6,366	7,078	7,847	8,403	8,686	9,483	9,329	10,104	10,494	10,781	10,905	11,070	11,228
70-74	1,106	1,367	1,500	1,603	2,077	2,845	2,861	3,396	3,725	4,243	4,628	5,397	6,075	7,141	7,933	8,366	9,356	9,476	10,524	11,003	11,396	11,771	11,970	12,104
75-79	555	769	873	926	1,187	1,799	1,939	2,238	2,703	3,005	3,414	4,153	4,529	5,313	5,911	6,176	7,059	7,266	8,300	9,155	9,963	10,975	11,205	11,203
80-84	168	272	320	337	447	744	796	1,000	1,189	1,422	1,644	2,035	2,359	2,725	3,201	3,369	3,937	4,210	4,876	5,639	6,064	6,677	7,237	7,373
85+	55	81	98	102	178	256	277	359	435	491	599	795	949	1,098	1,258	1,451	1,594	1,796	2,206	2,549	3,077	3,530	3,820	4,093
0-19	687	704	692	790	833	808	816	798	835	855	886	971	1,000	999	970	1,035	1,072	1,136	1,151	1,086	1,075	1,252	1,211	1,241
20-44	4,051	4,231	4,473	5,203	5,768	5,905	6,223	6,636	7,148	7,444	8,159	9,012	9,586	10,291	10,842	10,826	11,747	12,442	12,515	12,354	12,862	12,980	12,862	12,753
45-64	5,739	6,350	6,693	7,791	8,562	9,386	9,917	10,762	11,257	12,270	13,588	14,994	16,080	17,725	19,176	19,859	22,996	24,640	25,604	27,134	29,448	31,238	32,074	33,332
65-74	2,689	3,210	3,573	3,701	4,571	6,135	6,256	7,238	8,067	9,192	10,093	11,763	13,153	14,988	16,336	17,052	18,839	18,805	20,628	21,497	22,177	22,676	23,040	23,332
75+	778	1,122	1,291	1,365	1,812	2,799	3,012	3,597	4,327	4,918	5,657	6,983	7,837	9,136	10,370	10,996	12,590	13,272	15,382	17,343	19,104	21,182	22,262	22,669
Male	7,747	8,673	9,352	10,426	11,884	13,741	14,454	15,794	17,294	18,761	20,747	23,652	25,749	28,513	30,661	31,965	35,630	37,041	40,166	42,218	44,938	47,634	48,796	50,084
Female	6,197	6,944	7,370	8,424	9,662	11,292	11,770	13,237	14,340	15,918	17,636	20,071	21,907	24,626	27,033	27,803	31,614	33,254	35,114	37,196	39,728	41,694	42,653	43,243
White	9,033	9,948	10,637	12,273	14,683	16,618	17,425	19,338	21,077	22,840	25,134	28,660	31,349	34,805	37,535	38,262	42,648	44,091	47,163	51,398	54,189	58,117	60,074	61,230
Black	4,684	5,413	5,754	6,148	6,282	7,607	7,763	8,537	9,212	10,266	11,578	13,485	14,408	16,208	17,687	18,824	21,349	22,519	24,037	24,367	25,970	26,703	26,877	27,548
Native American	126	132	175	208	222	293	287	307	371	429	532	624	688	763	917	873	1,021	1,233	1,394	1,034	1,480	1,234	1,276	1,220
Asian	101	124	156	221	359	515	749	849	974	1,144	1,139	954	1,211	1,363	1,555	1,809	2,226	2,452	2,686	2,615	3,027	3,274	3,222	3,329
†Hispanic																			7,212	7,166	8,301	8,764	9,327	9,768
†Non-Hispanic																			68,068	72,248	76,365	80,564	82,122	83,559
Diabetes	1,355	1,577	2,162	3,536	4,960	5,843	7,000	8,124	9,332	10,436	11,755	14,338	16,167	18,769	20,763	20,743	24,790	28,091	31,805	34,218	36,783	38,694	40,349	41,312
Hypertension	1,841	2,038	2,544	3,967	5,481	5,986	6,714	7,695	8,363	9,547	10,773	12,802	13,898	15,688	17,467	16,674	19,665	18,061	19,601	21,049	22,339	23,716	24,175	24,942
Glomeruloneph.	1,884	2,016	2,113	3,023	3,840	4,027	4,264	4,481	4,597	4,892	5,176	5,567	5,876	6,179	6,465	6,349	7,127	7,510	8,026	7,960	8,153	8,138	7,837	7,687
Cystic kidney	534	581	620	849	1,014	1,058	1,095	1,146	1,238	1,257	1,266	1,270	1,433	1,514	1,606	1,545	1,716	1,846	1,826	1,927	2,082	2,130	2,095	2,143
Other urologic	205	236	266	386	392	482	482	631	628	637	692	770	819	1,116	1,153	1,029	1,120	1,300	1,541	1,456	1,523	1,614	1,568	1,539
Other cause	1,201	1,379	1,572	2,258	3,110	3,496	3,750	4,105	4,170	4,340	4,403	4,903	4,812	4,998	5,290	5,216	6,133	7,887	8,440	8,800	9,407	9,898	10,188	10,429
Unknown cause	1,207	1,293	1,306	1,538	1,348	1,342	1,385	1,412	1,631	1,885	1,930	1,756	1,870	2,260	2,510	2,231	2,420	2,521	2,909	3,066	3,359	3,420	3,704	3,793
Missing disease	5,717	6,497	6,139	3,293	1,401	2,799	1,534	1,437	1,675	1,685	2,388	2,317	2,781	2,615	2,440	5,981	4,273	3,079	1,132	938	1,020	1,718	1,533	1,482
All	13,944	15,617	16,722	18,850	21,546	25,033	26,224	29,031	31,634	34,679	38,383	43,723	47,656	53,139	57,694	59,768	67,244	70,295	75,280	79,414	84,666	89,328	91,449	93,327
Patients dropped	530	609	682	669	562	646	675	755	825	1,000	1,554	1,388	1,291	1,402	1,778	2,162	5,417	2,532	2,553	2,614	2,488	2,619	3,153	2,968

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule. The age of the incident patient is determined as of the date of ESRD initiation.

U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

On our website: Incident Counts of Reported ESRD, by Primary Diagnosis, (A.2.1-12), patients residing in Puerto Rico &amp; U.S. Territories (A.a).

Table A.3

**Incident Rates of Reported ESRD, Unadjusted**

per million population, by demographic characteristics &amp; primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	2	4	5	6	6	6	6	7	7	7	7	8	7	8	7	8	9	9	8	9	10	11
5-9	5	6	6	5	6	6	7	6	5	7	8	7	6	7	8	8	8	7	6	8	8	7
10-14	9	10	11	11	12	11	11	12	13	12	13	13	13	14	15	14	14	14	14	16	15	15
15-19	19	22	22	22	21	21	22	23	25	28	28	27	28	29	30	30	30	27	27	31	28	29
20-24	28	31	33	31	34	35	35	39	42	43	45	47	52	51	53	57	57	52	56	52	50	52
25-29	41	46	54	51	52	54	58	56	60	70	71	75	76	81	87	85	86	87	90	91	93	92
30-34	59	66	72	72	74	73	81	74	83	91	93	96	98	101	108	113	113	114	119	123	123	118
35-39	71	78	84	84	85	94	95	101	111	114	119	125	134	127	143	147	146	145	146	152	147	148
40-44	87	103	104	110	109	114	122	129	133	146	157	168	176	171	181	200	202	195	206	204	203	200
45-49	111	124	130	146	148	159	165	173	179	205	206	232	233	242	265	279	280	284	304	310	307	303
50-54	138	159	177	184	188	204	219	234	265	280	294	308	339	334	386	395	404	404	430	451	443	450
55-59	162	199	214	227	244	264	274	298	337	371	407	443	476	476	548	575	582	607	627	650	648	655
60-64	195	221	251	290	314	342	359	403	439	484	529	592	625	652	744	797	822	858	895	899	909	923
65-69	235	236	277	360	368	411	455	508	556	639	702	783	842	867	951	940	1,021	1,073	1,124	1,154	1,174	1,202
70-74	219	229	291	390	386	452	491	552	593	683	757	866	937	971	1,071	1,073	1,197	1,257	1,295	1,342	1,369	1,388
75-79	181	187	233	344	361	406	479	520	578	689	737	846	924	953	1,072	1,084	1,204	1,292	1,381	1,497	1,512	1,509
80-84	108	111	144	233	243	296	341	396	444	532	599	675	773	792	903	940	1,066	1,210	1,282	1,386	1,476	1,472
85+	43	43	73	102	107	135	159	174	208	268	310	344	379	421	447	487	580	651	760	845	889	929
0-19	10	11	12	11	12	11	12	12	12	14	14	14	13	14	14	15	15	14	14	16	15	16
20-44	53	60	65	65	67	70	74	77	83	91	96	102	107	107	116	123	124	122	127	129	128	126
45-64	150	175	193	211	223	241	252	274	299	327	347	379	397	401	452	472	477	489	514	528	525	528
65-74	228	233	283	374	376	429	471	527	573	658	727	820	886	915	1,007	1,003	1,104	1,160	1,206	1,245	1,268	1,292
75+	128	132	170	256	268	311	365	403	453	545	596	676	749	775	868	893	1,008	1,108	1,194	1,298	1,340	1,346
Male	85	94	106	121	126	136	148	159	174	197	212	232	246	254	280	289	310	323	340	357	362	369
Female	63	71	81	94	97	108	116	128	141	159	171	191	207	211	237	247	259	272	287	299	303	305
White	54	62	74	83	87	96	104	112	122	138	150	165	176	178	197	202	215	232	243	259	266	269
Black	215	227	228	273	275	299	318	350	390	447	470	521	558	585	653	680	717	717	754	766	761	771
Native American	122	140	144	184	173	179	208	232	277	312	332	361	427	399	459	547	609	445	627	515	524	494
Asian	41	52	78	105	143	151	163	180	169	134	160	172	187	208	246	261	275	258	289	303	286	288
†Hispanic																	257	246	274	280	287	291
†Non-Hispanic																	287	303	318	334	338	342
Diabetes	10	15	21	25	30	34	39	43	48	58	65	74	81	80	95	107	120	128	136	142	147	149
Hypertension	11	17	24	26	28	32	35	39	44	52	56	62	68	65	76	69	74	79	83	87	88	90
Glomerulonephritis	9	13	17	17	18	19	19	20	21	23	24	25	25	25	27	29	30	30	30	30	28	28
Cystic kidney	3	4	4	5	5	5	5	5	5	5	6	6	6	6	7	7	7	7	8	8	8	8
Other urologic	1	2	2	2	2	3	3	3	3	3	3	4	5	4	4	5	6	5	6	6	6	6
Other cause	7	10	13	15	16	17	17	18	18	20	19	20	21	20	24	30	32	33	35	36	37	38
Unknown cause	6	7	6	6	6	6	7	8	8	7	7	9	10	9	9	10	11	11	12	13	13	14
Missing disease	27	14	6	12	7	6	7	7	10	9	11	10	10	23	16	12	4	4	4	6	6	5
All	74	82	93	107	111	122	132	143	157	177	191	211	226	232	258	267	284	297	313	328	332	336

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule. The age of the incident patient is determined as of the date of ESRD initiation. U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.

†CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank. On our website: Percent Decrease in Incident Counts of ESRD Patients (A.b).

Table A.4

**Incident Rates of Reported ESRD, Adjusted**

per million population, by demographic characteristics & primary diagnosis

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	2	4	5	6	6	6	6	6	7	7	7	8	7	8	7	8	8	9	8	9	10	11
5-9	5	6	6	5	6	6	7	5	5	6	8	7	6	7	8	8	7	7	6	8	8	7
10-14	9	9	11	11	12	11	11	12	13	12	13	13	13	13	13	14	14	14	13	15	15	14
15-19	19	22	22	21	21	21	22	23	24	27	27	26	27	27	28	29	29	26	25	30	27	28
20-24	28	31	33	31	34	35	34	41	42	44	45	45	50	49	51	54	54	49	53	50	47	50
25-29	42	47	54	52	53	55	58	56	60	70	71	74	75	80	85	83	84	84	87	87	89	88
30-34	61	69	74	74	76	74	83	76	84	92	94	97	99	102	108	113	112	112	117	120	121	116
35-39	76	84	90	89	91	99	99	105	115	118	122	128	136	129	145	148	147	146	146	151	146	146
40-44	93	109	110	118	118	123	131	139	144	157	167	177	184	178	189	208	208	199	210	207	206	202
45-49	122	134	139	158	159	171	178	187	194	223	223	251	255	264	288	302	300	300	319	323	318	313
50-54	154	177	196	203	207	226	240	256	289	304	318	333	367	364	423	435	443	444	470	491	477	482
55-59	187	228	242	260	280	297	307	338	378	409	448	486	522	522	600	626	637	656	687	710	706	712
60-64	228	257	286	337	365	398	412	460	499	548	594	659	696	723	818	877	899	932	975	974	976	995
65-69	270	271	313	412	429	474	526	592	638	723	800	886	947	984	1,060	1,038	1,127	1,169	1,219	1,244	1,262	1,286
70-74	259	269	327	453	448	531	574	645	690	793	872	990	1,070	1,126	1,227	1,234	1,369	1,419	1,463	1,492	1,507	1,519
75-79	216	221	279	421	438	487	578	624	692	813	873	998	1,086	1,119	1,267	1,276	1,424	1,483	1,596	1,709	1,712	1,712
80-84	145	141	182	310	321	392	443	506	561	672	752	853	966	994	1,109	1,157	1,328	1,459	1,550	1,659	1,761	1,729
85+	61	61	107	140	157	204	233	261	314	367	440	496	528	568	613	657	814	860	1,005	1,102	1,146	1,184
0-19	9	10	11	11	11	11	12	12	12	13	14	14	13	14	14	15	15	14	13	16	15	15
20-44	60	68	72	73	74	77	81	83	89	96	100	104	109	107	116	121	121	118	123	123	122	120
45-64	173	199	216	239	253	273	284	310	340	371	396	432	460	468	532	560	570	583	613	624	619	625
65-74	265	270	320	433	439	502	550	618	664	758	836	938	1,009	1,055	1,144	1,136	1,248	1,294	1,341	1,368	1,384	1,402
75+	141	141	189	290	305	361	418	463	523	617	689	782	860	894	996	1,030	1,188	1,267	1,384	1,490	1,540	1,542
Male	101	111	124	145	151	163	176	189	206	231	248	270	286	293	323	329	353	364	382	398	400	404
Female	66	75	84	97	100	110	118	129	140	156	168	186	201	203	228	237	246	256	269	278	280	280
White	57	65	76	85	88	97	105	112	122	138	149	163	173	174	192	197	208	223	233	246	252	254
Black	292	306	306	372	371	404	430	473	524	602	634	704	753	788	872	897	949	944	987	994	984	988
Native American	196	205	224	291	268	283	333	366	437	509	537	582	692	640	704	827	915	661	935	749	758	696
Asian	50	68	106	150	204	227	243	271	259	199	240	257	277	304	358	387	406	373	414	428	401	395
†Hispanic																	437	415	463	467	471	471
†Non-Hispanic																	281	294	307	320	322	325
Diabetes	11	17	24	28	33	37	42	47	52	62	69	79	86	84	99	111	124	131	138	143	147	148
Hypertension	13	20	27	29	32	37	39	44	49	56	60	67	73	68	79	72	76	81	84	88	88	89
Glomerulonephritis	10	14	18	19	20	21	21	22	23	24	25	26	27	26	28	30	31	30	31	30	28	28
Cystic kidney	3	4	5	5	5	5	6	6	6	6	6	7	7	6	7	7	7	7	8	8	8	8
Other urologic	1	2	2	2	2	3	3	3	3	3	3	5	5	4	4	5	6	6	6	6	6	6
Other cause	7	10	14	16	17	18	18	19	19	21	20	20	21	21	24	31	33	33	35	36	37	37
Unknown cause	6	7	6	6	6	6	7	8	8	8	8	9	10	9	10	10	11	12	13	13	13	14
Missing disease	30	16	7	13	7	6	8	8	11	10	12	11	10	24	17	12	4	4	4	6	6	5
All (crude)	74	82	93	107	111	122	132	143	157	177	191	211	226	232	258	267	284	297	313	328	332	336
All (adjusted)	82	91	103	118	123	134	144	156	170	189	203	223	238	243	270	278	293	303	318	330	332	334

Rates by age are adjusted for gender & race, rates by gender are adjusted for age & race, rates by race are adjusted for age & gender, and primary diagnoses are adjusted for age, gender, & race. The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule. The age of the incident patient is determined as of the date of ESRD initiation. U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly. †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank. On our website: Incident Rates of Reported ESRD, Adjusted by Primary Diagnosis (A.4.1-20).

Table A.5

**Incident Counts of Reported ESRD Patients, by Time Period**

by age, gender, &amp; race

1996-1998	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-4	215	62	*	15	293	149	43	*	*	202	364	105	*	22	495
5-9	151	54	*	10	220	139	39	*	*	186	290	93	*	16	406
10-14	290	113	*	11	423	234	115	*	23	380	524	228	17	34	803
15-19	527	320	10	33	890	416	249	11	42	718	943	569	21	75	1,608
20-29	2,257	1,768	45	175	4,245	1,823	1,514	79	171	3,587	4,080	3,282	124	346	7,832
30-39	5,289	4,294	167	297	10,047	3,464	3,113	123	291	6,991	8,753	7,407	290	588	17,038
40-49	9,021	7,159	364	509	17,053	6,107	5,095	280	457	11,939	15,128	12,254	644	966	28,992
50-59	12,873	7,454	487	769	21,583	10,097	7,188	506	645	18,436	22,970	14,642	993	1,414	40,019
60-64	8,534	3,796	205	451	12,986	7,403	4,885	306	456	13,050	15,937	8,681	511	907	26,036
65-69	11,478	3,612	191	527	15,808	9,569	5,163	279	560	15,571	21,047	8,775	470	1,087	31,379
70-79	24,711	5,368	270	1,011	31,360	19,471	8,092	398	1,020	28,981	44,182	13,460	668	2,031	60,341
80+	10,182	1,751	58	423	12,414	8,350	3,127	101	419	11,997	18,532	4,878	159	842	24,411
0-19	1,183	549	25	69	1,826	938	446	24	78	1,486	2,121	995	49	147	3,312
20-44	11,571	9,389	374	692	22,026	7,843	6,902	305	655	15,705	19,414	16,291	679	1,347	37,731
45-64	26,403	15,082	894	1,509	43,888	21,051	14,893	989	1,365	38,298	47,454	29,975	1,883	2,874	82,186
65-74	24,567	6,686	358	1,046	32,657	20,107	9,856	544	1,138	31,645	44,674	16,542	902	2,184	64,302
75+	21,804	4,045	161	915	26,925	17,283	6,526	234	861	24,904	39,087	10,571	395	1,776	51,829
All	85,528	35,751	1,812	4,231	127,322	67,222	38,623	2,096	4,097	112,038	152,750	74,374	3,908	8,328	239,360
<b>1999-2001</b>															
0-4	300	70	*	*	381	163	40	*	*	212	463	110	*	13	593
5-9	205	52	*	*	264	144	47	*	*	194	349	99	*	*	458
10-14	338	126	14	16	494	281	119	*	17	421	619	245	18	33	915
15-19	620	270	13	40	943	467	276	12	40	795	1,087	546	25	80	1,738
20-29	2,363	1,628	53	220	4,264	1,818	1,467	57	169	3,511	4,181	3,095	110	389	7,775
30-39	5,285	4,211	118	345	9,959	3,592	3,114	114	308	7,128	8,877	7,325	232	653	17,087
40-49	10,157	7,602	303	587	18,649	6,948	5,666	276	489	13,379	17,105	13,268	579	1,076	32,028
50-59	16,326	9,138	520	964	26,948	12,642	8,282	512	770	22,206	28,968	17,420	1,032	1,734	49,154
60-64	9,929	4,237	238	566	14,970	8,428	5,023	285	489	14,225	18,357	9,260	523	1,055	29,195
65-69	12,101	3,970	174	598	16,843	10,196	5,253	290	621	16,360	22,297	9,223	464	1,219	33,203
70-79	28,639	5,863	240	1,204	35,946	23,003	8,662	363	1,254	33,282	51,642	14,525	603	2,458	69,228
80+	14,052	2,209	47	545	16,853	11,424	3,803	86	564	15,877	25,476	6,012	133	1,109	32,730
0-19	1,463	518	33	68	2,082	1,055	482	21	64	1,622	2,518	1,000	54	132	3,704
20-44	11,941	9,176	291	824	22,232	8,358	7,056	276	673	16,363	20,299	16,232	567	1,497	38,595
45-64	32,119	17,640	941	1,858	52,558	25,070	16,496	968	1,552	44,086	57,189	34,136	1,909	3,410	96,644
65-74	26,454	7,265	322	1,232	35,273	21,966	10,023	488	1,298	33,775	48,420	17,288	810	2,530	69,048
75+	28,338	4,777	139	1,115	34,369	22,657	7,695	251	1,141	31,744	50,995	12,472	390	2,256	66,113
All	100,315	39,376	1,726	5,097	146,514	79,106	41,752	2,004	4,728	127,590	179,421	81,128	3,730	9,825	274,104

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.

\*Values for cells with fewer than 10 patients are suppressed.

Table A.6  
**Incident Rates of Reported ESRD, by Time Period**  
*per million population, by age, gender, & race*

1996-1998	Unadjusted rates								Rates adjusted for:							
	Male				Female				Gender				Race		Gender & race	
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female		
0-4	9	14	*	11	7	10	*	*	8	12	*	8	10	7	8	
5-9	6	11	*	8	6	8	*	*	6	10	*	7	7	6	7	
10-14	12	25	*	9	11	26	*	20	11	26	23	15	14	13	14	
15-19	22	71	30	29	19	57	33	37	21	64	32	33	29	25	27	
20-29	51	232	78	74	42	187	143	67	46	209	111	70	75	62	69	
30-39	99	542	303	115	65	347	224	102	81	441	263	109	157	104	130	
40-49	180	1,110	831	236	121	678	605	187	152	909	737	215	313	203	256	
50-59	382	2,069	1,883	608	286	1,591	1,789	455	340	1,857	1,892	547	633	484	556	
60-64	683	2,930	2,402	1,078	541	2,822	3,146	905	610	2,874	2,774	988	1,002	871	935	
65-69	974	3,014	2,896	1,632	695	3,214	3,510	1,260	832	3,116	3,210	1,445	1,280	1,067	1,172	
70-79	1,356	3,568	3,041	2,376	801	3,573	3,474	1,760	1,078	3,567	3,195	2,111	1,711	1,217	1,459	
80+	1,312	2,967	1,514	2,488	535	2,469	1,482	1,832	885	2,675	1,477	2,089	1,516	837	1,169	
0-19	13	30	19	14	11	25	18	17	12	28	18	16	15	13	14	
20-44	93	490	273	113	64	326	225	97	76	407	257	104	144	98	121	
45-64	380	1,948	1,654	567	290	1,546	1,682	448	368	1,918	1,874	587	659	522	589	
65-74	1,112	3,221	3,014	1,815	747	3,425	3,762	1,437	931	3,358	3,417	1,648	1,442	1,151	1,295	
75+	1,391	3,322	2,168	2,675	646	2,888	1,989	1,870	965	2,961	1,907	2,183	1,616	957	1,280	
All	262	739	524	289	199	721	595	260	230	729	560	274	325	273	298	
All (age adjusted)	278	1,049	819	457	179	878	849	352	221	960	837	397	366	257	305	
<b>1999-2001</b>																
0-4	13	16	*	*	7	10	*	*	10	13	*	5	13	8	10	
5-9	9	11	*	*	6	10	*	*	7	11	*	*	9	7	8	
10-14	14	26	36	12	12	25	*	14	13	26	23	13	16	14	15	
15-19	25	58	36	31	20	61	34	32	23	60	35	32	30	26	28	
20-29	54	208	89	90	43	178	97	64	48	195	94	76	76	62	69	
30-39	103	537	210	121	71	353	210	99	86	441	210	110	160	109	133	
40-49	192	1,062	637	238	131	688	556	178	163	891	613	211	315	211	262	
50-59	426	2,183	1,774	629	316	1,581	1,597	438	380	1,926	1,743	554	689	509	596	
60-64	753	3,060	2,577	1,149	587	2,697	2,677	865	668	2,874	2,632	1,003	1,081	887	982	
65-69	1,068	3,302	2,515	1,637	780	3,251	3,424	1,298	921	3,276	2,980	1,466	1,391	1,142	1,264	
70-79	1,533	3,662	2,458	2,487	944	3,685	2,946	1,838	1,241	3,697	2,690	2,190	1,873	1,354	1,609	
80+	1,636	3,437	1,042	2,648	696	2,855	1,075	1,922	1,132	3,102	1,078	2,242	1,853	1,024	1,430	
0-19	15	28	24	13	12	27	16	12	13	27	19	13	17	14	15	
20-44	97	467	205	124	69	327	198	93	79	393	207	107	143	101	122	
45-64	421	2,012	1,567	590	315	1,518	1,477	431	406	1,953	1,730	593	711	540	623	
65-74	1,221	3,390	2,584	1,915	848	3,408	3,196	1,481	1,035	3,414	2,886	1,725	1,550	1,226	1,385	
75+	1,672	3,668	1,591	2,708	810	3,264	1,857	1,975	1,199	3,349	1,581	2,293	1,914	1,148	1,524	
All	301	782	478	314	229	751	543	271	264	766	511	292	363	302	332	
All (age adjusted)	314	1,088	713	478	203	897	748	355	251	988	734	408	401	280	332	

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.  
 The age of the incident patient is determined as of the date of ESRD initiation.  
 U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.  
 \*Values for cells with fewer than 10 patients are suppressed.



Table A.7  
**Incident Counts of Reported ESRD, by Primary Diagnosis**  
 1998-2001 combined, by age, gender, & race

DIABETES	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-4	*	*	.	.	*	*	*	.	.	15	12	11	.	.	23
5-9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
10-14	*	*	.	.	*	*	.	.	.	*	*	*	.	.	*
15-19	*	*	.	*	15	12	10	.	.	22	20	15	.	*	37
20-29	506	303	17	12	838	549	402	30	22	1,003	1,055	705	47	34	1,841
30-39	2,965	967	88	79	4,099	1,921	893	72	61	2,947	4,886	1,860	160	140	7,046
40-49	6,122	2,817	295	311	9,545	4,146	2,720	272	202	7,340	10,268	5,537	567	513	16,885
50-59	11,344	5,484	552	701	18,081	9,367	6,248	559	549	16,723	20,711	11,732	1,111	1,250	34,804
60-64	6,966	2,913	247	439	10,565	6,730	4,169	355	428	11,682	13,696	7,082	602	867	22,247
65-69	7,676	2,661	181	444	10,962	7,793	4,307	311	504	12,915	15,469	6,968	492	948	23,877
70-79	13,708	3,355	224	751	18,038	13,915	6,059	357	921	21,252	27,623	9,414	581	1,672	39,290
80+	3,919	812	37	238	5,006	3,967	1,747	69	296	6,079	7,886	2,559	106	534	11,085
0-19	13	10	.	*	25	21	17	.	.	38	34	27	.	*	63
20-44	5,936	2,313	224	197	8,670	4,161	2,303	195	142	6,801	10,097	4,616	419	339	15,471
45-64	21,967	10,171	975	1,345	34,458	18,552	12,129	1,093	1,120	32,894	40,519	22,300	2,068	2,465	67,352
65-74	15,309	4,666	330	859	21,164	15,671	7,881	517	1,009	25,078	30,980	12,547	847	1,868	46,242
75+	9,994	2,162	112	574	12,842	10,004	4,232	220	712	15,168	19,998	6,394	332	1,286	28,010
All	53,219	19,322	1,641	2,977	77,159	48,409	26,562	2,025	2,983	79,979	101,628	45,884	3,666	5,960	157,138
<b>HYPERTENSION</b>															
0-4	12	*	.	*	18	*	*	.	.	12	19	10	.	*	30
5-9	*	*	.	.	*	*	.	.	.	*	*	*	.	.	*
10-14	*	*	.	.	*	*	.	.	.	*	*	*	.	.	*
15-19	26	62	*	*	90	24	48	*	*	74	50	110	*	*	164
20-29	359	774	*	63	1,202	167	395	*	25	592	526	1,169	11	88	1,794
30-39	752	2,141	23	89	3,005	384	1,175	12	67	1,638	1,136	3,316	35	156	4,643
40-49	1,497	3,912	40	156	5,605	826	2,287	28	121	3,262	2,323	6,199	68	277	8,867
50-59	2,778	3,841	67	228	6,914	1,780	2,717	28	186	4,711	4,558	6,558	95	414	11,625
60-64	2,364	1,716	28	149	4,257	1,589	1,695	25	112	3,421	3,953	3,411	53	261	7,678
65-69	3,892	1,769	36	150	5,847	2,613	1,923	40	164	4,740	6,505	3,692	76	314	10,587
70-79	12,852	3,033	81	527	16,493	8,921	4,196	82	435	13,634	21,773	7,229	163	962	30,127
80+	8,326	1,465	23	322	10,136	6,701	2,451	38	312	9,502	15,027	3,916	61	634	19,638
0-19	47	69	*	*	120	35	56	*	*	93	82	125	*	*	213
20-44	1,770	4,700	48	226	6,744	891	2,599	29	143	3,662	2,661	7,299	77	369	10,406
45-64	5,980	7,684	116	459	14,239	3,855	5,670	69	368	9,962	9,835	13,354	185	827	24,201
65-74	9,769	3,361	76	401	13,607	6,618	4,058	85	381	11,142	16,387	7,419	161	782	24,749
75+	15,301	2,906	64	598	18,869	11,617	4,512	75	530	16,734	26,918	7,418	139	1,128	35,603
All	32,867	18,720	305	1,687	53,579	23,016	16,895	259	1,423	41,593	55,883	35,615	564	3,110	95,172

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.  
 The age of the incident patient is determined as of the date of ESRD initiation.  
 U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.  
 \*Values for cells with fewer than 10 patients are suppressed.  
 ." Zero values in this cell.

Table A.7 (continued)  
**Incident Counts of Reported ESRD, by Primary Diagnosis**  
 1998-2001 combined, by age, gender, & race

GLOMERU- LONEPHRITIS	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-4	21	*	.	*	28	19	*	*	*	24	40	*	*	*	52
5-9	48	11	*	*	63	51	22	*	*	77	99	33	*	*	140
10-14	79	52	*	*	145	80	54	*	*	142	159	106	11	11	287
15-19	251	154	*	28	440	157	137	*	23	326	408	291	16	51	766
20-29	1,023	549	26	125	1,723	618	422	30	90	1,160	1,641	971	56	215	2,883
30-39	1,420	885	29	185	2,519	766	643	35	157	1,601	2,186	1,528	64	342	4,120
40-49	1,965	1,158	46	179	3,348	1,060	730	32	174	1,996	3,025	1,888	78	353	5,344
50-59	2,140	871	40	172	3,223	1,239	520	30	124	1,913	3,379	1,391	70	296	5,136
60-64	1,069	282	22	72	1,445	586	231	14	55	886	1,655	513	36	127	2,331
65-69	1,241	261	15	78	1,595	780	215	10	56	1,061	2,021	476	25	134	2,656
70-79	2,913	299	19	126	3,357	1,712	333	22	108	2,175	4,625	632	41	234	5,532
80+	1,325	101	*	61	1,490	876	148	*	45	1,078	2,201	249	12	106	2,568
0-19	399	222	18	37	676	307	216	14	32	569	706	438	32	69	1,245
20-44	3,338	1,987	79	411	5,815	1,893	1,432	83	329	3,737	5,231	3,419	162	740	9,552
45-64	4,279	1,758	84	322	6,443	2,376	1,114	58	271	3,819	6,655	2,872	142	593	10,262
65-74	2,730	444	26	140	3,340	1,651	409	23	123	2,206	4,381	853	49	263	5,546
75+	2,749	217	11	125	3,102	1,717	287	18	86	2,108	4,466	504	29	211	5,210
All	13,495	4,628	218	1,035	19,376	7,944	3,458	196	841	12,439	21,439	8,086	414	1,876	31,815
<b>CYSTIC KIDNEY</b>															
0-4	25	*	.	.	28	26	*	*	*	31	51	*	*	*	59
5-9	10	*	.	*	13	11	*	.	.	13	21	*	.	*	26
10-14	24	.	*	*	26	22	*	*	*	25	46	*	*	*	51
15-19	19	*	.	.	20	24	*	.	*	29	43	*	.	*	49
20-29	46	*	.	*	59	45	*	.	*	51	91	11	.	*	110
30-39	327	44	*	*	382	193	54	.	*	252	520	98	*	12	634
40-49	1,058	137	10	30	1,235	811	170	*	22	1,011	1,869	307	18	52	2,246
50-59	1,070	135	*	23	1,235	978	165	*	32	1,177	2,048	300	*	55	2,412
60-64	297	52	*	12	362	335	53	*	12	402	632	105	*	24	764
65-69	273	44	.	*	326	282	34	*	*	323	555	78	*	15	649
70-79	491	68	*	17	580	424	66	*	16	507	915	134	*	33	1,087
80+	173	33	*	*	209	140	11	.	*	154	313	44	*	*	363
0-19	78	*	*	*	87	83	*	*	*	98	161	15	*	*	185
20-44	816	110	10	24	960	557	132	*	15	707	1,373	242	13	39	1,667
45-64	1,982	267	12	52	2,313	1,805	312	*	60	2,186	3,787	579	21	112	4,499
65-74	546	81	*	18	646	519	69	*	15	605	1,065	150	*	33	1,251
75+	391	64	*	10	469	327	42	.	10	379	718	106	*	20	848
All	3,813	528	28	106	4,475	3,291	564	16	104	3,975	7,104	1,092	44	210	8,450

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.  
 The age of the incident patient is determined as of the date of ESRD initiation.  
 U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.  
 \*Values for cells with fewer than 10 patients are suppressed.  
 ." Zero values in this cell.

Table A.7 (continued)

**Incident Counts of Reported ESRD, by Primary Diagnosis**

1998-2001 combined, by age, gender, &amp; race

OTHER UROLOGIC	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-4	*	.	.	.	*	*	.	.	.	*	*	.	.	.	*
5-9	11	*	.	.	12	16	*	.	.	18	27	*	.	.	30
10-14	29	*	*	*	33	25	*	*	*	33	54	*	*	*	66
15-19	47	*	.	*	55	58	11	.	.	69	105	17	.	*	124
20-29	114	15	*	*	138	148	*	*	*	161	262	21	*	*	299
30-39	172	46	*	*	224	211	20	*	*	238	383	66	*	10	462
40-49	236	52	*	*	298	231	44	*	*	280	467	96	*	12	578
50-59	359	94	*	11	467	294	73	*	11	386	653	167	11	22	853
60-64	284	51	*	*	346	162	30	*	*	199	446	81	*	13	545
65-69	332	66	*	13	413	184	45	*	*	236	516	111	*	19	649
70-79	1,010	146	*	24	1,184	411	62	*	12	489	1,421	208	*	36	1,673
80+	618	83	*	10	713	198	40	.	*	243	816	123	*	15	956
0-19	94	*	*	*	107	101	19	*	*	122	195	28	*	*	229
20-44	404	85	*	13	506	467	45	*	*	527	871	130	10	22	1,033
45-64	761	173	*	24	967	579	128	10	20	737	1,340	301	19	44	1,704
65-74	784	142	*	25	956	398	84	*	14	500	1,182	226	*	39	1,456
75+	1,176	153	*	22	1,354	395	63	*	*	468	1,571	216	*	31	1,822
All	3,219	562	22	87	3,890	1,940	339	22	53	2,354	5,159	901	44	140	6,244
<b>OTHER CAUSE</b>															
0-4	255	64	*	*	328	127	30	*	*	163	382	94	*	*	491
5-9	119	35	*	*	160	81	27	*	.	109	200	62	*	*	269
10-14	212	67	*	10	295	155	66	*	10	232	367	133	*	20	527
15-19	274	90	*	10	382	219	125	*	22	373	493	215	15	32	755
20-29	655	404	*	39	1,107	623	646	14	60	1,343	1,278	1,050	23	99	2,450
30-39	876	1,129	13	31	2,049	837	1,118	25	79	2,059	1,713	2,247	38	110	4,108
40-49	1,537	1,438	28	45	3,048	1,381	1,162	24	54	2,621	2,918	2,600	52	99	5,669
50-59	2,162	935	29	53	3,179	1,924	716	38	58	2,736	4,086	1,651	67	111	5,915
60-64	1,372	319	19	26	1,736	1,139	312	10	25	1,486	2,511	631	29	51	3,222
65-69	1,875	278	10	46	2,209	1,321	316	12	37	1,686	3,196	594	22	83	3,895
70-79	4,195	515	18	77	4,805	3,135	499	21	74	3,729	7,330	1,014	39	151	8,534
80+	2,043	165	*	36	2,249	1,554	247	*	32	1,838	3,597	412	10	68	4,087
0-19	860	256	20	29	1,165	582	248	12	35	877	1,442	504	32	64	2,042
20-44	2,196	2,273	32	87	4,588	2,082	2,383	52	168	4,685	4,278	4,656	84	255	9,273
45-64	4,406	1,952	66	107	6,531	3,822	1,571	59	108	5,560	8,228	3,523	125	215	12,091
65-74	3,977	580	24	84	4,665	2,905	587	25	78	3,595	6,882	1,167	49	162	8,260
75+	4,136	378	*	75	4,598	3,105	475	13	65	3,658	7,241	853	22	140	8,256
All	15,575	5,439	151	382	21,547	12,496	5,264	161	454	18,375	28,071	10,703	312	836	39,922

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.

\*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.7 (continued)  
**Incident Counts of Reported ESRD, by Primary Diagnosis**  
 1998-2001 combined, by age, gender, & race

UNKNOWN CAUSE	Male					Female					All				
	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All	White	Black	N Am	Asian	All
0-4	*	*	.	*	12	*	*	.	*	*	16	*	.	*	21
5-9	17	*	*	.	21	*	*	.	*	14	25	*	*	*	35
10-14	24	14	*	*	42	38	21	*	*	63	62	35	*	*	105
15-19	68	28	*	*	101	57	21	*	*	83	125	49	*	*	184
20-29	260	97	*	23	383	142	81	*	22	246	402	178	*	45	629
30-39	286	249	*	28	568	190	175	*	20	391	476	424	11	48	959
40-49	456	382	13	44	895	311	226	10	41	588	767	608	23	85	1,483
50-59	658	320	11	30	1,019	405	212	11	45	673	1,063	532	22	75	1,692
60-64	390	156	*	16	567	318	117	*	14	453	708	273	*	30	1,020
65-69	609	117	*	25	755	408	144	*	19	577	1,017	261	10	44	1,332
70-79	1,893	278	14	49	2,234	1,272	283	19	51	1,625	3,165	561	33	100	3,859
80+	1,445	150	*	25	1,625	1,063	224	*	40	1,332	2,508	374	10	65	2,957
0-19	118	46	*	*	176	110	48	*	*	169	228	94	*	18	345
20-44	744	526	12	70	1,352	485	366	*	58	918	1,229	892	21	128	2,270
45-64	1,306	678	25	71	2,080	881	445	23	84	1,433	2,187	1,123	48	155	3,513
65-74	1,464	259	12	57	1,792	987	280	14	45	1,326	2,451	539	26	102	3,118
75+	2,483	286	11	42	2,822	1,756	371	16	65	2,208	4,239	657	27	107	5,030
All	6,115	1,795	63	249	8,222	4,219	1,510	64	261	6,054	10,334	3,305	127	510	14,276
<b>MISSING CAUSE</b>															
0-4	40	*	.	.	47	18	*	.	.	19	58	*	.	.	66
5-9	41	16	.	.	57	20	*	.	.	24	61	20	.	.	81
10-14	59	20	*	.	81	35	10	.	*	48	94	30	*	*	129
15-19	83	24	.	*	112	54	12	.	*	69	137	36	.	*	181
20-29	162	65	*	10	240	137	44	*	10	193	299	109	*	20	433
30-39	289	122	*	26	439	263	86	*	17	367	552	208	*	43	806
40-49	509	170	*	22	705	338	122	*	24	489	847	292	*	46	1,194
50-59	505	177	*	29	717	346	162	*	19	533	851	339	12	48	1,250
60-64	191	92	*	11	295	170	100	*	*	277	361	192	*	17	572
65-69	127	42	*	*	177	95	61	*	*	162	222	103	*	11	339
70-79	183	49	*	*	236	166	75	*	*	249	349	124	*	*	485
80+	78	16	.	*	98	83	35	.	*	119	161	51	.	*	217
0-19	223	67	*	*	297	127	27	.	*	160	350	94	*	11	457
20-44	695	279	*	49	1,030	538	173	*	38	755	1,233	452	13	87	1,785
45-64	961	347	*	49	1,366	716	341	*	38	1,104	1,677	688	18	87	2,470
65-74	232	65	*	*	307	178	107	*	*	296	410	172	*	17	603
75+	156	42	*	*	204	166	64	*	*	234	322	106	*	*	438
All	2,267	800	20	117	3,204	1,725	712	19	93	2,549	3,992	1,512	39	210	5,753

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.  
 The age of the incident patient is determined as of the date of ESRD initiation.  
 U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.  
 \*Values for cells with fewer than 10 patients are suppressed.  
 ." Zero values in this cell.

Table A.8

**Incident Rates of Reported ESRD, by Primary Diagnosis**

per ten million population, 1998-2001 combined, by age, gender, &amp; race

DIABETES	Unadjusted rates								Rates adjusted for:							
	Male				Female				Gender				Race		Gender & Race	
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female		
0-4	*	*	.	.	*	*	.	.	2	10	.	.	*	4	3	
5-9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	
10-14	*	*	.	.	*	.	.	.	*	*	.	.	*	*	*	
15-19	*	*	.	*	4	17	.	.	3	12	.	*	4	5	4	
20-29	86	291	215	37	97	367	389	63	92	335	306	48	114	133	123	
30-39	432	923	1,181	212	282	757	994	149	352	832	1,085	180	488	342	413	
40-49	877	3,000	4,714	967	591	2,511	4,154	561	742	2,852	4,583	787	1,218	887	1,048	
50-59	2,263	10,074	14,403	3,537	1,789	9,169	13,336	2,425	2,076	9,966	14,398	3,134	3,531	2,963	3,240	
60-64	4,000	15,972	20,307	6,854	3,544	17,014	25,395	5,783	3,765	16,511	22,995	6,310	5,793	5,561	5,676	
65-69	5,053	16,604	19,797	9,299	4,441	20,005	27,848	7,987	4,743	18,341	23,904	8,622	6,841	6,791	6,822	
70-79	5,518	15,861	17,451	11,862	4,278	19,438	21,964	10,371	4,872	17,590	19,518	11,217	7,197	6,601	6,901	
80+	3,479	9,621	6,319	8,948	1,827	9,923	6,639	7,869	2,521	9,575	6,715	8,152	4,270	3,142	3,697	
0-19	1	4	.	*	2	7	.	.	1	6	.	*	1	2	2	
20-44	361	887	1,192	226	257	804	1,053	149	289	838	1,163	182	412	316	363	
45-64	2,193	8,883	12,386	3,288	1,777	8,540	12,729	2,396	2,211	10,073	14,480	3,425	3,608	3,158	3,378	
65-74	5,285	16,414	20,035	10,195	4,508	20,168	25,630	8,764	4,896	18,331	22,784	9,569	7,057	6,885	6,976	
75+	4,476	12,576	9,857	10,749	2,701	13,551	12,470	9,571	3,246	12,003	10,268	9,408	5,220	4,169	4,688	
All	1,201	2,898	3,431	1,400	1,055	3,605	4,146	1,303	1,127	3,270	3,793	1,350	1,440	1,428	1,434	
All (age adjusted)	1,226	4,210	5,261	2,163	948	4,403	5,829	1,764	1,072	4,327	5,584	1,945	1,570	1,331	1,439	
<b>HYPERTENSION</b>																
0-4	4	*	.	*	*	*	.	.	3	9	.	*	5	3	4	
5-9	*	*	.	.	*	.	.	.	*	*	.	.	*	*	*	
10-14	*	*	.	*	*	*	.	.	*	*	.	*	*	*	2	
15-19	8	100	*	*	8	80	*	*	8	90	*	*	20	17	18	
20-29	61	744	*	194	29	360	*	71	45	558	71	128	157	74	114	
30-39	109	2,044	309	238	56	996	166	164	82	1,499	236	201	363	181	268	
40-49	214	4,166	639	485	118	2,111	428	336	167	3,180	544	416	750	391	563	
50-59	554	7,056	1,748	1,151	340	3,987	668	821	460	5,593	1,254	1,029	1,456	855	1,143	
60-64	1,358	9,409	2,302	2,326	837	6,918	1,788	1,513	1,091	8,138	2,062	1,905	2,438	1,653	2,033	
65-69	2,562	11,038	3,938	3,141	1,489	8,932	3,582	2,599	2,014	9,962	3,787	2,869	3,685	2,509	3,082	
70-79	5,174	14,339	6,311	8,324	2,742	13,462	5,045	4,898	3,999	14,142	5,753	6,790	6,634	4,277	5,432	
80+	7,391	17,359	3,928	12,106	3,086	13,921	3,656	8,295	5,112	15,439	3,772	10,022	8,655	4,684	6,628	
0-19	4	28	*	*	3	24	*	*	3	26	*	*	7	6	6	
20-44	108	1,802	255	259	55	907	157	150	77	1,337	212	201	330	165	244	
45-64	597	6,711	1,474	1,122	369	3,992	804	787	553	5,778	1,303	1,113	1,560	958	1,248	
65-74	3,372	11,823	4,614	4,759	1,904	10,385	4,214	3,309	2,645	11,233	4,519	4,181	4,585	3,099	3,826	
75+	6,854	16,903	5,633	11,199	3,137	14,448	4,251	7,124	4,982	15,553	4,600	9,377	8,364	4,744	6,517	
All	742	2,808	638	793	502	2,293	530	622	620	2,538	583	704	1,000	742	868	
All (age adjusted)	809	4,023	1,090	1,365	417	2,816	791	895	578	3,386	932	1,095	1,157	663	872	
<b>GLOMERULONEPHRITIS</b>																
0-4	7	*	.	*	6	*	*	*	7	*	*	*	7	6	7	
5-9	15	17	*	*	17	36	*	*	16	27	*	*	15	19	17	
10-14	25	82	*	*	26	88	*	*	26	85	107	33	34	35	34	
15-19	77	248	*	167	52	228	*	140	64	238	169	155	104	79	91	
20-29	174	528	329	385	109	385	389	256	141	458	361	316	230	153	190	
30-39	207	845	389	496	112	545	483	385	158	690	437	440	301	182	240	
40-49	281	1,233	735	557	151	674	489	483	217	961	616	524	424	236	328	
50-59	427	1,600	1,044	868	237	763	716	548	335	1,167	887	719	606	325	461	
60-64	614	1,546	1,809	1,124	309	943	1,002	743	459	1,238	1,391	935	766	414	586	
65-69	817	1,629	1,641	1,634	444	999	895	887	626	1,307	1,267	1,253	962	538	744	
70-79	1,173	1,414	1,480	1,990	526	1,068	1,354	1,216	849	1,229	1,416	1,618	1,250	631	935	
80+	1,176	1,197	*	2,293	403	841	*	1,196	763	1,001	701	1,761	1,187	496	834	
0-19	31	90	98	52	25	91	78	47	28	89	83	52	40	35	37	
20-44	203	762	420	471	117	500	448	345	157	627	440	403	285	177	230	
45-64	427	1,535	1,067	787	228	784	675	580	343	1,164	948	730	615	331	469	
65-74	942	1,562	1,578	1,662	475	1,047	1,140	1,068	707	1,297	1,373	1,373	1,061	581	816	
75+	1,231	1,262	968	2,341	464	919	1,020	1,156	812	1,057	918	1,756	1,238	544	884	
All	305	694	456	487	173	469	401	367	238	576	428	425	362	222	290	
All (age adjusted)	314	831	593	621	160	511	480	414	229	664	535	505	388	212	291	

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.

\*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.8 (continued)

**Incident Rates of Reported ESRD, by Primary Diagnosis**

per ten million population, 1998-2001 combined, by age, gender, &amp; race

CYSTIC KIDNEY	Unadjusted rates				Rates adjusted for:				Rates adjusted for:				Race		Gender	
	Male				Female				Gender				Male	Female	& Race	
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian				
0-4	8	*	.	.	9	*	*	*	8	*	*	*	7	8	8	
5-9	3	*	.	*	4	*	.	.	3	*	.	*	3	3	3	
10-14	8	*	*	*	7	*	*	*	7	*	*	*	7	7	7	
15-19	6	*	.	.	8	*	.	*	7	*	.	*	5	8	6	
20-29	8	*	.	*	8	*	.	*	8	5	.	*	8	7	8	
30-39	48	42	*	*	28	46	*	*	37	43	*	16	44	29	37	
40-49	152	146	160	93	116	157	*	61	135	155	141	79	151	121	136	
50-59	213	248	*	116	187	242	*	141	201	246	*	133	214	192	203	
60-64	171	285	*	187	176	216	*	162	174	250	*	174	185	181	183	
65-69	180	275	*	*	161	158	*	*	170	215	*	141	191	157	173	
70-79	198	321	.	269	130	212	*	180	163	268	*	225	218	142	179	
80+	154	391	*	*	64	62	.	*	102	213	*	*	167	64	114	
0-19	6	*	*	*	7	*	*	*	7	3	*	*	6	7	6	
20-44	50	42	53	27	34	46	*	16	38	43	36	21	44	32	38	
45-64	198	233	152	127	173	220	*	128	186	233	120	136	200	179	189	
65-74	188	285	*	214	149	177	*	130	169	231	*	175	202	152	176	
75+	175	372	*	187	88	134	.	134	121	238	*	124	186	88	136	
All	86	79	59	50	72	77	33	45	79	78	46	48	84	71	77	
All (age adjusted)	86	111	82	65	68	88	39	53	76	97	59	58	87	69	78	
<b>OTHER UROLOGIC</b>																
0-4	*	.	.	.	*	.	.	.	*	.	.	.	*	*	*	
5-9	3	*	.	.	5	*	.	.	4	*	.	.	3	5	4	
10-14	9	*	*	*	8	*	*	*	9	*	*	*	8	8	8	
15-19	15	*	.	*	19	18	.	.	17	14	.	*	14	18	16	
20-29	19	14	*	*	26	*	*	*	23	10	*	*	19	23	21	
30-39	25	44	*	*	31	17	*	*	28	30	*	13	27	28	28	
40-49	34	55	*	*	33	41	*	*	34	49	*	19	37	33	35	
50-59	72	173	*	56	56	107	*	49	65	149	134	52	87	65	76	
60-64	163	280	*	*	85	122	*	*	123	199	*	95	177	90	132	
65-69	219	412	*	272	105	209	*	*	160	308	*	182	246	118	180	
70-79	407	690	*	379	126	199	*	135	268	445	*	257	451	137	290	
80+	549	983	*	376	91	227	.	*	316	603	*	242	598	109	348	
0-19	7	*	*	*	8	8	*	*	8	6	*	*	7	8	7	
20-44	25	33	*	15	29	16	*	*	26	24	27	12	25	26	25	
45-64	76	151	*	59	55	90	116	43	72	139	130	57	98	64	81	
65-74	271	500	*	297	115	215	*	122	192	360	*	211	305	129	215	
75+	527	890	*	412	107	202	*	*	315	561	*	253	578	117	342	
All	73	84	46	41	42	46	45	23	57	64	46	32	73	42	57	
All (age adjusted)	78	137	73	64	39	55	57	30	55	89	63	45	83	40	57	
<b>OTHER CAUSE</b>																
0-4	83	112	*	*	43	54	*	*	63	83	*	*	84	44	64	
5-9	37	55	*	*	27	44	*	.	32	50	*	*	39	28	33	
10-14	67	105	*	58	51	107	*	61	59	106	*	61	72	59	65	
15-19	85	145	*	60	72	208	*	134	78	177	159	97	92	93	93	
20-29	112	389	*	120	110	590	181	171	110	495	150	146	148	174	162	
30-39	128	1,078	175	83	123	948	345	194	125	1,007	261	140	247	233	240	
40-49	220	1,531	447	140	197	1,073	367	150	210	1,307	417	148	392	310	349	
50-59	431	1,718	757	267	368	1,051	907	256	409	1,377	848	272	603	462	530	
60-64	788	1,749	1,562	406	600	1,273	715	338	691	1,505	1,132	369	902	676	786	
65-69	1,234	1,735	1,094	963	753	1,468	1,075	586	989	1,598	1,088	770	1,287	841	1,059	
70-79	1,689	2,435	1,402	1,216	964	1,601	1,292	833	1,329	2,011	1,298	1,045	1,780	1,046	1,405	
80+	1,814	1,955	*	1,353	716	1,403	*	851	1,221	1,657	648	1,068	1,748	803	1,267	
0-19	68	104	109	41	48	104	67	52	58	104	87	48	72	56	64	
20-44	133	872	170	100	128	832	281	176	129	847	231	140	225	219	222	
45-64	440	1,705	838	262	366	1,106	687	231	439	1,410	832	271	639	485	559	
65-74	1,373	2,040	1,457	997	836	1,502	1,239	677	1,103	1,789	1,379	840	1,456	920	1,182	
75+	1,853	2,199	*	1,405	838	1,521	737	874	1,295	1,786	741	1,105	1,810	900	1,346	
All	351	816	316	180	272	715	330	198	311	763	323	189	402	328	364	
All (age adjusted)	367	1,009	437	259	248	775	412	230	298	884	423	240	439	311	365	

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.

\*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.8 (continued)

**Incident Rates of Reported ESRD, by Primary Diagnosis**

per ten million population, 1998-2001 combined, by age, gender, &amp; race

UNKNOWN CAUSE	Unadjusted rates								Rates adjusted for:							
	Male				Female				Gender				Race			
	White	Black	N Am	Asian	White	Black	N Am	Asian	White	Black	N Am	Asian	Male	Female	Gender & race	
0-4	*	*	.	*	*	*	.	*	3	*	.	*	3	*	3	
5-9	5	*	*	.	*	*	.	*	4	*	*	*	5	3	4	
10-14	8	22	*	*	13	34	*	*	10	28	*	*	10	16	13	
15-19	21	45	*	*	19	35	*	*	20	40	*	*	24	21	23	
20-29	44	93	*	71	25	74	*	63	35	84	*	66	52	33	42	
30-39	42	238	*	75	28	148	*	49	35	192	76	61	68	45	56	
40-49	65	407	208	137	44	209	153	114	55	311	189	128	115	70	92	
50-59	131	588	287	151	77	311	262	199	106	451	285	177	196	116	155	
60-64	224	855	*	250	167	477	*	189	195	661	*	223	308	209	257	
65-69	401	730	*	524	232	669	*	301	315	698	487	410	448	294	370	
70-79	762	1,314	1,091	774	391	908	1,169	574	583	1,135	1,145	671	854	478	662	
80+	1,283	1,777	*	940	490	1,272	*	1,063	872	1,527	678	1,030	1,325	613	962	
0-19	9	19	*	*	9	20	*	*	9	19	*	13	11	11	11	
20-44	45	202	64	80	30	128	*	61	37	163	57	70	67	43	55	
45-64	130	592	318	174	84	313	268	180	118	480	304	184	209	130	168	
65-74	505	911	729	676	284	717	694	391	395	828	736	548	576	349	460	
75+	1,112	1,664	968	787	474	1,188	907	874	811	1,455	888	905	1,218	592	899	
All	138	269	132	117	92	205	131	114	115	236	131	116	153	108	130	
All (age adjusted)	149	379	209	167	79	243	186	147	108	305	196	156	175	99	131	
<b>MISSING CAUSE</b>																
0-4	13	*	.	.	6	*	.	.	9	*	.	.	12	5	9	
5-9	13	25	.	.	7	*	.	.	10	16	.	.	14	6	10	
10-14	19	31	*	.	12	16	.	*	15	24	*	*	20	12	16	
15-19	26	39	.	*	18	20	.	*	22	29	.	*	27	18	22	
20-29	28	63	*	31	24	40	*	28	26	52	*	30	33	26	29	
30-39	42	116	*	70	39	73	*	42	40	94	*	55	52	43	48	
40-49	73	181	*	68	48	113	*	67	61	148	*	67	87	58	72	
50-59	101	325	*	146	66	238	*	84	84	284	155	118	133	90	111	
60-64	110	504	*	172	90	408	*	*	99	454	*	125	162	129	145	
65-69	84	262	*	*	54	283	*	*	69	273	*	103	109	85	97	
70-79	74	232	*	*	51	241	*	*	62	241	*	*	94	76	85	
80+	69	190	.	*	38	199	.	*	52	187	.	*	84	58	71	
0-19	18	27	*	*	11	11	.	*	14	19	*	8	18	10	14	
20-44	42	107	*	56	33	60	*	40	37	83	35	47	50	36	43	
45-64	96	303	*	120	69	240	*	81	84	298	114	108	131	96	113	
65-74	80	229	*	*	51	274	*	*	65	249	*	84	99	81	90	
75+	70	244	*	*	45	205	*	*	56	210	*	*	89	64	76	
All	51	120	42	55	38	97	39	41	44	108	40	48	60	46	52	
All (age adjusted)	51	146	51	63	36	110	49	43	43	128	51	52	62	44	53	

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

The age of the incident patient is determined as of the date of ESRD initiation.

U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.

\*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.9

**Mean Age at Start of ESRD Therapy**

by demographic characteristics & primary diagnosis

	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
0-4	2.0	2.1	1.8	1.9	1.6	1.5	1.6	1.5	1.5	1.4	1.4	1.7	1.4	1.2	1.4	1.6	1.4	1.3	1.5	1.6	1.0	1.3	1.1	1.2
5-9	7.4	7.5	7.4	7.5	7.1	7.3	7.2	7.0	7.1	7.2	7.3	7.2	7.2	7.1	7.2	7.1	7.2	7.1	7.1	7.4	7.4	7.3	7.1	7.1
10-14	12.4	12.2	12.1	12.3	12.3	12.2	12.3	12.3	12.2	12.1	12.1	12.4	12.2	12.3	12.2	12.2	12.5	12.3	12.3	12.3	12.2	12.4	12.1	12.2
15-19	17.3	17.3	17.1	17.3	17.3	17.3	17.2	17.2	17.3	17.2	17.2	17.3	17.3	17.3	17.3	17.2	17.2	17.2	17.2	17.2	17.2	17.2	17.3	17.4
20-24	22.2	22.1	22.2	22.1	22.1	22.2	22.2	22.2	22.3	22.3	22.3	22.2	22.2	22.2	22.2	22.2	22.2	22.3	22.2	22.2	22.2	22.1	22.1	22.1
25-29	27.1	27.1	27.0	27.2	27.1	27.1	27.2	27.2	27.1	27.2	27.1	27.2	27.2	27.2	27.2	27.2	27.2	27.2	27.1	27.2	27.2	27.2	27.2	27.2
30-34	31.9	31.9	32.0	32.0	32.0	32.1	32.1	32.1	32.1	32.1	32.1	32.1	32.2	32.1	32.1	32.1	32.1	32.1	32.2	32.2	32.2	32.2	32.2	32.1
35-39	36.9	37.0	37.0	37.1	36.9	37.0	36.9	37.0	37.0	37.0	37.1	37.0	37.1	37.1	37.1	37.1	37.1	37.1	37.2	37.1	37.1	37.1	37.1	37.1
40-44	41.9	42.1	42.0	42.0	42.0	42.1	42.0	42.0	42.0	42.1	42.0	41.9	42.0	42.1	42.1	42.1	42.1	42.1	42.1	42.1	42.1	42.1	42.2	42.2
45-49	47.1	47.1	47.1	47.0	47.1	47.1	47.1	47.0	47.1	47.1	47.1	47.0	47.1	47.1	47.0	47.0	47.0	47.0	47.1	47.1	47.1	47.1	47.1	47.1
50-54	52.1	52.1	52.1	52.1	52.1	52.1	52.0	52.1	52.1	52.1	52.1	52.1	52.1	52.1	52.1	52.0	52.1	52.1	52.1	52.1	52.0	52.0	52.1	52.1
55-59	57.0	57.0	57.1	57.1	57.0	57.1	57.1	57.1	57.2	57.1	57.1	57.1	57.1	57.1	57.1	57.1	57.1	57.1	57.1	57.1	57.1	57.0	57.0	57.1
60-64	62.0	62.0	62.0	61.9	62.1	62.0	62.0	62.1	62.1	62.1	62.1	62.1	62.1	62.1	62.2	62.1	62.1	62.1	62.1	62.1	62.1	62.1	62.1	62.1
65-69	66.9	66.9	66.9	67.0	67.0	67.0	67.0	67.0	67.0	66.9	67.0	67.0	67.0	67.0	67.0	67.0	67.0	67.0	67.1	67.0	67.0	67.1	67.0	67.0
70-74	71.8	71.8	71.8	71.9	71.8	71.9	71.9	71.9	71.9	71.9	72.0	71.9	71.9	71.9	71.9	71.9	72.0	72.0	72.0	72.0	72.0	72.0	72.0	72.0
75-79	76.7	76.7	76.7	76.7	76.7	76.7	76.7	76.8	76.8	76.8	76.8	76.8	76.8	76.8	76.9	76.9	76.9	76.8	76.8	76.8	76.9	76.9	76.9	77.0
80-84	81.5	81.5	81.6	81.7	81.7	81.5	81.6	81.6	81.6	81.5	81.6	81.6	81.6	81.7	81.7	81.7	81.7	81.7	81.7	81.7	81.8	81.8	81.7	81.8
85+	87.9	87.0	87.3	87.7	88.8	88.1	87.8	87.9	87.8	87.3	87.2	87.3	87.4	87.3	87.4	87.3	87.3	87.4	87.4	87.6	87.5	87.6	87.6	87.7
0-19	14.2	14.2	13.8	13.8	13.1	13.1	12.8	12.5	12.6	12.8	12.7	12.8	12.6	12.2	12.5	12.3	12.6	12.4	12.4	12.3	12.3	12.5	12.1	12.0
20-44	33.0	33.1	33.2	33.4	33.2	33.6	33.5	33.7	33.9	34.2	34.1	34.2	34.6	34.8	34.8	34.8	35.0	35.2	35.3	35.4	35.5	35.6	35.6	35.5
45-64	55.2	55.3	55.5	55.6	55.7	55.9	56.0	56.1	56.0	56.1	56.0	55.9	56.0	56.0	55.9	55.7	55.6	55.6	55.6	55.6	55.5	55.5	55.5	55.5
65-74	68.9	69.0	69.0	69.1	69.2	69.2	69.2	69.3	69.3	69.2	69.3	69.3	69.3	69.3	69.4	69.4	69.5	69.5	69.6	69.6	69.6	69.6	69.6	69.6
75+	78.5	78.6	78.7	78.7	79.1	79.0	79.0	79.2	79.2	79.2	79.3	79.4	79.6	79.6	79.7	79.7	79.7	79.8	79.9	80.0	80.1	80.2	80.3	80.4
Male	50.3	51.3	52.1	51.5	52.2	54.2	54.3	55.0	55.5	55.9	56.1	56.8	57.3	57.8	58.3	58.3	58.3	58.5	59.5	60.1	60.3	60.7	60.8	60.9
Female	51.1	52.5	53.0	52.7	53.5	56.0	55.9	56.8	57.2	57.9	57.8	58.5	59.1	59.8	60.1	60.4	60.0	60.5	61.0	61.7	61.8	62.0	62.4	62.4
Unknown	.	61.0	.	.	.	41.0	65.5	.	.	62.0	.	53.8	.	43.0	56.0	58.6	59.3	41.3	76.0	.	.	.	68.0	
White	50.1	51.5	52.3	52.1	53.3	55.5	55.7	56.5	57.1	57.8	58.1	58.9	59.4	60.1	60.6	60.8	61.3	61.7	62.4	62.9	63.1	63.5	63.6	63.7
Black	51.8	52.8	53.1	52.4	52.2	54.5	54.2	54.8	55.1	55.3	54.9	55.2	55.9	56.3	56.5	56.8	56.0	55.6	56.6	57.0	57.3	57.2	57.7	57.8
Native American	49.9	50.2	51.4	47.5	50.2	52.4	51.6	53.1	53.8	54.2	54.2	55.9	55.6	56.2	57.6	57.8	56.0	56.0	56.4	57.0	57.6	57.5	57.7	56.5
Asian	44.6	45.1	44.0	47.1	49.4	52.1	52.4	54.3	53.5	55.1	54.8	54.4	55.4	56.3	56.0	56.9	57.5	59.5	60.2	59.9	60.3	61.1	60.8	61.1
Other/unknown	50.0	49.9	51.1	52.1	44.9	46.5	42.8	43.9	44.8	44.1	48.0	48.4	46.6	49.0	51.0	52.2	50.5	54.2	54.4	55.1	53.8	54.9	53.4	52.6
†Hispanic																			57.0	57.3	57.6	58.1	57.7	57.8
†Non-Hispanic																			60.6	61.3	61.5	61.7	62.1	62.1
Diabetes	49.3	50.0	50.9	51.7	52.5	53.5	54.0	54.6	55.4	56.1	57.0	57.4	58.4	59.0	59.3	59.5	60.0	60.4	61.0	61.5	61.8	62.1	62.3	62.5
Hypertension	54.4	55.4	56.6	58.3	59.2	60.9	61.0	62.0	62.6	63.5	63.5	64.1	64.5	64.9	64.8	65.0	64.9	65.0	65.4	66.0	66.1	66.4	66.6	66.6
Glomerulonephritis	41.9	43.6	44.7	46.6	46.7	48.4	49.0	50.0	50.2	50.6	50.5	51.3	51.4	52.3	51.8	51.6	52.8	52.4	53.1	53.1	53.0	53.6	53.2	52.7
Cystic kidney	51.1	51.7	51.9	52.4	52.9	53.3	53.2	53.7	53.6	54.0	53.7	53.5	53.9	53.6	54.3	53.8	54.9	53.6	54.3	54.4	54.1	54.7	54.6	54.4
Other urologic	55.3	56.5	56.9	59.6	54.4	58.2	60.4	58.9	60.6	61.5	62.2	62.2	61.7	60.9	60.4	59.1	59.5	59.3	60.0	59.9	61.1	60.4	61.4	60.7
Other cause	45.0	44.5	46.3	48.1	49.5	50.1	50.3	51.8	52.4	52.4	52.5	53.1	52.0	52.2	53.1	52.3	52.7	53.2	54.0	54.9	55.2	55.5	56.2	56.3
Unknown cause	51.9	54.0	54.6	56.5	56.6	58.7	59.5	59.5	60.5	61.0	61.2	61.1	61.5	61.4	61.7	60.3	60.0	61.6	61.5	62.7	62.1	63.7	62.7	62.8
Missing disease	53.3	54.7	54.9	49.7	48.9	59.4	57.1	55.7	53.5	50.3	48.3	47.8	49.8	48.8	50.8	58.3	51.8	53.5	51.2	50.3	50.3	49.1	47.5	46.6
U.S.	50.7	51.9	52.5	52.1	52.9	55.1	55.1	55.9	56.4	57.0	57.3	57.8	58.3	58.9	59.3	59.5	59.7	59.5	60.2	60.9	61.1	61.3	61.6	61.6
U.S. territories	56.8	49.9	48.8	43.5	53.9	53.9	51.8	52.0	54.0	53.4	51.8	53.5	53.1	56.3	53.7	56.5	54.9	54.9	55.0	55.0	56.5	57.9	58.1	57.1
Puerto Rico	48.3	50.1	54.0	53.9	52.3	54.7	55.1	55.4	56.7	55.2	57.2	58.4	57.0	56.6	58.1	58.6	57.4	57.8	58.8	59.8	58.9	60.4	59.6	59.8
Foreign	44.6	45.7	59.1	56.1	50.1	50.8	60.0	48.8	55.1	54.0	45.0	46.2	47.8	44.8	45.6	45.5	45.9	46.6	47.5	48.2	51.7	57.8	51.7	55.2
Unknown	40.0	44.0	45.8	43.6	41.0	42.6	38.2	41.5	40.7	39.1	39.3	40.0	41.6	46.1	48.3	48.7	49.4	49.2	46.3	39.0	43.7	45.9	52.8	55.9
All	50.6	51.8	52.5	52.0	52.8	55.0	55.0	55.8	56.3	56.8	56.9	57.6	58.1	58.7	59.1	59.3	59.1	59.4	60.2	60.8	61.0	61.3	61.5	61.6

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule. The age of the incident patient is determined as of the date of ESRD initiation.

Patients with unknown age are excluded. †CMS began collecting Hispanic ethnicity data in April 1995; cells for years prior to 1996 have therefore been left blank.

"." Zero values in this cell. On our website: Median Age at Start of ESRD Therapy; Incident patients by Demographic Characteristics & Primary Diagnosis (A.c).



Table A.10

**Incidence of Reported ESRD: All Patients, Row Percent**

1997-2001 combined, by detailed primary diagnosis

	Total Patients	Percent Incident	Median Age	Percent Male	Percent White	Black	N Am	Asian	% Tx 1st yr	% Died 1st yr
All ESRD (reference)	452,026	100.0	64	53.4	63.8	29.2	1.4	3.5	5.3	23.3
Diabetes	198,397	44.6	63	49.2	63.4	28.5	2.2	3.8	2.8	22.8
Type 1 (juvenile)	23,706	5.3	48	53.1	72.8	22.3	1.3	1.9	12.3	16.5
Type 2 (adult-onset or unspecified)	174,691	39.3	65	48.6	62.1	29.3	2.3	4.0	1.5	23.7
Glomerulonephritis (GN)	41,218	9.3	53	60.9	66.1	24.6	1.2	5.7	12.1	12.9
Focal glomerulosclerosis, focal GN	10,340	2.3	49	60.2	58.2	36.5	0.8	2.9	13.9	10.0
Membranous nephropathy	2,108	0.5	59	67.2	69.4	25.5	0.9	2.7	11.6	12.6
Membranoproliferative GN, types 1 & 2	1,682	0.4	49	59.2	71.2	19.1	2.0	5.1	16.8	11.3
IgA nephropathy, Berger's disease	3,409	0.8	42	67.7	75.0	7.2	1.9	13.1	28.7	4.9
IgM nephropathy	367	0.1	47	64.6	76.3	9.5	1.4	12.0	26.7	6.3
Rapidly progressive GN	1,682	0.4	62	51.5	79.0	13.8	2.1	2.9	5.8	19.7
Goodpasture's Syndrome	560	0.1	55	47.5	89.6	7.0	1.1	1.4	6.8	17.7
Post-infectious GN, SBE	405	0.1	54	67.7	79.8	13.6	2.5	3.5	10.9	17.5
Glomerulonephritis	19,410	4.4	58	61.0	65.2	23.9	1.2	6.8	8.2	15.3
Other proliferative GN	1,255	0.3	54	54.3	71.6	20.4	1.4	3.4	12.3	12.8
Secondary GN/vasculitis	10,183	2.3	47	31.6	61.2	32.0	1.2	3.3	7.4	18.6
Lupus erythematosus (SLE nephritis)	5,111	1.1	38	17.7	43.3	47.6	1.1	4.7	9.2	12.4
Polyarteritis	272	0.1	65	52.2	79.4	14.3	1.8	2.9	4.0	23.9
Wegener's granulomatosis	1,191	0.3	64	58.2	90.8	6.4	0.7	1.2	5.7	21.7
Henoch-Schonlein syndrome	161	.	31	50.9	82.6	9.3	1.2	3.1	23.0	6.8
Vasculitis and its derivatives	1,115	0.3	68	45.2	85.5	8.7	2.8	1.8	2.8	27.4
Scleroderma	850	0.2	56	22.5	77.9	18.5	1.1	1.4	2.8	37.6
Hemolytic uremic syndrome	771	0.2	45	33.7	76.1	20.0	1.0	1.4	10.8	18.7
Nephropathy from heroin/related abuse	243	0.1	45	73.3	34.2	62.6	.	1.6	2.5	15.2
Secondary GN, other	469	0.1	54	56.9	63.5	29.6	1.5	3.6	4.7	24.9
Interstitial nephritis/pyelonephritis	16,968	3.8	65	56.3	80.4	14.9	0.6	2.5	7.5	22.9
Chronic pyelonephritis, reflux nephritis	2,342	0.5	45	39.2	86.0	8.8	1.0	2.1	22.2	11.4
Analgesic abuse	977	0.2	67	38.8	78.4	17.4	0.8	2.4	4.9	20.2
Nephropathy caused by other agents	2,554	0.6	62	57.6	81.0	16.0	0.4	1.4	6.3	27.8
Nephrolithiasis, obstruction, gouty	5,750	1.3	69	72.4	78.0	16.6	0.5	3.1	2.5	26.4
Nephrocalcinosis	310	0.1	67	50.6	81.3	13.5	.	2.6	8.7	20.3
Chronic interstitial nephritis	4,194	0.9	65	48.6	79.7	15.4	0.7	2.7	8.3	20.8
Acute interstitial nephritis	841	0.2	69	50.7	84.3	13.0	0.4	1.2	2.7	30.6
Hypertensive/large vessel disease	118,463	26.7	70	56.4	57.9	37.0	0.5	3.2	1.8	26.2
Hypertension (no primary renal disease)	105,088	23.6	69	56.2	53.5	41.1	0.6	3.4	2.0	24.9
Renal artery stenosis or occlusion	9,010	2.0	74	54.3	91.7	6.0	0.4	1.4	0.6	36.8
Cholesterol emboli, renal emboli	4,365	1.0	73	66.0	94.4	3.1	0.5	1.4	0.5	36.3
Cystic/hereditary/congenital diseases	14,509	3.3	50	56.6	81.2	13.3	0.7	2.5	24.7	6.5
Polycystic kidneys, adult (dominant)	10,227	2.3	54	53.4	82.2	13.1	0.5	2.5	20.6	6.5
Polycystic kidneys, infantile (recessive)	238	0.1	17	47.9	82.8	10.1	0.8	1.3	40.8	8.0
Medullary cystic, including nephronophthisis	204	.	25	47.5	83.3	8.3	1.5	4.4	45.1	2.5
Alport's, other hereditary/familial disease	1,067	0.2	36	64.9	85.6	8.3	0.9	3.2	33.2	2.9
Tuberous sclerosis	141	.	56	48.9	75.9	18.4	0.7	2.1	12.1	22.0
Cystinosis	65	.	15	47.7	81.5	10.8	1.5	3.1	50.8	9.2
Primary oxalosis	48	.	46	37.5	81.3	4.2	4.2	4.2	29.2	6.3
Fabry's disease	78	.	43	88.5	89.7	5.1	2.6	.	20.5	9.0
Congenital nephrotic syndrome	268	0.1	23	60.1	69.4	19.0	1.1	3.4	28.0	10.4
Drash syndrome, mesangial sclerosis	33	.	35	54.5	78.8	6.1	.	6.1	21.2	15.2
Congenital obstructive uropathy	1,183	0.3	22	75.4	77.1	16.5	0.8	2.5	34.4	7.9
Renal hypoplasia, dysplasia	839	0.2	13	56.6	73.9	16.8	1.4	2.5	38.6	5.0
Prune belly syndrome	118	.	12	97.5	73.7	23.7	0.8	.	39.0	6.8
Neoplasms/tumors	8,769	2.0	69	60.8	77.5	19.2	0.7	1.5	0.9	49.7
Renal or urological neoplasms	2,532	0.6	70	73.0	79.7	17.3	0.7	1.0	1.3	39.7
Multiple myeloma	4,496	1.0	69	55.0	74.5	22.0	0.5	1.8	.	58.3
Light chain nephropathy	575	0.1	70	59.3	80.0	17.0	1.0	1.6	1.6	43.3
Amyloidosis	1,166	0.3	67	57.2	82.8	13.8	0.9	1.1	2.7	40.8
Miscellaneous conditions	18,096	4.1	58	62.2	61.3	35.1	0.5	1.5	3.4	35.8
Complication post-bone marrow/other tx	550	0.1	55	64.0	87.3	8.4	0.5	2.2	15.6	23.3
Sickle cell disease/anemia or trait	516	0.1	41	51.4	3.9	95.2	.	0.8	3.1	25.8
AIDS nephropathy	4,218	0.9	40	69.5	7.0	90.2	0.4	0.2	.	32.7
Traumatic/surgical loss of kidney(s)	494	0.1	67	66.0	81.2	16.8	0.2	1.2	4.0	26.1
Hepatorenal syndrome	864	0.2	54	68.2	78.9	13.8	2.1	2.9	11.8	57.2
Tubular necrosis (no recovery)	6,376	1.4	70	58.9	81.9	15.0	0.5	1.3	0.8	39.4
Post-partum failure, other renal disorders	5,078	1.1	66	59.8	78.5	16.8	0.5	2.6	6.7	33.5
Etiology uncertain	17,862	4.0	68	57.9	70.8	22.3	0.8	3.5	4.8	28.9
Missing	7,561	1.7	50	55.4	63.3	24.7	0.6	3.6	56.0	15.7

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

"." Zero values in this cell.

Table A.11

**Incidence of Reported ESRD: All Patients, Column Percent**

1997-2001 combined, by detailed primary diagnosis

	Total Patients	Counts					Percent			
		White	Black	N Am	Asian	White	Black	N Am	Asian	
All ESRD (reference)	452,026	288,530	132,076	6,250	16,011	100.0	100.0	100.0	100.0	
Diabetes	198,397	125,712	56,495	4,411	7,472	44.3	43.4	71.1	47.5	
Type 1, juvenile type	23,706	17,258	5,281	312	457	6.1	4.1	5.0	2.9	
Type 2, adult-onset or unspecified type	174,691	108,454	51,214	4,099	7,015	38.2	39.3	66.1	44.6	
Glomerulonephritis	41,218	27,232	10,126	511	2,352	9.6	7.8	8.2	14.9	
Focal glomerulosclerosis, focal GN	10,340	6,017	3,777	83	296	2.1	2.9	1.3	1.9	
Membranous nephropathy	2,108	1,463	537	19	57	0.5	0.4	0.3	0.4	
Membranoproliferative GN, types 1&2	1,682	1,198	321	33	85	0.4	0.2	0.5	0.5	
IgA nephropathy, Berger's disease	3,409	2,556	244	66	445	0.9	0.2	1.1	2.8	
IgM nephropathy	367	280	35	*	44	0.1	.	0.1	0.3	
Rapidly progressive GN	1,682	1,329	232	35	48	0.5	0.2	0.6	0.3	
Goodpasture's Syndrome	560	502	39	*	*	0.2	.	0.1	0.1	
Post infectious GN, SBE	405	323	55	10	14	0.1	.	0.2	0.1	
Glomerulonephritis (GN)	19,410	12,665	4,630	236	1,312	4.5	3.6	3.8	8.3	
Other proliferative GN	1,255	899	256	18	43	0.3	0.2	0.3	0.3	
Secondary GN/vasculitis	10,183	6,228	3,262	125	331	2.2	2.5	2.0	2.1	
Lupus erythematosus (SLE nephritis)	5,111	2,215	2,433	55	240	0.8	1.9	0.9	1.5	
Polyarteritis	272	216	39	*	*	0.1	.	0.1	0.1	
Wegener's granulomatosis	1,191	1,081	76	*	14	0.4	0.1	0.1	0.1	
Henoch-Schonlein syndrome	161	133	15	*	*	.	.	.	.	
Vasculitis and its derivatives	1,115	953	97	31	20	0.3	0.1	0.5	0.1	
Scleroderma	850	662	157	*	12	0.2	0.1	0.1	0.1	
Hemolytic uremic syndrome	771	587	154	*	11	0.2	0.1	0.1	0.1	
Nephropathy from heroin /related abuse	243	83	152	.	*	.	0.1	.	.	
Secondary GN, other	469	298	139	*	17	0.1	0.1	0.1	0.1	
Interstitial nephritis/pyelonephritis	16,968	13,638	2,534	104	418	4.8	1.9	1.7	2.7	
Chronic pyelonephritis, reflux neph.	2,342	2,014	207	23	50	0.7	0.2	0.4	0.3	
Analgesic abuse	977	766	170	*	23	0.3	0.1	0.1	0.1	
Nephropathy caused by other agents	2,554	2,069	408	*	35	0.7	0.3	0.1	0.2	
Nephrolithiasis, obstruction, gouty	5,750	4,485	952	31	178	1.6	0.7	0.5	1.1	
Nephrocalcinosis	310	252	42	.	*	0.1	.	.	0.1	
Chronic interstitial nephritis	4,194	3,343	646	30	114	1.2	0.5	0.5	0.7	
Acute interstitial nephritis	841	709	109	*	10	0.2	0.1	.	0.1	
Hypertensive/large vessel disease	118,463	68,617	43,840	649	3,782	24.2	33.7	10.5	24.0	
Hypertension (no primary renal disease)	105,088	56,237	43,161	588	3,598	19.8	33.1	9.5	22.9	
Renal artery stenosis or occlusion	9,010	8,259	544	38	123	2.9	0.4	0.6	0.8	
Cholesterol emboli, renal emboli	4,365	4,121	135	23	61	1.5	0.1	0.4	0.4	
Cystic/hereditary/congenital diseases	14,509	11,782	1,930	97	365	4.2	1.5	1.6	2.3	
Polycystic kidneys, adult (dominant)	10,227	8,402	1,344	51	251	3.0	1.0	0.8	1.6	
Polycystic kidneys, infantile (recessive)	238	197	24	*	*	0.1	.	.	.	
Medullary cystic, including nephronophthisis	204	170	17	*	*	0.1	.	.	0.1	
Alport's, other hereditary/familial disease	1,067	913	89	10	34	0.3	0.1	0.2	0.2	
Tuberous sclerosis	141	107	26	*	*	.	.	.	.	
Cystinosis	65	53	*	*	*	.	.	.	.	
Primary oxalosis	48	39	*	*	*	.	.	.	.	
Fabry's disease	78	70	*	*	.	.	.	.	.	
Congenital nephrotic syndrome	268	186	51	*	*	0.1	.	.	0.1	
Drash syndrome, mesangial sclerosis	33	26	*	.	*	.	.	.	.	
Congenital obstructive uropathy	1,183	912	195	*	29	0.3	0.1	0.1	0.2	
Renal hypoplasia, dysplasia	839	620	141	12	21	0.2	0.1	0.2	0.1	
Prune belly syndrome	118	87	28	*	.	.	.	.	.	
Neoplasms/tumors	8,769	6,794	1,684	57	129	2.4	1.3	0.9	0.8	
Renal or urological neoplasms	2,532	2,018	438	17	25	0.7	0.3	0.3	0.2	
Multiple myeloma	4,496	3,351	987	24	82	1.2	0.8	0.4	0.5	
Light chain nephropathy	575	460	98	*	*	0.2	0.1	0.1	0.1	
Amyloidosis	1,166	965	161	10	13	0.3	0.1	0.2	0.1	
Miscellaneous conditions	18,096	11,091	6,353	96	268	3.9	4.9	1.5	1.7	
Complication post bone marrow/other txp	550	480	46	*	12	0.2	.	.	0.1	
Sickle cell disease/anemia or trait	516	20	491	.	*	.	0.4	.	.	
AIDS nephropathy	4,218	297	3,804	15	*	0.1	2.9	0.2	0.1	
Traumatic/surgical loss of kidney(s)	494	401	83	*	*	0.1	0.1	.	.	
Hepatorenal syndrome	864	682	119	18	25	0.2	0.1	0.3	0.2	
Tubular necrosis (no recovery)	6,376	5,223	957	32	82	1.8	0.7	0.5	0.5	
Post-partum failure, other renal disorders	5,078	3,988	853	27	130	1.4	0.7	0.4	0.8	
Etiology uncertain	17,862	12,649	3,988	151	619	4.5	3.1	2.4	3.9	
Missing	7,561	4,787	1,864	49	275	1.7	1.4	0.8	1.7	

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

\*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.12

**Incidence of Reported ESRD: Hispanics, Row Percent**

1997-2001 combined, by detailed primary diagnosis

	Total Patients	Percent Incident	Median Age	Percent Males	Percent White	Black	N Am	Asian	% Tx 1st yr	% Died 1st yr
All ESRD (reference)	53,528	100.0	60	53.3	81.5	3.9	1.1	1.7	4.1	17.8
Diabetes	31,885	60.3	62	50.4	83.9	3.3	1.0	1.4	1.3	18.7
Type 1, juvenile type	2,446	4.6	50	52.5	80.8	3.6	1.2	1.3	5.6	16.0
Type 2, adult-onset or unspecified type	29,439	55.7	62	50.2	84.2	3.3	1.0	1.4	0.9	18.9
Glomerulonephritis	4,547	8.6	43	59.6	77.3	4.3	1.0	2.0	11.2	8.0
Focal glomerulosclerosis, focal GN	866	1.6	40	59.4	78.6	5.7	1.5	1.4	16.2	5.7
Membranous nephropathy	170	0.3	52	67.6	78.8	4.7	1.2	1.2	10.6	7.6
Membranoproliferative GN, types 1&2	192	0.4	42	60.4	77.1	4.2	0.5	2.6	14.6	9.4
IgA nephropathy, Berger's disease	403	0.8	37	56.1	79.2	1.7	1.7	3.5	17.4	3.7
IgM nephropathy	34	0.1	42	50.0	82.4	2.9	2.9	8.8	14.7	2.9
Rapidly progressive GN	176	0.3	47	44.9	73.9	5.1	1.7	1.1	5.1	13.1
Goodpasture's Syndrome	37	0.1	39	24.3	89.2	.	.	.	13.5	10.8
Post infectious GN, SBE	46	0.1	48	58.7	91.3	2.2	.	2.2	10.9	13.0
Glomerulonephritis (GN)	2,492	4.7	45	61.7	76.6	4.3	0.7	1.9	8.6	9.1
Other proliferative GN	131	0.2	39	53.4	67.2	3.8	0.8	3.1	9.9	6.9
Secondary GN/vasculitis	1,226	2.3	36	26.0	79.0	3.3	1.5	1.3	7.3	11.4
Lupus erythematosus (SLE nephritis)	827	1.6	32	17.4	77.4	3.4	1.1	1.5	8.5	8.8
Polyarteritis	26	.	58	42.3	80.8	.	3.8	.	11.5	3.8
Wegener's granulomatosis	87	0.2	56	59.8	85.1	3.4	2.3	.	5.7	16.1
Henoch-Schonlein syndrome	15	.	19	40.0	80.0	.	.	.	26.7	.
Vasculitis and its derivatives	95	0.2	55	40.0	88.4	2.1	1.1	1.1	2.1	22.1
Scleroderma	60	0.1	51	18.3	85.0	3.3	.	.	5.0	23.3
Hemolytic uremic syndrome	51	0.1	41	31.4	72.5	3.9	7.8	2.0	5.9	13.7
Nephropathy from heroin /related abuse	27	0.1	39	77.8	74.1	7.4	.	3.7	.	11.1
Secondary GN, other	38	0.1	48	52.6	76.3	2.6	2.6	2.6	.	18.4
Interstitial nephritis/pyelonephritis	1,239	2.3	59	60.0	78.5	4.4	0.6	1.9	6.1	20.7
Chronic pyelonephritis, reflux neph.	194	0.4	31	41.2	82.0	3.1	0.5	1.0	14.9	9.3
Analgesic abuse	58	0.1	66	44.8	79.3	1.7	.	8.6	3.4	17.2
Nephropathy caused by other agents	128	0.2	58	60.2	75.0	3.9	.	2.3	4.7	33.6
Nephrolithiasis, obstruction, gouty	527	1.0	65	72.9	78.0	6.1	0.6	1.9	1.5	24.5
Nephrocalcinosis	15	.	58	40.0	60.0	.	.	13.3	6.7	26.7
Chronic interstitial nephritis	256	0.5	57	52.7	78.1	3.9	0.8	0.8	11.3	13.7
Acute interstitial nephritis	61	0.1	59	57.4	83.6	1.6	1.6	.	.	29.5
Hypertensive/large vessel disease	8,940	16.9	65	59.0	78.7	5.6	1.4	2.5	2.6	19.7
Hypertension (no primary renal disease)	8,531	16.1	65	59.2	78.5	5.8	1.3	2.5	2.7	19.1
Renal artery stenosis or occlusion	298	0.6	72	50.3	83.9	2.3	2.3	3.4	0.3	32.9
Cholesterol emboli, renal emboli	111	0.2	73	67.6	78.4	2.7	4.5	1.8	0.9	33.3
Cystic/hereditary/congenital diseases	1,416	2.7	44	56.1	80.5	3.7	1.0	1.4	15.0	5.3
Polycystic kidneys, adult (dominant)	852	1.6	51	52.7	81.6	3.9	1.1	1.4	9.5	5.2
Polycystic kidneys, infantile (recessive)	41	0.1	8	43.9	90.2	2.4	.	.	19.5	12.2
Medullary cystic, including nephronophthisis	15	.	24	60.0	80.0	.	.	6.7	20.0	6.7
Alport's, other hereditary/familial disease	106	0.2	24	65.1	83.0	2.8	0.9	1.9	24.5	1.9
Tuberous sclerosis	11	.	66	54.5	72.7	18.2	.	.	9.1	27.3
Cystinosis	*	.	32	66.7	33.3	.	.	.	33.3	33.3
Primary oxalosis	*	.	19	33.3	100.0	.	.	.	33.3	.
Fabry's disease	11	.	37	81.8	72.7	.	9.1	.	9.1	18.2
Congenital nephrotic syndrome	37	0.1	6	56.8	64.9	5.4	.	.	18.9	10.8
Drash syndrome, mesangial sclerosis	*	.	23	50.0	37.5	12.5	.	12.5	25.0	12.5
Congenital obstructive uropathy	144	0.3	17	74.3	78.5	4.9	0.7	1.4	27.1	4.2
Renal hypoplasia, dysplasia	168	0.3	12	49.4	80.4	1.2	0.6	1.2	20.2	3.6
Prune belly syndrome	17	.	12	100.0	76.5	11.8	5.9	.	52.9	.
Neoplasms/tumors	520	1.0	66	60.8	81.2	4.4	2.5	0.6	1.5	46.3
Renal or urological neoplasms	157	0.3	67	72.6	73.9	5.1	1.3	1.9	1.3	42.7
Multiple myeloma	251	0.5	66	55.0	84.1	4.0	2.0	.	0.4	57.0
Light chain nephropathy	25	.	58	44.0	80.0	8.0	12.0	.	.	36.0
Amyloidosis	87	0.2	63	60.9	86.2	3.4	3.4	.	5.7	25.3
Miscellaneous conditions	1,169	2.2	53	64.0	71.9	6.5	1.1	2.3	5.1	32.6
Complication post bone marrow/other txp	26	.	41	57.7	73.1	3.8	.	.	23.1	11.5
Sickle cell disease/anemia or trait	13	.	41	61.5	76.9	23.1	.	.	7.7	15.4
AIDS nephropathy	245	0.5	39	73.9	50.6	13.9	0.4	1.6	.	34.3
Traumatic/surgical loss of kidney(s)	26	.	61	46.2	80.8	11.5	.	3.8	3.8	15.4
Hepatorenal syndrome	118	0.2	53	72.9	77.1	3.4	1.7	4.2	20.3	46.6
Tubular necrosis (no recovery)	377	0.7	65	65.3	76.9	4.5	1.6	1.1	1.1	36.9
Post-partum failure, other renal disorders	364	0.7	58	54.9	78.6	3.8	1.1	3.6	6.6	25.8
Etiology uncertain	1,899	3.6	49	61.2	77.3	4.0	1.3	1.4	6.3	15.9
Missing	687	1.3	40	56.3	76.6	3.8	0.7	1.7	70.7	4.8

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

\*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.13

**Incidence of Reported ESRD: Hispanics, Column Percent**

1997-2001 combined, by primary diagnosis

	Total Patients	Counts				Percent			
		White	Black	N Am	Asian	White	Black	N Am	Asian
All ESRD (reference)	53,528	43,638	2,114	576	886	100.0	100.0	100.0	100.0
Diabetes	31,885	26,752	1,068	314	443	62.1	51.1	55.0	50.7
Type 1, juvenile type	2,446	1,977	88	29	32	4.6	4.2	5.1	3.7
Type 2, adult-onset or unspecified type	29,439	24,775	980	285	411	57.5	46.9	49.9	47.0
Glomerulonephritis	4,547	3,513	194	46	91	8.1	9.3	8.1	10.4
Focal glomerulosclerosis, focal GN	866	681	49	13	12	1.6	2.3	2.3	1.4
Membranous nephropathy	170	134	*	*	*	0.3	0.4	0.4	0.2
Membranoproliferative GN, types 1&2	192	148	*	*	*	0.3	0.4	0.2	0.6
IgA nephropathy, Berger's disease	403	319	*	*	14	0.7	0.3	1.2	1.6
IgM nephropathy	34	28	*	*	*	0.1	.	0.2	0.3
Rapidly progressive GN	176	130	*	*	*	0.3	0.4	0.5	0.2
Goodpasture's Syndrome	37	33	.	.	.	0.1	.	.	.
Post infectious GN, SBE	46	42	*	.	*	0.1	.	.	0.1
Glomerulonephritis (GN)	2,492	1,910	106	18	48	4.4	5.1	3.2	5.5
Other proliferative GN	131	88	*	*	*	0.2	0.2	0.2	0.5
Secondary GN/vasculitis	1,226	968	40	18	16	2.2	1.9	3.2	1.8
Lupus erythematosus (SLE nephritis)	827	640	28	*	12	1.5	1.3	1.6	1.4
Polyarteritis	26	21	.	*	.	.	.	0.2	.
Wegener's granulomatosis	87	74	*	*	.	0.2	0.1	0.4	.
Henoch-Schonlein syndrome	15	12	.	.	.	.	.	.	.
Vasculitis and its derivatives	95	84	*	*	*	0.2	0.1	0.2	0.1
Scleroderma	60	51	*	.	.	0.1	0.1	.	.
Hemolytic uremic syndrome	51	37	*	*	*	0.1	0.1	0.7	0.1
Nephropathy from heroin /related abuse	27	20	*	.	*	.	0.1	.	0.1
Secondary GN, other	38	29	*	*	*	0.1	.	0.2	0.1
Interstitial nephritis/pyelonephritis	1,239	972	55	*	24	2.3	2.6	1.2	2.7
Chronic pyelonephritis, reflux neph.	194	159	*	*	*	0.4	0.3	0.2	0.2
Analgesic abuse	58	46	*	.	*	0.1	.	.	0.6
Nephropathy caused by other agents	128	96	*	.	*	0.2	0.2	.	0.3
Nephrolithiasis, obstruction, gouty	527	411	32	*	10	1.0	1.5	0.5	1.1
Nephrocalcinosis	15	*	.	.	*	.	.	.	0.2
Chronic interstitial nephritis	256	200	10	*	*	0.5	0.5	0.4	0.2
Acute interstitial nephritis	61	51	*	*	.	0.1	.	0.2	.
Hypertensive/large vessel disease	8,940	7,037	503	122	224	16.3	24.1	21.4	25.6
Hypertension (no primary renal disease)	8,531	6,700	493	110	212	15.5	23.6	19.3	24.3
Renal artery stenosis or occlusion	298	250	*	*	10	0.6	0.3	1.2	1.1
Cholesterol emboli, renal emboli	111	87	*	*	*	0.2	0.1	0.9	0.2
Cystic/hereditary/congenital diseases	1,416	1,140	53	14	20	2.6	2.5	2.5	2.3
Polycystic kidneys, adult (dominant)	852	695	33	*	12	1.6	1.6	1.6	1.4
Polycystic kidneys, infantile (recessive)	41	37	*	.	.	0.1	.	.	.
Medullary cystic, including nephronophthisis	15	12	.	.	*	.	.	.	0.1
Alport's, other hereditary/familial disease	106	88	*	*	*	0.2	0.1	0.2	0.2
Tuberous sclerosis	11	*	*	.	.	.	0.1	.	.
Cystinosis	*	*	.	.	.	.	.	.	.
Primary oxalosis	*	*	.	.	.	.	.	.	.
Fabry's disease	11	*	.	*	.	.	.	0.2	.
Congenital nephrotic syndrome	37	24	*	.	.	0.1	0.1	.	.
Drash syndrome, mesangial sclerosis	*	*	*	.	*	.	.	.	0.1
Congenital obstructive uropathy	144	113	*	*	*	0.3	0.3	0.2	0.2
Renal hypoplasia, dysplasia	168	135	*	*	*	0.3	0.1	0.2	0.2
Prune belly syndrome	17	13	*	*	.	.	0.1	0.2	.
Neoplasms/tumors	520	422	23	13	*	1.0	1.1	2.3	0.3
Renal or urological neoplasms	157	116	*	*	*	0.3	0.4	0.4	0.3
Multiple myeloma	251	211	10	*	.	0.5	0.5	0.9	.
Light chain nephropathy	25	20	*	*	.	.	0.1	0.5	.
Amyloidosis	87	75	*	*	.	0.2	0.1	0.5	.
Miscellaneous conditions	1,169	841	76	13	27	2.0	3.6	2.3	3.1
Complication post bone marrow/other txp	26	19	*	.	.	.	.	.	.
Sickle cell disease/anemia or trait	13	10	*	.	.	.	0.1	.	.
AIDS nephropathy	245	124	34	*	*	0.3	1.6	0.2	0.5
Traumatic/surgical loss of kidney(s)	26	21	*	.	*	.	0.1	.	0.1
Hepatorenal syndrome	118	91	*	*	*	0.2	0.2	0.4	0.6
Tubular necrosis (no recovery)	377	290	17	*	*	0.7	0.8	1.1	0.5
Post-partum failure, other renal disorders	364	286	14	*	13	0.7	0.7	0.7	1.5
Etiology uncertain	1,899	1,467	76	24	26	3.4	3.6	4.2	3.0
Missing	687	526	26	*	12	1.2	1.2	.	1.4

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

\*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

Table A.14

**Incidence of Reported ESRD: Non-Hispanics, Row Percent**

1997-2001 combined, by detailed primary diagnosis

	Total Patients	Percent Incident	Median Age	Percent Males	Percent White	Black	N Am	Asian	% Tx 1st yr	% Died 1st yr
All ESRD (reference)	398,498	100.0	64	53.5	61.5	32.6	1.4	3.8	5.5	24.1
Diabetes	166,512	42.5	64	48.9	59.4	33.3	2.5	4.2	3.1	23.6
Type 1, juvenile type	21,260	5.4	48	53.1	71.9	24.4	1.3	2.0	13.1	16.5
Type 2, adult-onset or unspecified type	145,252	37.1	65	48.3	57.6	34.6	2.6	4.5	1.6	24.6
Glomerulonephritis	36,671	9.4	55	61.1	64.7	27.1	1.3	6.2	12.2	13.5
Focal glomerulosclerosis, focal GN	9,474	2.4	49	60.2	56.3	39.3	0.7	3.0	13.7	10.4
Membranous nephropathy	1,938	0.5	59	67.2	68.6	27.3	0.9	2.8	11.7	13.1
Membranoproliferative GN, types 1&2	1,490	0.4	49	59.1	70.5	21.0	2.1	5.4	17.0	11.5
IgA nephropathy, Berger's disease	3,006	0.8	42	69.2	74.4	7.9	2.0	14.3	30.3	5.1
IgM nephropathy	333	0.1	47	66.1	75.7	10.2	1.2	12.3	27.9	6.6
Rapidly progressive GN	1,506	0.4	64	52.3	79.6	14.8	2.1	3.1	5.9	20.5
Goodpasture's Syndrome	523	0.1	56	49.1	89.7	7.5	1.1	1.5	6.3	18.2
Post infectious GN, SBE	359	0.1	55	68.8	78.3	15.0	2.8	3.6	10.9	18.1
Glomerulonephritis (GN)	16,918	4.3	60	60.9	63.6	26.7	1.3	7.5	8.2	16.2
Other proliferative GN	1,124	0.3	55	54.4	72.2	22.3	1.5	3.5	12.5	13.5
Secondary GN/vasculitis	8,957	2.3	48	32.4	58.7	36.0	1.2	3.5	7.4	19.6
Lupus erythematosus (SLE nephritis)	4,284	1.1	39	17.8	36.8	56.1	1.1	5.3	9.3	13.1
Polyarteritis	246	0.1	66	53.3	79.3	15.9	1.6	3.3	3.3	26.0
Wegener's granulomatosis	1,104	0.3	65	58.1	91.2	6.6	0.5	1.3	5.7	22.1
Henoch-Schonlein syndrome	146	.	32	52.1	82.9	10.3	1.4	3.4	22.6	7.5
Vasculitis and its derivatives	1,020	0.3	69	45.7	85.2	9.3	2.9	1.9	2.8	27.9
Scleroderma	790	0.2	57	22.8	77.3	19.6	1.1	1.5	2.7	38.7
Hemolytic uremic syndrome	720	0.2	46	33.9	76.4	21.1	0.6	1.4	11.1	19.0
Nephropathy from heroin /related abuse	216	0.1	45	72.7	29.2	69.4	.	1.4	2.8	15.7
Secondary GN, other	431	0.1	54	57.3	62.4	32.0	1.4	3.7	5.1	25.5
Interstitial nephritis/pyelonephritis	15,729	4.0	65	56.0	80.5	15.8	0.6	2.5	7.6	23.1
Chronic pyelonephritis, reflux neph.	2,148	0.5	47	39.1	86.4	9.4	1.0	2.2	22.8	11.6
Analgesic abuse	919	0.2	67	38.4	78.3	18.4	0.9	2.0	5.0	20.3
Nephropathy caused by other agents	2,426	0.6	62	57.4	81.3	16.6	0.4	1.3	6.4	27.5
Nephrolithiasis, obstruction, gouty	5,223	1.3	70	72.4	78.0	17.6	0.5	3.2	2.6	26.6
Nephrocalcinosis	295	0.1	67	51.2	82.4	14.2	.	2.0	8.8	20.0
Chronic interstitial nephritis	3,938	1.0	65	48.3	79.8	16.2	0.7	2.8	8.1	21.3
Acute interstitial nephritis	780	0.2	69	50.1	84.4	13.8	0.3	1.3	2.9	30.6
Hypertensive/large vessel disease	109,523	28.0	70	56.2	56.2	39.6	0.5	3.2	1.8	26.8
Hypertension (no primary renal disease)	96,557	24.7	70	56.0	51.3	44.2	0.5	3.5	1.9	25.4
Renal artery stenosis or occlusion	8,712	2.2	74	54.4	91.9	6.2	0.4	1.3	0.6	36.9
Cholesterol emboli, renal emboli	4,254	1.1	73	66.0	94.8	3.1	0.4	1.4	0.5	36.4
Cystic/hereditary/congenital diseases	13,093	3.3	51	56.6	81.3	14.3	0.6	2.6	25.8	6.6
Polycystic kidneys, adult (dominant)	9,375	2.4	54	53.4	82.2	14.0	0.4	2.5	21.6	6.6
Polycystic kidneys, infantile (recessive)	197	0.1	21	48.7	81.2	11.7	1.0	1.5	45.2	7.1
Medullary cystic, including nephronophthisis	189	.	25	46.6	83.6	9.0	1.6	4.2	47.1	2.1
Alport's, other hereditary/familial disease	961	0.2	38	64.9	85.8	8.9	0.9	3.3	34.1	3.0
Tuberous sclerosis	130	.	56	48.5	76.2	18.5	0.8	2.3	12.3	21.5
Cystinosis	62	.	15	46.8	83.9	11.3	1.6	3.2	51.6	8.1
Primary oxalosis	45	.	47	37.8	80.0	4.4	4.4	4.4	28.9	6.7
Fabry's disease	67	.	44	89.6	92.5	6.0	1.5	.	22.4	7.5
Congenital nephrotic syndrome	231	0.1	27	60.6	70.1	21.2	1.3	3.9	29.4	10.4
Drash syndrome, mesangial sclerosis	25	.	35	56.0	92.0	4.0	.	4.0	20.0	16.0
Congenital obstructive uropathy	1,039	0.3	23	75.6	76.9	18.1	0.8	2.6	35.4	8.4
Renal hypoplasia, dysplasia	671	0.2	14	58.4	72.3	20.7	1.6	2.8	43.2	5.4
Prune belly syndrome	101	.	12	97.0	73.3	25.7	.	.	36.6	7.9
Neoplasms/tumors	8,249	2.1	69	60.8	77.2	20.1	0.5	1.5	0.8	49.9
Renal or urological neoplasms	2,375	0.6	70	73.1	80.1	18.1	0.6	0.9	1.3	39.5
Multiple myeloma	4,245	1.1	70	55.0	74.0	23.0	0.4	1.9	.	58.4
Light chain nephropathy	550	0.1	71	60.0	80.0	17.5	0.5	1.6	1.6	43.6
Amyloidosis	1,079	0.3	67	56.9	82.5	14.6	0.6	1.2	2.5	42.1
Miscellaneous conditions	16,927	4.3	59	62.1	60.6	37.1	0.5	1.4	3.3	36.0
Complication post bone marrow/other txp	524	0.1	56	64.3	88.0	8.6	0.6	2.3	15.3	23.9
Sickle cell disease/anemia or trait	503	0.1	41	51.1	2.0	97.0	.	0.8	3.0	26.0
AIDS nephropathy	3,973	1.0	40	69.2	4.4	94.9	0.4	0.1	.	32.6
Traumatic/surgical loss of kidney(s)	468	0.1	67	67.1	81.2	17.1	0.2	1.1	4.1	26.7
Hepatorenal syndrome	746	0.2	54	67.4	79.2	15.4	2.1	2.7	10.5	58.8
Tubular necrosis (no recovery)	5,999	1.5	70	58.5	82.2	15.7	0.4	1.3	0.7	39.5
Post-partum failure, other renal disorders	4,714	1.2	67	60.2	78.5	17.8	0.5	2.5	6.7	34.1
Etiology uncertain	15,963	4.1	69	57.5	70.0	24.5	0.8	3.7	4.6	30.5
Missing	6,874	1.7	50	55.3	62.0	26.7	0.6	3.8	54.6	16.8

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

"." Zero values in this cell.

Table A.15

**Incidence of Reported ESRD: Non-Hispanics, Column Percent**

1997-2001 combined, by detailed primary diagnosis

	Total Patients	Counts				Percent			
		White	Black	N Am	Asian	White	Black	N Am	Asian
All ESRD (reference)	398,498	244,892	129,962	5,674	15,125	100.0	100.0	100.0	100.0
Diabetes	166,512	98,960	55,427	4,097	7,029	41.1	43.3	72.8	47.3
Type 1, juvenile type	21,260	15,281	5,193	283	425	6.4	4.1	5.0	2.9
Type 2, adult-onset or unspecified type	145,252	83,679	50,234	3,814	6,604	34.8	39.2	67.7	44.4
Glomerulonephritis	36,671	23,719	9,932	465	2,261	9.9	7.8	8.3	15.2
Focal glomerulosclerosis, focal GN	9,474	5,336	3,728	70	284	2.2	2.9	1.2	1.9
Membranous nephropathy	1,938	1,329	529	17	55	0.6	0.4	0.3	0.4
Membranoproliferative GN, types 1&2	1,490	1,050	313	32	80	0.4	0.2	0.6	0.5
IgA nephropathy, Berger's disease	3,006	2,237	237	59	431	0.9	0.2	1.0	2.9
IgM nephropathy	333	252	34	*	41	0.1	.	0.1	0.3
Rapidly progressive GN	1,506	1,199	223	32	46	0.5	0.2	0.6	0.3
Goodpasture's Syndrome	523	469	39	*	*	0.2	.	0.1	0.1
Post infectious GN, SBE	359	281	54	10	13	0.1	.	0.2	0.1
Glomerulonephritis (GN)	16,918	10,755	4,524	218	1,264	4.5	3.5	3.9	8.5
Other proliferative GN	1,124	811	251	17	39	0.3	0.2	0.3	0.3
Secondary GN/vasculitis	8,957	5,260	3,222	107	315	2.2	2.5	1.9	2.1
Lupus erythematosus (SLE nephritis)	4,284	1,575	2,405	46	228	0.7	1.9	0.8	1.5
Polyarteritis	246	195	39	*	*	0.1	.	0.1	0.1
Wegener's granulomatosis	1,104	1,007	73	*	14	0.4	0.1	0.1	0.1
Henoch-Schonlein syndrome	146	121	15	*	*	0.1	.	.	.
Vasculitis and its derivatives	1,020	869	95	30	19	0.4	0.1	0.5	0.1
Scleroderma	790	611	155	*	12	0.3	0.1	0.2	0.1
Hemolytic uremic syndrome	720	550	152	*	10	0.2	0.1	0.1	0.1
Nephropathy from heroin/related abuse	216	63	150	.	*	.	0.1	.	.
Secondary GN, other	431	269	138	*	16	0.1	0.1	0.1	0.1
Interstitial nephritis/pyelonephritis	15,729	12,666	2,479	97	394	5.3	1.9	1.7	2.7
Chronic pyelonephritis, reflux neph.	2,148	1,855	201	22	48	0.8	0.2	0.4	0.3
Analgesic abuse	919	720	169	*	18	0.3	0.1	0.1	0.1
Nephropathy caused by other agents	2,426	1,973	403	*	32	0.8	0.3	0.2	0.2
Nephrolithiasis, obstruction, gouty	5,223	4,074	920	28	168	1.7	0.7	0.5	1.1
Nephrocalcinosis	295	243	42	.	*	0.1	.	.	.
Chronic interstitial nephritis	3,938	3,143	636	28	112	1.3	0.5	0.5	0.8
Acute interstitial nephritis	780	658	108	*	10	0.3	0.1	.	0.1
Hypertensive/large vessel disease	109,523	61,580	43,337	527	3,558	25.6	33.8	9.4	23.9
Hypertension (no primary renal disease)	96,557	49,537	42,668	478	3,386	20.6	33.3	8.5	22.8
Renal artery stenosis or occlusion	8,712	8,009	537	31	113	3.3	0.4	0.6	0.8
Cholesterol emboli, renal emboli	4,254	4,034	132	18	59	1.7	0.1	0.3	0.4
Cystic/hereditary/congenital diseases	13,093	10,642	1,877	83	345	4.4	1.5	1.5	2.3
Polycystic kidneys, adult (dominant)	9,375	7,707	1,311	42	239	3.2	1.0	0.7	1.6
Polycystic kidneys, infantile (recessive)	197	160	23	*	*	0.1	.	.	.
Medullary cystic, including nephronophthisis	189	158	17	*	*	0.1	.	0.1	0.1
Alport's, other hereditary/familial disease	961	825	86	*	32	0.3	0.1	0.2	0.2
Tuberous sclerosis	130	99	24	*	*	.	.	.	.
Cystinosis	62	52	*	*	*	.	.	.	.
Primary oxalosis	45	36	*	*	*	.	.	.	.
Fabry's disease	67	62	*	*	.	.	.	.	.
Congenital nephrotic syndrome	231	162	49	*	*	0.1	.	0.1	0.1
Drash syndrome, mesangial sclerosis	25	23	*	.	*	.	.	.	.
Congenital obstructive uropathy	1,039	799	188	*	27	0.3	0.1	0.1	0.2
Renal hypoplasia, dysplasia	671	485	139	11	19	0.2	0.1	0.2	0.1
Prune belly syndrome	101	74	26	.	.	.	.	.	.
Neoplasms/tumors	8,249	6,372	1,661	44	126	2.6	1.3	0.8	0.8
Renal or urological neoplasms	2,375	1,902	430	15	22	0.8	0.3	0.3	0.1
Multiple myeloma	4,245	3,140	977	19	82	1.3	0.8	0.3	0.6
Light chain nephropathy	550	440	96	*	*	0.2	0.1	0.1	0.1
Amyloidosis	1,079	890	158	*	13	0.4	0.1	0.1	0.1
Miscellaneous conditions	16,927	10,250	6,277	83	241	4.3	4.9	1.5	1.6
Complication post bone marrow/other txp	524	461	45	*	12	0.2	.	0.1	0.1
Sickle cell disease/anemia or trait	503	10	488	.	*	.	0.4	.	.
AIDS nephropathy	3,973	173	3,770	14	*	0.1	2.9	0.2	.
Traumatic/surgical loss of kidney(s)	468	380	80	*	*	0.2	0.1	.	.
Hepatorenal syndrome	746	591	115	16	20	0.2	0.1	0.3	0.1
Tubular necrosis (no recovery)	5,999	4,933	940	26	78	2.1	0.7	0.5	0.5
Post-partum failure, other renal disorders	4,714	3,702	839	23	117	1.5	0.7	0.4	0.8
Etiology uncertain	15,963	11,182	3,912	127	593	4.6	3.1	2.3	4.0
Missing	6,874	4,261	1,838	44	263	1.7	1.4	0.8	1.7

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

\*Values for cells with fewer than 10 patients are suppressed.

." Zero values in this cell.

On our website: Incidence of Reported ESRD, by Age &amp; Detailed Primary Diagnosis; row &amp; columns percent (A.d-l).



Table A.16

**Incident Counts of Reported ESRD Patients, by Diabetic Status & State/Territory: All Patients**

ALL	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Alabama	292	344	332	368	400	526	503	550	573	672	787	906	886	1,045	1,150	1,135	1,273	1,378	1,488	1,650	1,581	1,716	1,756	1,778
Alaska	*	*	10	*	13	19	14	14	34	26	31	45	31	51	55	50	191	324	68	81	67	74	85	94
Arizona	174	210	238	250	299	373	374	428	500	547	602	684	726	825	1,009	1,032	1,101	1,205	1,300	1,379	1,532	1,660	1,691	1,761
Arkansas	85	141	134	150	175	238	253	265	283	359	382	394	412	508	527	570	695	734	723	826	764	830	857	885
California	1,550	1,761	1,847	2,279	2,431	2,878	2,955	3,264	3,709	3,925	4,394	4,961	5,547	6,096	6,227	6,657	7,684	7,971	8,546	9,150	9,931	10,503	11,016	11,375
Colorado	159	150	164	189	171	192	224	253	311	309	329	417	407	484	520	539	564	556	668	700	780	767	806	812
Connecticut	173	220	225	239	285	372	348	489	451	490	494	557	610	668	681	683	876	854	900	922	939	939	1,024	973
Delaware	40	40	44	59	79	58	68	94	90	105	129	132	140	179	205	195	222	237	223	230	241	274	283	269
District of Columbia	138	110	118	127	176	168	157	197	158	186	188	275	260	317	328	324	296	403	398	408	412	426	464	444
Florida	774	963	1,088	1,203	1,288	1,463	1,630	1,748	2,024	2,277	2,396	2,759	2,932	3,312	3,678	3,697	4,028	4,344	4,984	4,964	5,188	5,570	5,714	5,858
Georgia	401	495	478	641	628	774	793	810	938	1,075	1,183	1,380	1,431	1,715	1,905	1,889	2,182	2,294	2,494	2,507	2,665	2,953	3,141	3,214
Hawaii	89	90	83	101	103	119	124	178	174	206	211	232	275	270	289	323	406	392	383	426	447	490	523	475
Idaho	28	37	52	43	53	58	67	86	88	94	101	136	140	138	127	137	179	191	213	224	215	251	258	276
Illinois	755	748	830	978	1,126	1,275	1,322	1,517	1,645	1,741	1,780	1,964	2,304	2,692	2,755	3,114	3,456	3,512	3,684	3,802	4,089	4,336	4,331	4,300
Indiana	281	326	336	409	441	560	539	599	608	719	829	871	942	1,023	1,175	1,257	1,163	1,557	1,541	1,594	1,827	1,815	1,899	1,900
Iowa	114	157	165	188	203	239	225	262	316	280	326	381	432	460	527	527	581	536	607	610	666	805	718	738
Kansas	98	116	126	138	200	183	210	220	244	275	296	360	406	411	437	416	518	500	567	655	665	686	701	665
Kentucky	161	175	233	250	269	286	325	371	410	458	493	538	604	711	792	816	755	969	985	1,021	1,129	1,229	1,220	1,264
Louisiana	259	340	326	401	422	481	554	603	681	766	874	992	1,040	1,171	1,328	1,313	1,479	1,616	1,619	1,834	2,017	2,165	2,045	2,211
Maine	33	33	37	89	65	75	109	94	105	116	118	108	151	139	155	165	197	230	218	270	263	242	296	292
Maryland	286	296	316	389	430	461	544	586	576	748	759	948	1,059	1,206	1,287	1,334	1,368	1,775	1,881	1,895	2,068	2,134	2,201	2,219
Massachusetts	358	354	401	334	469	604	570	574	621	659	774	870	922	1,060	1,190	1,238	1,402	1,383	1,514	1,578	1,642	1,464	1,702	1,646
Michigan	519	607	647	719	798	920	1,039	1,053	1,148	1,215	1,425	1,666	1,742	1,868	2,121	2,241	2,515	2,576	2,936	2,931	3,141	3,229	3,341	3,508
Minnesota	209	223	251	270	289	314	376	414	436	515	513	568	644	713	769	795	960	844	931	1,003	1,049	1,080	1,115	1,233
Mississippi	156	206	212	200	242	337	330	358	381	419	484	535	586	655	744	775	964	912	1,015	1,082	1,129	1,202	1,144	1,229
Missouri	253	256	323	356	438	480	549	607	661	740	799	857	1,002	1,102	1,166	1,243	1,396	1,446	1,516	1,631	1,797	1,842	1,897	1,923
Montana	35	33	28	62	41	66	74	65	67	78	76	111	116	142	125	142	146	165	150	146	162	200	168	211
Nebraska	81	85	88	113	101	109	117	143	146	171	194	220	219	258	299	276	332	329	351	409	421	468	495	534
Nevada	50	56	67	75	78	108	94	128	154	155	165	183	192	246	244	281	363	355	374	410	459	561	545	608
New Hampshire	43	38	50	70	62	69	71	87	79	103	107	130	130	143	155	149	182	185	162	199	224	230	276	234
New Jersey	647	670	773	752	907	1,081	975	1,190	1,233	1,320	1,382	1,614	1,748	1,954	2,086	2,234	2,497	2,621	2,650	2,895	3,059	3,304	3,163	3,215
New Mexico	74	85	119	89	134	147	132	173	159	188	257	240	269	347	339	360	367	435	478	489	471	555	580	559
New York	1,266	1,345	1,419	1,515	1,720	1,956	2,046	2,141	2,421	2,501	2,760	3,089	3,405	3,630	4,064	4,304	5,191	5,097	5,566	5,901	6,170	6,385	6,589	6,632
North Carolina	431	452	508	483	609	703	705	878	922	1,016	1,125	1,332	1,410	1,635	1,804	1,945	2,193	2,123	2,428	2,629	2,810	2,800	3,047	3,070
North Dakota	26	38	25	40	42	41	50	50	60	74	105	97	99	126	126	152	117	134	138	139	137	163	193	193
Ohio	602	682	710	803	946	1,054	1,111	1,252	1,341	1,459	1,697	1,846	1,972	2,127	2,432	2,501	2,561	3,266	3,381	3,407	3,735	3,985	4,257	4,140
Oklahoma	171	174	195	223	242	263	301	297	351	385	470	496	583	556	653	709	747	786	819	949	1,036	1,047	1,092	1,132
Oregon	113	105	124	153	177	221	216	253	307	307	353	398	411	504	480	539	580	578	607	632	667	722	763	813
Pennsylvania	848	924	927	1,010	1,139	1,310	1,496	1,686	1,772	1,812	2,017	2,263	2,635	2,727	2,966	2,867	3,631	3,652	3,962	4,142	4,214	4,433	4,514	4,432
Rhode Island	83	77	73	76	73	106	119	124	101	115	133	168	177	203	206	229	262	234	279	269	290	285	329	317
South Carolina	200	236	268	337	368	422	456	544	563	606	702	808	896	967	1,045	1,082	1,342	1,238	1,385	1,459	1,595	1,652	1,593	1,680
South Dakota	36	42	34	58	53	53	62	68	62	89	95	86	89	101	114	128	143	183	193	199	202	220	242	220
Tennessee	238	315	329	354	414	533	471	556	586	740	748	976	988	1,160	1,218	1,184	1,466	1,493	1,556	1,703	1,778	1,963	1,902	1,833
Texas	880	1,012	1,057	1,266	1,515	1,728	1,703	1,927	2,133	2,362	2,702	3,130	3,585	3,926	4,396	4,454	4,791	4,997	5,510	5,821	6,225	6,708	6,971	7,146
Utah	49	66	87	102	80	100	146	119	131	145	186	182	179	197	197	265	249	268	265	262	344	356	338	403
Vermont	23	28	34	29	34	38	37	43	38	47	52	58	66	87	64	74	87	105	109	112	112	118	121	103
Virginia	395	477	503	517	595	737	735	760	815	929	1,017	1,120	1,199	1,455	1,585	1,577	1,683	1,970	2,128	2,343	2,335	2,462	2,305	2,495
Washington	194	204	231	239	287	334	366	397	451	478	526	653	685	749	777	813	941	963	1,001	1,052	1,095	1,248	1,337	1,305
West Virginia	89	110	117	123	156	191	215	198	232	242	296	277	300	359	384	408	443	505	544	617	655	653	705	728
Wisconsin	282	279	285	285	390	369	435	442	501	581	709	758	770	867	966	930	1,071	1,073	1,171	1,227	1,360	1,340	1,397	1,472
Wyoming	20	12	15	24	25	22	26	38	25	39	46	47	35	46	42	53	44	64	69	70	75	89	84	88
American Samoa	.	.	.	*	*	*	*	*	*	*	*	11	*	*	14	*	*	*	12	*	*	15	20	17
Guam	*	*	*	*	*	*	*	*	12	*	15	18	27	33	40	34	39	50	62	69	68	73	71	86
Puerto Rico	148	167	234	240	292	302	378	385	390	427	470	561	568	643	769	740	870	852	950	966	1,049	1,121	1,114	1,150
Saipan	.	*	.	.	.	.	.	*	*	*	*	*	*	*	*	*	11	14	17	22	15	18	18	*
Virgin Islands	*	*	*	*	12	*	*	13	*	17	14	14	18	18	24	17	22	33	32	44	43	35	32	42
Foreign	*	14	*	10	*	12	11	18	12	15	24	32	47	44	56	53	72	43	42	37	49	32	42	34
Unknown	49	84	73	80	107	134	136	164	208															

Table A.16 (continued)

## Incident Counts of Reported ESRD Patients, by Diabetic Status &amp; State/Territory: All Patients

DIABETIC	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001		
Alabama	25	29	25	39	61	87	102	116	137	180	179	249	201	311	385	365	460	532	587	717	661	764	774	817		
Alaska	*	.	*	.	*	*	*	*	11	*	*	21	10	14	16	24	57	108	32	44	30	38	36	48		
Arizona	34	37	48	42	84	118	128	135	191	213	239	303	291	380	480	483	517	628	644	731	790	850	896	924		
Arkansas	*	*	*	22	26	51	57	66	73	111	99	117	119	183	174	178	223	281	303	319	301	338	358	367		
California	90	121	191	449	586	705	800	1,015	1,177	1,214	1,367	1,813	2,004	2,305	2,373	2,417	3,035	3,360	3,747	4,262	4,543	4,851	5,222	5,217		
Colorado	24	20	24	28	41	64	71	82	123	117	136	170	162	200	213	244	226	257	329	319	376	354	391	383		
Connecticut	39	44	26	59	64	92	112	149	134	144	141	174	193	229	235	220	323	329	348	418	378	376	436	382		
Delaware	*	*	*	12	15	11	17	24	29	29	46	56	45	63	57	63	72	77	83	86	97	123	125	106		
District of Columbia	13	10	10	24	43	34	47	69	57	49	44	66	81	84	110	86	72	117	162	149	146	154	166	159		
Florida	23	42	94	188	260	283	359	420	556	607	625	748	867	978	1,127	1,090	1,288	1,346	1,832	1,891	1,953	2,187	2,300	2,405		
Georgia	44	48	47	122	150	149	191	219	266	330	309	411	474	534	648	612	756	902	1,075	1,042	1,124	1,227	1,324	1,338		
Hawaii	24	13	22	36	32	35	26	58	74	103	96	104	142	141	147	181	227	229	234	248	262	274	315	297		
Idaho	*	*	*	10	16	20	18	15	28	36	36	50	49	40	60	55	77	74	87	100	99	115	115	105		
Illinois	90	70	135	189	254	293	328	439	456	493	495	595	672	846	829	882	1,166	1,320	1,449	1,451	1,559	1,772	1,733	1,709		
Indiana	36	51	43	79	77	130	131	154	157	224	246	243	327	360	410	373	348	591	654	659	810	766	794	795		
Iowa	*	13	25	48	53	68	66	85	105	68	100	126	127	146	187	196	217	231	259	249	273	325	294	297		
Kansas	16	12	22	32	52	51	67	63	56	78	97	105	135	161	148	154	209	188	231	264	317	307	336	304		
Kentucky	15	16	36	46	49	78	106	95	113	144	139	161	196	242	243	271	232	349	425	437	491	544	535	588		
Louisiana	18	18	31	57	77	75	131	130	182	196	259	324	331	438	499	428	547	617	714	794	905	950	873	974		
Maine	*	*	*	11	15	17	21	24	25	39	35	30	39	43	52	59	62	75	78	103	97	99	125	124		
Maryland	17	31	36	76	93	113	137	180	157	209	203	300	371	421	472	432	464	578	722	790	829	843	818	892		
Massachusetts	56	50	62	83	99	105	113	122	149	155	172	253	288	344	405	378	503	522	597	598	640	522	632	703		
Michigan	37	66	73	148	182	235	268	309	373	349	460	574	655	729	828	786	981	1,061	1,309	1,308	1,413	1,397	1,479	1,593		
Minnesota	35	25	31	62	82	112	135	129	158	187	174	221	231	260	271	283	340	332	356	387	395	388	414	441		
Mississippi	15	11	22	36	44	50	77	80	92	106	134	153	160	225	260	262	338	364	450	442	498	529	495	536		
Missouri	16	16	17	70	120	102	136	180	174	212	237	271	319	371	421	461	513	588	658	741	797	777	826	804		
Montana	*	*	*	12	*	12	24	22	17	27	33	51	55	62	66	54	66	85	66	68	80	94	81	113		
Nebraska	10	18	16	32	29	35	32	38	47	54	65	82	80	100	114	110	125	164	156	175	173	216	209	241		
Nevada	*	*	*	*	17	15	17	25	37	46	41	61	66	87	80	92	121	163	135	184	206	256	250	277		
New Hampshire	*	*	*	*	11	15	16	21	20	28	34	40	41	45	43	41	54	70	56	76	85	80	99	82		
New Jersey	51	52	87	138	200	240	249	310	355	350	403	470	603	658	660	703	881	1,045	1,087	1,175	1,312	1,350	1,319	1,301		
New Mexico	*	*	10	13	36	55	45	52	73	75	118	113	108	190	192	202	193	248	288	277	283	343	361	350		
New York	95	122	187	278	380	438	514	532	684	711	837	917	1,103	1,206	1,353	1,339	1,656	1,892	2,228	2,365	2,437	2,547	2,684	2,786		
North Carolina	41	56	68	75	127	148	174	234	241	309	313	403	481	580	629	693	848	861	1,038	1,139	1,271	1,197	1,348	1,324		
North Dakota	*	*	*	*	*	16	17	14	22	24	32	51	41	38	61	50	65	52	50	58	67	41	63	84		
Ohio	95	115	140	200	259	276	330	394	433	508	567	623	673	712	902	889	921	1,294	1,485	1,537	1,713	1,854	1,976	1,942		
Oklahoma	25	22	23	39	65	79	87	95	124	135	200	185	245	242	308	307	335	386	382	456	550	541	547	551		
Oregon	*	*	19	28	55	57	51	70	88	100	118	131	144	162	174	188	215	228	238	255	251	301	309	325		
Pennsylvania	99	124	171	187	260	311	429	441	509	549	617	695	880	962	1,054	938	1,285	1,502	1,585	1,659	1,747	1,821	1,916	1,934		
Rhode Island	*	*	*	13	13	15	20	24	21	33	46	44	56	52	67	67	81	84	111	107	117	98	103	114		
South Carolina	15	27	41	51	78	88	124	165	152	188	202	251	287	346	371	364	483	478	593	599	737	725	707	762		
South Dakota	*	*	*	16	10	17	25	29	21	33	41	29	30	52	57	61	63	94	91	91	88	120	110	100		
Tennessee	13	18	31	47	74	94	114	127	134	188	201	280	252	355	423	394	505	597	623	682	704	782	824	798		
Texas	94	111	138	250	394	415	539	622	660	780	953	1,263	1,444	1,566	1,740	1,883	2,140	2,404	2,750	3,014	3,173	3,377	3,677	3,704		
Utah	12	11	31	32	25	38	57	51	63	61	81	61	81	83	111	111	111	143	130	127	157	162	161	205		
Vermont	*	*	*	*	14	*	10	15	11	15	10	23	20	31	18	28	41	50	43	51	48	54	44	43		
Virginia	35	43	58	72	124	168	183	173	222	243	296	335	361	460	516	524	606	657	826	984	994	1,021	997	1,097		
Washington	28	25	42	38	61	70	99	137	118	132	190	227	237	284	318	307	349	382	409	458	463	526	565	557		
West Virginia	*	17	19	21	32	55	56	53	82	76	90	92	108	125	156	138	169	204	239	283	288	322	377	370		
Wisconsin	60	57	61	62	111	105	140	125	163	191	218	266	295	338	378	344	387	442	479	531	553	534	547	583		
Wyoming	*	*	*	*	10	*	14	10	15	15	15	23	12	14	*	25	22	38	31	36	32	42	43	35		
American Samoa	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	17	12
Guam	*	*	*	.	*	*	*	*	*	*	*	*	12	19	25	17	23	34	45	47	45	53	40	57		
Puerto Rico	12	17	38	49	84	101	142	135	164	196	200	269	258	330	415	343	451	444	540	544	626	690	701	719		
Saipan	.	.	.	.	.	.	.	.	.	.	*	*	*	*	*	*	*	10	*	13	17	10	14	*		
Virgin Islands	.	.	.	*	*	*	*	*	*	*	*	*	*	*	*	*	*	18	19	20	20	20	19	22		
Foreign	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	*	
Unknown	*	15	*	12	12	23	10	19	28	26	32	25	44	78	137	202	268	97	*	.	.	.	.	*		
All	1,428	1,658	2,272	3,670	5,079	5,981	7,166	8,310	9,563	10,701	12,048	14,671	16,518	19,242	21,421	21,412	26,052	29,233	33,110	35,567	38,034	40,060	41,924	42,813		

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule. \*Values for cells with fewer than 10 patients are suppressed. . Zero values in this cell.



Table A.16 (continued)

## Incident Counts of Reported ESRD Patients, by Diabetic Status &amp; State/Territory: All Patients

NON-DIABETIC	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	
Alabama	267	315	307	329	339	439	401	434	436	492	608	657	685	734	765	770	813	846	901	933	920	952	982	961	
Alaska	*	*	*	*	10	16	*	11	23	18	23	24	21	37	39	26	134	216	36	37	37	36	49	46	
Arizona	140	173	190	208	215	255	246	293	309	334	363	381	435	445	529	549	584	577	656	648	742	810	795	837	
Arkansas	80	133	128	128	149	187	196	199	210	248	283	277	293	325	353	392	472	453	420	507	463	492	499	518	
California	1,460	1,640	1,656	1,830	1,845	2,173	2,155	2,249	2,532	2,711	3,027	3,148	3,543	3,791	3,854	4,240	4,649	4,611	4,799	4,888	5,388	5,652	5,794	6,158	
Colorado	135	130	140	161	130	128	153	171	188	192	193	247	245	284	307	295	338	299	339	381	404	413	415	429	
Connecticut	134	176	199	180	221	280	236	340	317	346	353	383	417	439	446	463	553	525	552	504	561	563	588	591	
Delaware	35	33	37	47	64	47	51	70	61	76	83	76	95	116	148	132	150	160	140	144	144	151	158	163	
District of Columbia	125	100	108	103	133	134	110	128	101	137	144	209	179	233	218	238	224	286	236	259	266	272	298	285	
Florida	751	921	994	1,015	1,028	1,180	1,271	1,328	1,468	1,670	1,771	2,011	2,065	2,334	2,551	2,607	2,740	2,998	3,152	3,073	3,235	3,383	3,414	3,453	
Georgia	357	447	431	519	478	625	602	591	672	745	874	969	957	1,181	1,257	1,277	1,426	1,392	1,419	1,465	1,541	1,726	1,817	1,876	
Hawaii	65	77	61	65	71	84	98	120	100	103	115	128	133	129	142	142	179	163	149	178	185	216	208	178	
Idaho	26	29	43	33	37	38	49	71	60	58	65	86	91	98	67	82	102	117	126	124	116	136	143	171	
Illinois	665	678	695	789	872	982	994	1,078	1,189	1,248	1,285	1,369	1,632	1,846	1,926	2,232	2,290	2,192	2,235	2,351	2,530	2,564	2,598	2,591	
Indiana	245	275	293	330	364	430	408	445	451	495	583	628	615	663	765	884	815	966	887	935	1,017	1,049	1,105	1,105	
Iowa	108	144	140	140	150	171	159	177	211	212	226	255	305	314	340	331	364	305	348	361	393	480	424	441	
Kansas	82	104	104	106	148	132	143	157	188	197	199	255	271	250	289	262	309	312	336	391	348	379	365	361	
Kentucky	146	159	197	204	220	208	219	276	297	314	354	377	408	469	549	545	523	620	560	584	638	685	685	676	
Louisiana	241	322	295	344	345	406	423	473	499	570	615	668	709	733	829	885	932	999	905	1,040	1,112	1,215	1,172	1,237	
Maine	29	32	30	78	50	58	88	70	80	77	83	78	112	96	103	106	135	155	140	167	166	143	171	168	
Maryland	269	265	280	313	337	348	407	406	419	539	556	648	688	785	815	902	904	1,197	1,159	1,105	1,239	1,291	1,383	1,327	
Massachusetts	302	304	339	251	370	499	457	452	472	504	602	617	634	716	785	860	899	861	917	980	1,002	942	1,070	943	
Michigan	482	541	574	571	616	685	771	744	775	866	965	1,092	1,087	1,139	1,293	1,455	1,534	1,515	1,627	1,623	1,728	1,832	1,862	1,915	
Minnesota	174	198	220	208	207	202	241	285	278	328	339	347	413	453	498	512	620	512	575	616	654	692	701	792	
Mississippi	141	195	190	164	198	287	253	278	289	313	350	382	426	430	484	513	626	548	565	640	631	673	649	693	
Missouri	237	240	306	286	318	378	413	427	487	528	562	586	683	731	745	782	883	858	858	890	1,000	1,065	1,071	1,119	
Montana	34	31	23	50	34	54	50	43	50	51	43	60	61	80	59	88	80	80	84	78	82	106	87	98	
Nebraska	71	67	72	81	72	74	85	105	99	117	129	138	139	158	185	166	207	165	195	234	248	252	286	293	
Nevada	49	53	63	66	61	93	77	103	117	109	124	122	126	159	164	189	242	192	239	226	253	305	295	331	
New Hampshire	39	35	44	62	51	54	55	66	59	75	73	90	89	98	112	108	128	115	106	123	139	150	177	152	
New Jersey	596	618	686	614	707	841	726	880	878	970	979	1,144	1,145	1,296	1,426	1,531	1,616	1,576	1,563	1,720	1,747	1,954	1,844	1,914	
New Mexico	69	79	109	76	98	92	87	121	86	113	139	127	161	157	147	158	174	187	190	212	188	212	219	209	
New York	1,171	1,223	1,232	1,237	1,340	1,518	1,532	1,609	1,737	1,790	1,923	2,172	2,302	2,424	2,711	2,965	3,535	3,205	3,338	3,536	3,733	3,838	3,905	3,846	
North Carolina	390	396	440	408	482	555	531	644	681	707	812	929	929	1,055	1,175	1,252	1,345	1,262	1,390	1,490	1,539	1,603	1,699	1,746	
North Dakota	21	33	20	35	34	25	33	36	48	36	42	54	56	61	65	76	87	65	84	80	72	96	100	109	
Ohio	507	567	570	603	687	778	781	858	908	951	1,130	1,223	1,299	1,415	1,530	1,612	1,640	1,972	1,896	1,870	2,022	2,131	2,281	2,198	
Oklahoma	146	152	172	184	177	184	214	202	227	250	270	311	338	314	345	402	412	400	437	493	486	506	545	518	
Oregon	110	101	105	125	122	164	165	183	219	207	235	267	267	342	306	351	365	350	369	377	416	421	454	488	
Pennsylvania	749	800	756	823	879	999	1,067	1,245	1,263	1,263	1,400	1,568	1,755	1,765	1,912	1,929	2,346	2,150	2,377	2,483	2,467	2,612	2,598	2,498	
Rhode Island	82	71	64	63	60	91	99	100	80	82	87	124	121	151	139	162	181	150	168	162	173	187	226	203	
South Carolina	185	209	227	286	290	334	332	379	411	418	500	557	609	621	674	718	859	760	792	860	858	927	886	918	
South Dakota	29	38	33	42	43	36	37	39	41	56	54	57	59	49	57	67	80	89	102	108	114	100	132	120	
Tennessee	225	297	298	307	340	439	357	429	452	552	547	696	736	805	795	790	961	896	933	1,021	1,074	1,181	1,078	1,035	
Texas	786	901	919	1,016	1,121	1,313	1,164	1,305	1,473	1,582	1,749	1,867	2,141	2,360	2,656	2,571	2,651	2,593	2,760	2,807	3,052	3,331	3,294	3,442	
Utah	37	55	56	70	55	62	89	68	68	84	105	121	98	114	114	154	138	125	135	135	187	194	177	198	
Vermont	20	24	28	22	20	34	27	28	27	32	42	35	46	56	46	46	46	55	66	61	64	64	77	60	
Virginia	360	434	445	445	471	569	552	587	593	686	721	785	838	995	1,069	1,053	1,077	1,313	1,302	1,359	1,341	1,441	1,308	1,398	
Washington	166	179	189	201	226	264	267	260	333	346	336	426	448	465	459	506	592	581	592	594	632	722	772	748	
West Virginia	80	93	98	102	124	136	159	145	150	166	206	185	192	234	228	270	274	301	305	334	367	331	328	358	
Wisconsin	222	222	224	223	279	264	295	317	338	390	491	492	475	529	588	586	684	631	692	696	807	806	850	889	
Wyoming	14	10	14	18	15	17	19	24	15	24	31	24	23	32	33	28	22	26	38	34	43	47	41	53	
American Samoa	.	.	.	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
Guam	*	*	*	*	*	*	*	.	*	*	*	10	15	14	15	17	16	16	17	22	23	20	31	29	
Puerto Rico	136	150	196	191	208	201	236	250	226	231	270	292	310	313	354	397	419	408	410	422	423	431	413	431	
Saipan	.	*	.	.	.	.	.	*	.	.	*	*	*	*	*	*	*	*	*	*	*	*	*	*	.
Virgin Islands	*	*	*	*	11	*	*	12	*	15	11	11	18	13	18	11	18	15	13	24	23	15	13	20	
Foreign	*	14	*	10	*	12	10	16	10	13	24	27	43	37	50	51	52	37	37	34	43	25	38	27	
Unknown	42	69	70	68	95	111	126	145	180	332	781	619	445	409	509	774	3,158	192	46	34	35	53	101	51	
All	13,046	14,568	15,132	15,849	17,029	19,698	19,733	21,476	22,896	24,978	27,889	30,440	32,429	35,299	38,051	40,518	46,609	43,594	44,723	46,461	49,120	51,887	52,678	53,482	

The incident cohorts are determined at the

Table A.17

## Incident Counts of Reported ESRD Patients, by Diabetic Status &amp; State: U.S. Only, with Unknowns Dropped

ALL	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Alabama	288	340	329	368	399	526	500	549	571	670	787	905	886	1,045	1,145	1,129	1,269	1,376	1,487	1,649	1,577	1,712	1,752	1,773
Alaska	*	*	*	*	10	19	14	14	34	25	30	45	31	51	55	50	179	309	68	79	67	72	85	94
Arizona	164	199	230	231	294	368	371	422	492	538	594	680	725	820	1,007	1,024	1,086	1,192	1,280	1,358	1,506	1,622	1,653	1,711
Arkansas	84	141	134	149	175	237	253	265	283	359	381	394	412	508	527	569	695	733	722	821	759	822	845	880
California	1,448	1,646	1,718	2,148	2,394	2,831	2,919	3,225	3,661	3,886	4,300	4,927	5,496	6,024	6,146	6,501	7,524	7,636	8,145	8,705	9,715	10,240	10,628	11,111
Colorado	155	149	158	182	171	190	224	251	311	307	325	416	406	483	519	534	562	548	661	688	769	764	800	801
Connecticut	170	218	223	238	285	372	348	488	451	490	493	556	609	667	681	681	871	845	889	903	923	911	996	948
Delaware	40	40	43	59	79	58	67	93	90	105	128	132	140	179	204	193	221	237	221	226	238	272	280	266
District of Columbia	138	110	118	127	175	168	156	196	157	183	180	274	259	316	324	322	295	394	390	401	405	422	450	434
Florida	765	952	1,075	1,192	1,288	1,457	1,627	1,747	2,022	2,275	2,394	2,756	2,931	3,308	3,676	3,694	4,013	4,301	4,929	4,920	5,140	5,490	5,652	5,789
Georgia	400	495	477	641	627	772	793	810	938	1,075	1,182	1,380	1,431	1,715	1,899	1,888	2,174	2,284	2,477	2,498	2,644	2,923	3,097	3,168
Hawaii	27	44	23	52	100	106	117	173	166	201	207	224	269	268	285	316	395	378	357	411	437	481	504	464
Idaho	28	35	51	43	52	57	67	86	88	93	101	136	140	138	124	136	179	191	212	223	215	249	257	276
Illinois	725	725	809	957	1,094	1,231	1,277	1,480	1,594	1,704	1,775	1,963	2,302	2,689	2,752	3,099	3,424	3,455	3,638	3,747	4,027	4,314	4,258	4,228
Indiana	278	320	335	406	441	559	539	598	608	718	829	867	941	1,022	1,171	1,254	1,159	1,543	1,526	1,587	1,819	1,800	1,883	1,888
Iowa	114	157	164	187	202	239	225	262	315	279	326	381	432	460	527	579	534	604	602	662	804	717	736	736
Kansas	96	116	126	138	200	183	210	219	244	275	296	360	406	411	437	413	515	489	556	633	652	685	698	659
Kentucky	160	174	232	249	269	286	325	371	409	457	492	537	602	707	789	814	752	964	982	1,017	1,127	1,224	1,218	1,255
Louisiana	255	336	322	399	421	480	552	603	673	764	873	992	1,039	1,171	1,328	1,313	1,475	1,609	1,617	1,830	2,008	2,160	2,034	2,198
Maine	33	33	37	89	64	75	109	93	104	115	118	108	151	139	155	165	197	228	218	269	263	242	296	290
Maryland	285	295	314	389	430	461	544	586	575	744	758	946	1,058	1,205	1,285	1,334	1,365	1,755	1,854	1,871	2,041	2,106	2,171	2,187
Massachusetts	356	350	397	334	467	602	570	570	619	656	770	869	921	1,056	1,186	1,230	1,393	1,361	1,469	1,560	1,614	1,427	1,669	1,602
Michigan	515	604	647	717	797	920	1,038	1,052	1,148	1,210	1,424	1,666	1,740	1,866	2,117	2,240	2,497	2,568	2,929	2,908	3,129	3,214	3,321	3,485
Minnesota	206	217	245	268	287	313	376	414	436	514	512	567	644	713	769	791	957	837	925	995	1,040	1,075	1,100	1,214
Mississippi	154	206	211	198	242	335	330	358	379	419	482	534	586	653	744	775	953	912	1,012	1,081	1,129	1,202	1,140	1,225
Missouri	251	253	317	356	438	480	548	606	661	740	798	857	1,000	1,102	1,166	1,243	1,389	1,439	1,511	1,622	1,791	1,839	1,890	1,920
Montana	33	31	28	62	41	62	73	63	66	77	76	111	116	142	125	142	146	162	150	145	162	200	168	209
Nebraska	81	84	87	111	101	109	117	143	146	171	193	220	219	258	299	276	332	324	345	402	418	466	495	533
Nevada	49	53	63	71	74	107	93	128	153	154	164	182	192	245	244	280	358	351	369	399	455	550	524	581
New Hampshire	43	38	50	70	62	69	71	87	78	102	107	129	130	143	155	148	182	184	161	197	222	229	273	233
New Jersey	643	663	772	751	901	1,077	973	1,181	1,227	1,316	1,375	1,604	1,739	1,941	2,069	2,216	2,460	2,575	2,586	2,825	2,967	3,216	3,065	3,102
New Mexico	66	80	108	79	133	144	129	172	158	185	252	240	268	346	332	359	361	430	465	479	458	530	563	542
New York	1,246	1,315	1,391	1,498	1,705	1,932	2,026	2,119	2,401	2,477	2,745	3,081	3,397	3,616	4,041	4,274	5,006	4,873	5,341	5,659	5,909	6,120	6,267	6,337
North Carolina	431	452	508	481	609	702	705	877	922	1,013	1,124	1,332	1,409	1,634	1,803	1,941	2,187	2,114	2,420	2,615	2,785	2,783	3,017	3,032
North Dakota	26	37	24	38	42	40	50	50	70	60	74	105	97	99	126	126	151	117	133	138	139	136	162	193
Ohio	597	676	705	796	946	1,051	1,110	1,250	1,335	1,459	1,694	1,843	1,968	2,125	2,423	2,498	2,554	3,247	3,360	3,381	3,704	3,960	4,224	4,110
Oklahoma	169	169	187	223	241	263	301	296	350	385	470	496	583	556	653	707	743	779	814	936	1,026	1,033	1,070	1,120
Oregon	112	101	121	150	177	220	215	252	306	306	353	398	411	504	479	538	578	574	602	630	664	718	758	810
Pennsylvania	845	921	922	1,006	1,137	1,308	1,495	1,684	1,770	1,808	2,010	2,257	2,621	2,723	2,955	2,864	3,605	3,616	3,926	4,098	4,178	4,383	4,452	4,376
Rhode Island	82	77	73	76	73	106	119	124	100	115	133	167	177	202	206	228	262	230	273	268	288	279	323	309
South Carolina	200	234	268	337	368	422	455	544	563	606	702	808	896	967	1,045	1,082	1,340	1,232	1,381	1,456	1,593	1,646	1,589	1,675
South Dakota	32	39	30	54	52	53	62	68	61	89	94	86	89	101	113	128	143	183	193	199	202	220	241	220
Tennessee	238	313	325	352	412	532	471	556	585	739	748	976	988	1,160	1,218	1,183	1,456	1,484	1,556	1,700	1,776	1,952	1,900	1,828
Texas	874	1,009	1,053	1,262	1,510	1,725	1,701	1,923	2,126	2,357	2,691	3,122	3,570	3,905	4,381	4,438	4,754	4,812	5,277	5,641	6,096	6,604	6,744	6,992
Utah	47	62	85	100	79	99	146	118	131	145	185	182	179	197	197	262	249	263	262	258	337	355	333	395
Vermont	22	28	34	29	34	38	37	43	38	47	52	58	66	87	64	74	87	104	109	112	112	118	120	103
Virginia	393	476	503	515	593	736	735	759	815	928	1,013	1,120	1,194	1,454	1,584	1,572	1,678	1,944	2,105	2,314	2,309	2,438	2,271	2,451
Washington	189	201	225	237	286	333	366	387	448	476	523	653	685	748	774	809	937	942	995	1,047	1,086	1,241	1,332	1,297
West Virginia	89	110	117	123	156	191	215	198	231	242	296	277	300	359	384	408	443	504	542	617	654	651	702	727
Wisconsin	278	273	284	284	388	367	434	440	500	581	708	757	770	865	965	928	1,070	1,069	1,168	1,225	1,354	1,339	1,383	1,463
Wyoming	19	12	15	21	25	22	26	38	25	39	46	47	35	46	41	52	44	64	68	69	75	89	79	87
All	13,944	15,617	16,722	18,850	21,546	25,033	26,224	29,031	31,634	34,679	38,383	43,723	47,656	53,139	57,694	59,768	67,244	70,295	75,280	79,414	84,666	89,328	91,449	93,327

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule. U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.

Table A.17 (continued)

## Incident Counts of Reported ESRD Patients, by Diabetic Status &amp; State: U.S. Only, with Unknowns Dropped

DIABETIC	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Alabama	24	28	25	39	61	87	102	116	137	180	179	249	201	311	385	365	459	531	586	716	661	764	772	816
Alaska	*	.	*	.	*	*	*	*	11	*	*	21	10	14	16	24	55	105	32	44	30	36	36	48
Arizona	30	31	43	41	83	117	128	134	190	210	238	303	290	377	478	479	506	623	633	718	780	830	876	901
Arkansas	*	*	*	22	26	51	57	66	73	111	99	117	119	183	174	178	223	280	303	318	298	334	356	363
California	78	114	167	417	578	701	796	1,008	1,162	1,200	1,346	1,801	1,992	2,288	2,342	2,365	2,971	3,210	3,530	4,024	4,444	4,730	5,039	5,121
Colorado	22	20	22	27	41	64	71	81	123	117	134	170	161	200	213	242	226	252	324	310	370	351	389	378
Connecticut	39	44	26	58	64	92	112	149	134	144	140	174	193	229	235	220	320	326	342	407	370	368	420	369
Delaware	*	*	*	12	15	11	17	24	29	29	46	56	45	63	57	62	72	77	81	83	96	122	124	105
District of Columbia	13	10	10	24	43	34	47	69	57	49	44	66	81	84	110	86	72	116	160	147	144	153	162	156
Florida	23	42	92	187	260	283	358	419	555	607	624	748	867	978	1,127	1,089	1,284	1,333	1,809	1,871	1,934	2,152	2,269	2,370
Georgia	44	48	47	122	150	149	191	219	266	330	309	411	474	534	645	612	754	901	1,071	1,038	1,115	1,220	1,308	1,322
Hawaii	*	*	*	15	32	34	26	58	73	101	95	102	137	140	146	177	220	219	216	241	256	268	303	291
Idaho	*	*	*	10	16	20	18	15	28	36	36	50	49	40	59	54	77	74	87	99	99	113	114	105
Illinois	89	70	135	188	253	293	327	439	455	492	493	595	672	845	829	876	1,161	1,295	1,420	1,419	1,525	1,762	1,707	1,678
Indiana	36	50	43	79	77	130	131	153	157	224	246	243	326	360	410	373	348	588	646	655	805	757	782	789
Iowa	*	13	25	48	53	68	66	85	105	68	100	126	127	146	187	196	217	231	257	244	271	325	293	297
Kansas	16	12	22	32	52	51	67	62	56	78	97	105	135	161	148	153	208	181	222	252	311	307	334	303
Kentucky	15	16	36	46	49	78	106	95	113	143	139	161	196	241	243	271	231	349	425	435	490	543	535	585
Louisiana	18	18	31	57	77	75	131	130	182	196	259	324	331	438	499	428	546	615	713	793	902	950	871	969
Maine	*	*	*	11	15	17	21	24	25	39	35	30	39	43	52	59	62	74	78	103	97	99	125	124
Maryland	17	31	35	76	93	113	137	180	157	207	203	300	371	421	472	432	463	571	718	784	821	833	807	882
Massachusetts	56	49	61	83	98	104	113	120	148	154	172	253	288	344	405	378	501	511	578	587	630	508	619	684
Michigan	36	65	73	147	182	235	268	309	373	348	459	574	655	729	827	786	978	1,057	1,306	1,300	1,412	1,391	1,471	1,584
Minnesota	34	24	29	62	82	112	135	129	158	186	174	221	231	260	271	282	339	330	355	385	395	385	406	434
Mississippi	15	11	22	36	44	50	77	80	92	106	134	153	160	225	260	262	335	364	450	442	498	529	495	535
Missouri	16	16	16	70	120	102	136	180	174	212	237	271	319	371	421	461	511	586	656	738	795	776	823	803
Montana	*	*	*	12	*	12	24	22	17	27	33	51	55	62	66	54	66	84	66	67	80	94	81	111
Nebraska	10	18	16	31	29	35	32	38	47	54	65	82	80	100	114	110	125	161	151	170	170	215	209	240
Nevada	*	*	*	17	15	17	15	25	37	46	41	61	66	87	80	92	120	161	133	178	205	252	244	265
New Hampshire	*	*	*	*	11	15	16	21	19	28	34	40	41	45	43	41	54	69	56	76	85	80	98	82
New Jersey	51	52	87	138	199	240	249	308	353	348	403	470	602	656	655	701	876	1,028	1,055	1,144	1,266	1,302	1,278	1,245
New Mexico	*	*	10	12	36	55	45	52	72	74	116	113	107	190	186	202	189	246	286	273	277	328	354	340
New York	93	118	186	274	378	438	512	530	683	708	833	917	1,102	1,205	1,349	1,332	1,616	1,790	2,131	2,245	2,328	2,421	2,532	2,654
North Carolina	41	56	68	75	127	147	174	234	241	308	312	403	481	580	629	693	848	860	1,034	1,136	1,265	1,193	1,339	1,315
North Dakota	*	*	*	*	*	15	17	14	22	24	32	51	41	38	61	50	64	52	49	58	67	40	63	84
Ohio	94	112	139	198	259	276	330	394	433	508	566	623	673	712	900	889	920	1,288	1,476	1,521	1,701	1,841	1,964	1,931
Oklahoma	23	19	22	39	65	79	87	95	124	135	200	185	245	242	308	306	334	383	380	447	540	535	537	544
Oregon	*	*	19	28	55	57	51	70	88	99	118	131	144	162	174	187	214	228	238	253	251	300	308	325
Pennsylvania	98	124	170	187	259	311	429	441	509	549	615	695	879	962	1,053	937	1,283	1,490	1,569	1,643	1,728	1,798	1,886	1,908
Rhode Island	*	*	*	13	13	15	20	24	21	33	46	44	56	52	67	67	81	82	108	107	116	95	100	111
South Carolina	15	26	41	51	78	88	124	165	152	188	202	251	287	346	371	364	483	477	593	599	737	724	707	760
South Dakota	*	*	.	15	10	17	25	29	21	33	41	29	30	52	56	61	63	94	91	91	88	120	110	100
Tennessee	13	18	31	47	74	94	114	127	133	187	201	280	252	355	423	394	503	595	623	681	703	779	824	795
Texas	94	110	138	250	393	415	539	621	658	780	951	1,261	1,443	1,564	1,739	1,877	2,127	2,304	2,622	2,924	3,104	3,314	3,565	3,630
Utah	12	*	30	31	25	38	57	51	63	61	81	61	81	83	83	111	111	141	129	125	155	162	160	201
Vermont	*	*	*	*	14	*	10	15	11	15	10	23	20	31	18	28	41	49	43	51	48	54	44	43
Virginia	35	43	58	72	123	168	183	173	222	243	296	335	361	460	516	524	606	655	822	974	990	1,018	986	1,079
Washington	27	24	41	37	61	70	99	136	118	131	190	227	237	283	318	306	349	374	406	454	461	525	563	555
West Virginia	*	17	19	21	32	55	56	53	82	76	90	92	108	125	156	138	169	204	239	283	288	322	375	370
Wisconsin	59	54	60	62	110	105	140	125	163	191	218	266	295	338	378	344	387	439	477	530	549	534	544	578
Wyoming	*	*	*	*	10	*	*	14	10	15	15	23	12	14	*	25	22	38	30	35	32	42	42	34
All	1,355	1,577	2,162	3,536	4,960	5,843	7,000	8,124	9,332	10,436	11,755	14,338	16,167	18,769	20,763	20,743	24,790	28,091	31,805	34,218	36,783	38,694	40,349	41,312

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.

\*Values for cells with fewer than 10 patients are suppressed. "." Zero values in this cell.

Table A.17 (continued)

## Incident Counts of Reported ESRD Patients, by Diabetic Status &amp; State: U.S. Only with Unknowns Dropped

NON-DIABETIC	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Alabama	264	312	304	329	338	439	398	433	434	490	608	656	685	734	760	764	810	845	901	933	916	948	980	957
Alaska	*	*	*	*	*	16	*	11	23	17	22	24	21	37	39	26	124	204	36	35	37	36	49	46
Arizona	134	168	187	190	211	251	243	288	302	328	356	377	435	443	529	545	580	569	647	640	726	792	777	810
Arkansas	79	133	128	127	149	186	196	199	210	248	282	277	293	325	353	391	472	453	419	503	461	488	489	517
California	1,370	1,532	1,551	1,731	1,816	2,130	2,123	2,217	2,499	2,686	2,954	3,126	3,504	3,736	3,804	4,136	4,553	4,426	4,615	4,681	5,271	5,510	5,589	5,990
Colorado	133	129	136	155	130	126	153	170	188	190	191	246	245	283	306	292	336	296	337	378	399	413	411	423
Connecticut	131	174	197	180	221	280	236	339	317	346	353	382	416	438	446	461	551	519	547	496	553	543	576	579
Delaware	35	33	37	47	64	47	50	69	61	76	82	76	95	116	147	131	149	160	140	143	142	150	156	161
District of Columbia	125	100	108	103	132	134	109	127	100	134	136	208	178	232	214	236	223	278	230	254	261	269	288	278
Florida	742	910	983	1,005	1,028	1,174	1,269	1,328	1,467	1,668	1,770	2,008	2,064	2,330	2,549	2,605	2,729	2,968	3,120	3,049	3,206	3,338	3,383	3,419
Georgia	356	447	430	519	477	623	602	591	672	745	873	969	957	1,181	1,254	1,276	1,420	1,383	1,406	1,460	1,529	1,703	1,789	1,846
Hawaii	24	41	19	37	68	72	91	115	93	100	112	122	132	128	139	139	175	159	141	170	181	213	201	173
Idaho	26	27	43	33	36	37	49	71	60	57	65	86	91	98	65	82	102	117	125	124	116	136	143	171
Illinois	636	655	674	769	841	938	950	1,041	1,139	1,212	1,282	1,368	1,630	1,844	1,923	2,223	2,263	2,160	2,218	2,328	2,502	2,552	2,551	2,550
Indiana	242	270	292	327	364	429	408	445	451	494	583	624	615	662	761	881	811	955	880	932	1,014	1,043	1,101	1,099
Iowa	108	144	139	139	149	171	159	177	210	211	226	255	305	314	340	331	362	303	347	358	391	479	424	439
Kansas	80	104	104	106	148	132	143	157	188	197	199	255	271	250	289	260	307	308	334	381	341	378	364	356
Kentucky	145	158	196	203	220	208	219	276	296	314	353	376	406	466	546	543	521	615	557	582	637	681	683	670
Louisiana	237	318	291	342	344	405	421	473	491	568	614	668	708	733	829	885	929	994	904	1,037	1,106	1,210	1,163	1,229
Maine	29	32	30	78	49	58	88	69	79	76	83	78	112	96	103	106	135	154	140	166	166	143	171	166
Maryland	268	264	279	313	337	348	407	406	418	537	555	646	687	784	813	902	1,184	1,136	1,087	1,220	1,273	1,364	1,305	1,305
Massachusetts	300	301	336	251	369	498	457	450	471	502	598	616	633	712	781	852	892	850	891	973	984	919	1,050	918
Michigan	479	539	574	570	615	685	770	743	775	862	965	1,092	1,085	1,137	1,290	1,454	1,519	1,511	1,623	1,608	1,717	1,823	1,850	1,901
Minnesota	172	193	216	206	205	201	241	285	278	328	338	346	413	453	498	509	618	507	570	610	645	690	694	780
Mississippi	139	195	189	162	198	285	253	278	287	313	348	381	426	428	484	513	618	548	562	639	631	673	645	690
Missouri	235	237	301	286	318	378	412	426	487	528	561	586	681	731	745	782	878	853	855	884	996	1,063	1,067	1,117
Montana	32	29	23	50	34	50	49	41	49	50	43	60	61	80	59	88	80	78	84	78	82	106	87	98
Nebraska	71	66	71	80	72	74	85	105	99	117	128	138	139	158	185	166	207	163	194	232	248	251	286	293
Nevada	48	50	60	62	57	92	76	103	116	108	123	121	126	158	164	188	238	190	236	221	250	298	280	316
New Hampshire	39	35	44	62	51	54	55	66	59	74	73	89	89	98	112	107	128	115	105	121	137	149	175	151
New Jersey	592	611	685	613	702	837	724	873	874	968	972	1,134	1,137	1,285	1,414	1,515	1,584	1,547	1,531	1,681	1,701	1,914	1,787	1,857
New Mexico	62	74	98	67	97	89	84	120	86	111	136	127	161	156	146	157	172	184	179	206	181	202	209	202
New York	1,153	1,197	1,205	1,224	1,327	1,494	1,514	1,589	1,718	1,769	1,912	2,164	2,295	2,411	2,692	2,942	3,390	3,083	3,210	3,414	3,581	3,699	3,735	3,683
North Carolina	390	396	440	406	482	555	531	643	681	705	812	929	928	1,054	1,174	1,248	1,339	1,254	1,386	1,479	1,520	1,590	1,678	1,717
North Dakota	21	32	20	34	34	25	33	36	48	36	42	54	56	61	65	76	87	65	84	80	72	96	99	109
Ohio	503	564	566	598	687	775	780	856	902	951	1,128	1,220	1,295	1,413	1,523	1,609	1,634	1,959	1,884	1,860	2,003	2,119	2,260	2,179
Oklahoma	146	150	165	184	176	184	214	201	226	250	270	311	338	314	345	401	409	396	434	489	486	498	533	576
Oregon	109	97	102	122	122	163	164	182	218	207	235	267	267	342	305	351	364	346	364	377	413	418	450	485
Pennsylvania	747	797	752	819	878	997	1,066	1,243	1,261	1,259	1,395	1,562	1,742	1,761	1,902	1,927	2,322	2,126	2,357	2,455	2,450	2,585	2,566	2,468
Rhode Island	81	71	64	63	60	91	99	100	79	82	87	123	121	150	139	161	181	148	165	161	172	184	223	198
South Carolina	185	208	227	286	290	334	331	379	411	418	500	557	609	621	674	718	857	755	788	857	856	922	882	915
South Dakota	25	36	30	39	42	36	37	39	40	56	53	57	59	49	57	67	80	89	102	108	114	100	131	120
Tennessee	225	295	294	305	338	438	357	429	452	552	547	696	736	805	795	789	953	889	933	1,019	1,073	1,173	1,076	1,033
Texas	780	899	915	1,012	1,117	1,310	1,162	1,302	1,468	1,577	1,740	1,861	2,127	2,341	2,642	2,561	2,627	2,508	2,655	2,717	2,992	3,290	3,179	3,362
Utah	35	53	55	69	54	61	89	67	68	84	104	121	98	114	114	151	138	122	133	133	182	193	173	194
Vermont	19	24	28	22	20	34	27	28	27	32	42	35	46	56	46	46	55	66	61	64	64	64	76	60
Virginia	358	433	445	443	470	568	552	586	593	685	717	785	833	994	1,068	1,048	1,072	1,289	1,283	1,340	1,319	1,420	1,285	1,372
Washington	162	177	184	200	225	263	267	251	330	345	333	426	448	465	456	503	588	568	589	593	625	716	769	742
West Virginia	80	93	98	102	124	136	159	145	149	166	206	185	192	234	228	270	274	300	303	334	366	329	327	357
Wisconsin	219	219	224	222	278	262	294	315	337	390	490	491	475	527	587	584	683	630	691	695	805	805	839	885
Wyoming	14	10	14	15	15	17	19	24	15	24	31	24	23	32	32	27	22	26	38	34	43	47	37	53
All	12,589	14,040	14,560	15,314	16,586	19,190	19,224	20,907	22,302	24,243	26,628	29,385	31,489	34,370	36,931	39,025	42,454	42,204	43,475	45,196	47,883	50,634	51,100	52,015

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.  
U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.  
\*Values for cells with fewer than 10 patients are suppressed.

Table A.18  
**Incident Rates of Reported ESRD, by Diabetic Status & State, Adjusted**  
*per million population*

<b>ALL</b>	<b>1990</b>	<b>1991</b>	<b>1992</b>	<b>1993</b>	<b>1994</b>	<b>1995</b>	<b>1996</b>	<b>1997</b>	<b>1998</b>	<b>1999</b>	<b>2000</b>	<b>2001</b>
Alabama	173	204	224	211	250	260	286	300	297	303	313	304
Alaska	113	198	182	198	656	1,098	227	294	198	170	233	208
Arizona	214	251	290	280	278	292	313	319	342	346	344	360
Arkansas	163	202	211	220	261	292	274	313	279	305	299	312
California	229	246	244	251	288	288	300	315	344	346	357	367
Colorado	160	192	198	193	204	198	222	232	248	237	250	233
Connecticut	199	228	233	223	293	277	291	287	296	288	315	291
Delaware	214	262	302	252	285	302	277	277	285	314	320	307
District of Columbia	164	179	219	198	152	239	230	202	220	248	312	222
Florida	205	225	245	243	252	266	307	284	293	303	307	308
Georgia	188	225	244	236	267	345	377	282	296	324	335	333
Hawaii	178	167	173	223	216	183	180	198	157	217	187	177
Idaho	257	192	272	384	333	201	305	337	211	249	212	346
Illinois	205	237	258	267	292	290	304	309	329	350	344	338
Indiana	197	208	236	258	235	302	304	300	344	338	348	344
Iowa	229	241	263	254	310	263	342	261	315	344	321	295
Kansas	214	206	209	209	251	242	275	295	307	312	308	303
Kentucky	186	220	258	245	224	299	290	292	321	343	338	333
Louisiana	216	245	265	259	284	300	292	333	355	400	371	393
Maine	143	200	409	209	391	562	343	269	290	210	299	212
Maryland	195	218	228	228	229	284	295	300	319	339	330	337
Massachusetts	183	203	236	231	272	269	280	285	298	252	289	274
Michigan	195	204	228	239	272	269	301	297	317	320	328	340
Minnesota	220	231	237	272	326	288	288	288	299	313	298	344
Mississippi	169	196	211	220	263	266	273	291	293	329	303	325
Missouri	207	219	235	258	279	284	306	310	338	345	351	354
Montana	334	302	118	137	295	376	129	159	274	341	143	298
Nebraska	172	218	220	253	288	235	280	279	315	352	343	402
Nevada	197	229	211	238	297	271	248	258	283	334	303	324
New Hampshire	169	218	232	177	231	219	199	168	267	198	235	263
New Jersey	224	245	259	272	300	310	307	330	341	366	345	346
New Mexico	210	234	220	205	236	273	270	289	241	290	296	292
New York	182	193	212	222	257	249	272	288	296	304	307	307
North Carolina	178	207	219	232	257	288	320	296	303	295	320	318
North Dakota	119	127	179	1,233	466	609	162	310	165	161	279	261
Ohio	193	205	232	234	232	299	308	307	330	352	367	356
Oklahoma	194	182	205	240	231	243	247	285	301	301	300	308
Oregon	173	248	204	247	262	245	253	216	305	280	271	319
Pennsylvania	227	230	248	238	303	301	317	327	331	348	349	339
Rhode Island	233	227	234	257	323	286	342	313	321	315	356	335
South Carolina	204	219	241	235	289	382	452	296	304	314	298	311
South Dakota	358	459	366	125	157	212	234	347	341	198	263	385
Tennessee	198	236	244	223	274	276	284	302	313	333	325	307
Texas	247	269	292	289	304	299	321	334	365	373	371	377
Utah	149	176	179	257	228	248	271	201	275	263	253	261
Vermont	214	633	229	357	137	459	327	417	355	212	212	314
Virginia	184	220	235	230	238	272	290	312	307	319	295	310
Washington	189	202	219	218	236	228	241	244	245	263	294	265
West Virginia	191	238	238	268	296	335	339	355	371	371	387	400
Wisconsin	206	227	256	255	267	273	290	291	322	319	328	345
Wyoming	125	314	135	187	138	179	238	208	197	266	194	270
All	203	223	238	243	270	278	293	303	318	330	332	334

Rates are adjusted by age, race, & gender.

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.

Table A.18 (continued)

**Incident Rates of Reported ESRD, by Diabetic Status & State, Adjusted***per million population*

<b>DIABETIC</b>	<b>1990</b>	<b>1991</b>	<b>1992</b>	<b>1993</b>	<b>1994</b>	<b>1995</b>	<b>1996</b>	<b>1997</b>	<b>1998</b>	<b>1999</b>	<b>2000</b>	<b>2001</b>
Alabama	35	57	75	66	89	98	112	128	115	129	135	133
Alaska	37	41	49	115	237	307	103	191	102	67	109	102
Arizona	66	104	130	120	120	144	141	162	161	165	169	177
Arkansas	47	72	73	71	85	113	113	117	110	126	126	128
California	83	93	93	92	114	121	131	147	158	160	170	170
Colorado	61	78	79	82	80	91	112	98	118	108	118	107
Connecticut	65	80	84	72	112	109	115	134	121	119	135	115
Delaware	68	87	83	81	94	97	103	102	114	140	140	125
District of Columbia	34	37	65	33	25	70	93	68	57	74	91	77
Florida	64	69	79	75	83	85	115	110	114	120	124	127
Georgia	64	74	83	77	93	134	162	117	122	134	139	138
Hawaii	97	39	53	69	110	88	94	86	84	97	87	96
Idaho	44	35	54	213	66	60	130	155	97	81	88	174
Illinois	60	74	76	74	99	108	119	117	124	144	139	135
Indiana	66	71	83	79	71	113	127	124	152	143	143	142
Iowa	68	79	79	103	121	127	156	128	157	149	139	130
Kansas	71	86	71	80	105	93	108	123	147	143	154	146
Kentucky	66	75	85	84	69	109	123	125	139	155	148	152
Louisiana	71	85	96	87	99	114	125	138	156	175	150	167
Maine	28	115	193	41	111	161	125	95	157	65	187	81
Maryland	65	74	83	74	78	93	113	124	127	136	123	135
Massachusetts	59	67	82	71	102	105	110	110	126	95	108	121
Michigan	71	79	88	84	104	110	135	133	143	138	145	155
Minnesota	82	82	83	105	106	113	115	122	119	117	121	132
Mississippi	52	70	76	69	94	111	118	120	132	145	133	139
Missouri	67	75	89	90	103	118	131	142	151	147	155	146
Montana	250	164	57	49	89	186	50	50	105	237	59	98
Nebraska	56	91	89	109	108	130	118	124	136	174	152	188
Nevada	66	73	64	74	92	124	81	113	127	147	140	142
New Hampshire	60	41	55	72	66	101	59	62	133	60	90	104
New Jersey	78	82	81	85	107	124	125	134	145	148	143	139
New Mexico	77	109	101	100	105	134	152	153	127	170	163	166
New York	59	64	70	68	83	92	108	114	117	120	123	128
North Carolina	62	70	75	80	97	115	131	126	132	124	137	133
North Dakota	45	49	77	681	302	384	56	204	75	42	160	122
Ohio	66	67	85	84	82	115	133	138	150	161	169	167
Oklahoma	70	75	87	92	93	108	109	121	146	143	137	136
Oregon	61	76	75	89	104	100	110	91	101	120	106	146
Pennsylvania	72	80	88	76	106	125	126	129	136	141	145	148
Rhode Island	88	56	83	71	110	106	145	123	136	113	125	136
South Carolina	64	82	81	79	108	138	176	116	139	139	127	133
South Dakota	21	328	269	53	51	98	77	126	162	93	75	241
Tennessee	50	75	88	75	97	110	113	121	121	135	140	135
Texas	101	108	116	122	135	144	160	173	186	187	196	195
Utah	53	72	75	132	89	147	121	111	168	133	124	132
Vermont	32	157	154	254	64	159	132	154	83	83	99	62
Virginia	52	66	76	75	85	91	111	130	130	130	128	135
Washington	74	85	101	93	84	97	100	111	105	113	128	119
West Virginia	71	87	92	87	104	140	150	155	161	195	200	201
Wisconsin	79	88	91	91	92	111	123	131	134	136	133	145
Wyoming	77	29	999	46	73	71	55	127	83	94	72	128
All	69	79	86	84	99	111	124	131	138	143	147	148

Rates are adjusted by age, race, &amp; gender.

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.

Table A.18 (continued)  
**Incident Rates of Reported ESRD, by Diabetic Status & State, Adjusted**  
*per million population*

<b>NON-DIABETIC</b>	<b>1990</b>	<b>1991</b>	<b>1992</b>	<b>1993</b>	<b>1994</b>	<b>1995</b>	<b>1996</b>	<b>1997</b>	<b>1998</b>	<b>1999</b>	<b>2000</b>	<b>2001</b>
Alabama	138	147	149	145	161	163	174	172	182	174	178	171
Alaska	76	157	133	83	420	791	124	103	96	103	124	106
Arizona	148	147	160	160	158	148	172	158	181	181	175	182
Arkansas	116	130	139	149	176	179	161	195	169	178	173	184
California	146	152	151	160	174	166	169	168	186	186	187	198
Colorado	98	114	119	112	124	107	110	134	130	129	132	127
Connecticut	135	148	150	150	181	168	176	153	175	169	180	176
Delaware	146	175	220	170	191	205	174	175	171	174	180	182
District of Columbia	130	142	154	166	127	169	137	133	163	174	221	145
Florida	141	157	166	169	169	181	191	173	179	183	183	180
Georgia	124	151	161	160	174	210	215	165	174	190	196	195
Hawaii	82	128	120	154	106	95	86	112	73	120	100	81
Idaho	212	157	219	171	267	141	175	183	114	169	124	173
Illinois	144	163	182	192	193	182	185	192	204	207	205	204
Indiana	131	137	153	179	164	190	177	176	192	195	205	202
Iowa	160	161	183	151	189	136	186	133	158	195	182	164
Kansas	143	120	138	129	146	149	167	172	160	169	155	157
Kentucky	120	144	172	161	155	190	167	168	182	187	189	181
Louisiana	145	161	169	173	185	187	167	195	199	225	222	226
Maine	115	85	215	168	280	401	218	174	132	145	111	130
Maryland	129	144	145	154	150	190	182	177	192	203	207	202
Massachusetts	124	136	154	160	170	164	169	175	172	157	181	154
Michigan	124	125	140	156	168	159	166	164	174	182	183	185
Minnesota	138	149	154	168	220	175	172	167	181	196	177	212
Mississippi	117	126	135	152	168	155	155	170	161	184	170	186
Missouri	140	144	146	167	176	166	175	168	187	198	197	207
Montana	84	138	62	87	206	189	79	109	168	103	85	200
Nebraska	116	127	131	144	180	105	163	155	178	178	191	214
Nevada	130	156	147	164	205	147	167	146	156	187	162	182
New Hampshire	110	177	177	106	166	118	140	106	134	139	145	159
New Jersey	146	163	178	186	192	186	182	196	196	219	201	208
New Mexico	133	125	120	105	131	139	118	136	113	120	133	126
New York	123	129	142	153	174	157	165	173	179	184	184	179
North Carolina	116	137	144	152	160	174	189	170	171	171	183	186
North Dakota	74	78	102	552	165	225	105	106	89	120	119	138
Ohio	127	138	147	150	149	184	175	169	179	191	198	189
Oklahoma	123	107	117	147	138	135	138	164	155	158	163	173
Oregon	111	172	129	159	158	146	143	125	203	160	165	173
Pennsylvania	155	149	160	162	197	176	192	197	195	207	204	191
Rhode Island	144	171	151	186	213	180	196	191	185	203	231	199
South Carolina	140	137	160	156	181	244	277	180	165	175	171	178
South Dakota	337	131	97	72	105	114	157	221	179	106	187	144
Tennessee	149	161	156	148	177	165	171	182	192	198	185	172
Texas	146	162	176	167	168	155	161	161	180	186	175	182
Utah	95	103	104	125	138	101	149	90	107	130	129	130
Vermont	182	477	76	102	73	301	195	263	271	129	113	252
Virginia	131	155	159	155	153	181	179	182	177	188	167	175
Washington	116	116	118	125	152	131	141	133	139	150	166	146
West Virginia	120	151	146	181	193	195	189	201	209	176	187	199
Wisconsin	127	139	166	163	175	162	167	160	188	184	195	200
Wyoming	48	285	120	141	65	108	183	81	113	172	123	142
All	134.5	145	153	159	170	167	169	172	180	187	186	186

Rates are adjusted by age, race, & gender.

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.



Table A.19  
Incident Counts of Reported ESRD Patients, by Diabetic Status & ESRD Network: All Patients

ALL	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	
1 CT, MA, ME, NH, RI, VT	716	753	822	844	997	1,275	1,262	1,416	1,407	1,540	1,713	1,913	2,069	2,323	2,483	2,596	3,132	3,012	3,185	3,352	3,470	3,246	3,727	3,556	
2 NY	1,270	1,355	1,431	1,521	1,737	1,970	2,063	2,157	2,435	2,519	2,801	3,115	3,425	3,658	4,099	4,331	5,930	5,178	5,565	5,894	6,154	6,353	6,590	6,617	
3 NJ, PR, VI	802	846	1,017	1,001	1,217	1,396	1,366	1,599	1,649	1,780	1,884	2,197	2,363	2,660	2,948	3,118	3,633	3,530	3,624	3,900	4,143	4,441	4,291	4,395	
4 DE, PA	890	973	972	1,077	1,223	1,381	1,569	1,787	1,869	1,922	2,159	2,399	2,785	2,907	3,182	3,048	4,130	3,786	4,192	4,374	4,447	4,681	4,770	4,686	
5 MD, DC, VA, WV	910	996	1,056	1,160	1,362	1,562	1,656	1,745	1,784	2,119	2,289	2,632	2,821	3,343	3,582	3,628	3,845	4,655	4,949	5,260	5,475	5,643	5,640	5,862	
6 NC, SC, GA	1,033	1,185	1,256	1,466	1,609	1,903	1,957	2,234	2,430	2,702	3,018	3,532	3,747	4,323	4,759	4,919	5,958	5,682	6,311	6,590	7,064	7,386	7,753	7,953	
7 FL	775	967	1,089	1,208	1,289	1,464	1,632	1,750	2,028	2,282	2,411	2,771	2,936	3,318	3,681	3,704	4,041	4,341	4,993	4,968	5,195	5,571	5,709	5,855	
8 AL, MS, TN	688	867	880	925	1,060	1,404	1,313	1,467	1,546	1,832	2,015	2,418	2,461	2,870	3,133	3,117	3,982	3,809	4,056	4,434	4,480	4,865	4,789	4,834	
9 IN, KY, OH	1,052	1,187	1,285	1,467	1,659	1,904	1,979	2,231	2,364	2,647	3,036	3,263	3,502	3,864	4,404	4,555	4,496	5,817	5,889	6,007	6,676	7,003	7,345	7,274	
10 IL	759	755	836	984	1,131	1,284	1,332	1,531	1,671	1,766	1,815	2,008	2,331	2,731	2,804	3,179	3,798	3,557	3,677	3,792	4,072	4,306	4,315	4,287	
11 MI, MN, ND, SD, WI	1,075	1,203	1,249	1,383	1,579	1,708	1,973	2,040	2,234	2,479	2,847	3,199	3,348	3,657	4,106	4,244	5,205	4,851	5,371	5,495	5,893	5,954	6,212	6,617	
12 IA, KS, MO, NE	551	618	704	797	945	1,019	1,103	1,237	1,376	1,473	1,621	1,817	2,065	2,230	2,427	2,461	3,005	2,832	3,040	3,304	3,550	3,791	3,797	3,868	
13 AR, LA, OK	517	657	657	776	842	984	1,109	1,169	1,319	1,518	1,729	1,890	2,040	2,238	2,512	2,589	3,008	3,153	3,156	3,606	3,818	4,033	3,981	4,226	
14 TX	883	1,018	1,061	1,267	1,518	1,731	1,706	1,935	2,140	2,385	2,721	3,167	3,593	3,937	4,424	4,549	4,819	5,037	5,504	5,815	6,219	6,686	6,964	7,134	
15 AZ, CO, NV, NM, UT, WY	527	584	691	731	797	958	1,004	1,156	1,300	1,406	1,595	1,763	1,821	2,167	2,398	2,606	2,801	2,916	3,150	3,313	3,656	3,977	4,021	4,227	
16 AK, ID, MT, OR, WA	375	389	449	508	573	700	738	818	949	992	1,091	1,343	1,382	1,587	1,556	1,667	1,953	1,966	2,041	2,138	2,200	2,479	2,586	2,691	
17 N. CA, HI, Guam, AS	615	799	848	874	977	1,189	1,238	1,370	1,535	1,676	2,026	2,163	2,460	2,638	2,737	2,938	3,411	3,395	3,538	3,799	4,088	4,367	4,529	4,545	
18 S. CA	1,030	1,067	1,086	1,520	1,573	1,827	1,857	2,099	2,385	2,496	2,726	3,161	3,505	3,891	4,037	4,348	5,343	5,188	5,477	5,860	6,371	6,684	7,051	7,370	
Unknown	*	*	15	10	20	20	42	45	38	145	440	360	293	199	200	333	171	122	115	127	183	481	532	298	
All	14,474	16,226	17,404	19,519	22,108	25,679	26,899	29,786	32,459	35,679	39,937	45,111	48,947	54,541	59,472	61,930	72,661	72,827	77,833	82,028	87,154	91,947	94,602	96,295	
DIABETIC	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	
1 CT, MA, ME, NH, RI, VT	108	109	116	181	217	252	293	355	360	414	439	564	637	744	822	797	1,077	1,136	1,233	1,353	1,366	1,229	1,439	1,449	
2 NY	95	123	187	280	381	441	515	535	685	713	838	918	1,105	1,213	1,359	1,344	1,705	1,906	2,229	2,365	2,437	2,548	2,684	2,786	
3 NJ, PR, VI	64	69	125	188	285	343	395	446	523	550	606	743	862	996	1,081	1,054	1,369	1,518	1,645	1,739	1,958	2,060	2,040	2,042	
4 DE, PA	104	134	178	200	277	325	445	466	538	578	663	753	926	1,024	1,114	999	1,360	1,530	1,668	1,745	1,844	1,944	2,040	2,040	
5 MD, DC, VA, WV	74	101	124	193	293	372	424	476	518	578	634	793	921	1,093	1,257	1,180	1,309	1,559	1,949	2,206	2,259	2,341	2,359	2,518	
6 NC, SC, GA	100	131	156	250	356	387	490	618	663	830	825	1,066	1,243	1,461	1,651	1,676	2,122	2,256	2,707	2,780	3,132	3,150	3,379	3,424	
7 FL	23	42	95	188	260	283	360	421	558	607	626	748	868	980	1,127	1,090	1,284	1,343	1,832	1,890	1,954	2,188	2,301	2,405	
8 AL, MS, TN	53	58	78	123	179	232	295	323	364	475	516	683	614	891	1,071	1,020	1,334	1,504	1,660	1,841	1,863	2,076	2,093	2,151	
9 IN, KY, OH	149	183	219	328	385	487	568	644	704	879	953	1,031	1,197	1,318	1,559	1,540	1,517	2,247	2,561	2,634	3,014	3,164	3,305	3,325	
10 IL	92	71	135	189	255	294	328	439	457	496	497	598	675	848	835	887	1,189	1,339	1,451	1,450	1,560	1,771	1,733	1,707	
11 MI, MN, ND, SD, WI	144	161	172	295	395	485	586	608	739	784	926	1,141	1,253	1,419	1,596	1,531	1,876	2,001	2,291	2,375	2,517	2,481	2,613	2,802	
12 IA, KS, MO, NE	48	59	80	182	254	256	301	368	386	412	500	584	662	778	871	956	1,097	1,177	1,305	1,429	1,561	1,625	1,665	1,648	
13 AR, LA, OK	48	50	60	119	169	205	276	291	379	446	561	627	696	863	984	915	1,132	1,294	1,399	1,569	1,756	1,829	1,778	1,892	
14 TX	94	111	137	250	395	415	539	626	660	784	955	1,264	1,445	1,566	1,750	1,924	2,150	2,419	2,752	3,016	3,175	3,378	3,680	3,705	
15 AZ, CO, NV, NM, UT, WY	82	80	118	130	213	298	326	362	500	530	634	731	728	969	1,081	1,189	1,252	1,497	1,555	1,675	1,844	2,009	2,106	2,179	
16 AK, ID, MT, OR, WA	35	39	77	88	142	162	197	247	262	303	385	482	499	567	636	620	742	810	833	926	922	1,074	1,107	1,148	
17 N. CA, HI, Guam, AS	39	46	76	180	223	250	278	411	446	545	625	797	918	976	1,061	1,143	1,426	1,508	1,644	1,819	1,925	2,017	2,173	2,140	
18 S. CA	76	91	137	306	400	494	548	673	819	775	863	1,145	1,268	1,534	1,564	1,575	2,109	2,189	2,396	2,755	2,947	3,176	3,429	3,452	
Unknown	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
All	1,428	1,658	2,272	3,670	5,079	5,981	7,166	8,310	9,563	10,701	12,048	14,671	16,518	19,242	21,421	21,412	26,052	29,233	33,110	35,567	38,034	40,606	41,924	42,813	
NON-DIABETIC	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	
1 CT, MA, ME, NH, RI, VT	608	644	706	663	780	1,023	969	1,061	1,047	1,126	1,274	1,349	1,432	1,579	1,661	1,799	2,055	1,876	1,952	1,999	2,104	2,017	2,288	2,107	
2 NY	1,175	1,232	1,244	1,241	1,356	1,529	1,548	1,622	1,750	1,806	1,963	2,197	2,320	2,445	2,740	2,987	4,225	3,272	3,336	3,529	3,717	3,805	3,906	3,831	
3 NJ, PR, VI	738	777	892	813	932	1,053	971	1,153	1,126	1,230	1,278	1,454	1,501	1,664	1,867	2,064	2,264	2,012	1,979	2,161	2,185	2,381	2,251	2,353	
4 DE, PA	786	839	794	877	946	1,056	1,124	1,321	1,331	1,344	1,496	1,646	1,859	1,883	2,068	2,049	2,770	2,256	2,524	2,629	2,603	2,737	2,730	2,646	
5 MD, DC, VA, WV	836	895	932	967	1,069	1,190	1,232	1,269	1,266	1,541	1,655	1,839	1,900	2,250	2,325	2,448	2,536	3,096	3,000	3,054	3,216	3,302	3,281	3,344	
6 NC, SC, GA	933	1,054	1,100	1,216	1,253	1,516	1,467	1,616	1,767	1,872	2,193	2,466	2,504	2,862	3,108	3,243	3,836	3,426	3,604	3,810	3,932	4,236	4,374	4,529	
7 FL	752	925	994	1,020	1,029	1,181	1,272	1,329	1,470	1,675	1,785	2,023	2,068	2,338	2,554	2,614	2,757	2,998	3,161	3,078	3,241	3,383	3,408	3,450	
8 AL, MS, TN	635	809	802	802	881	1,172	1,018	1,144	1,182	1,357	1,499	1,735	1,847	1,979	2,062	2,097	2,648	2,305	2,396	2,593	2,617	2,789	2,696		



Table A.20

## Incident Counts of Reported ESRD Patients, by Diabetic Status &amp; ESRD Network; U.S. Only, with Unknowns Dropped

	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
<b>ALL</b>																								
1 CT, MA, ME, NH, RI, VT	706	744	814	836	985	1,262	1,254	1,405	1,390	1,525	1,668	1,880	2,044	2,285	2,443	2,510	2,990	2,962	3,116	3,304	3,418	3,173	3,650	3,472
2 NY	1,246	1,315	1,391	1,498	1,705	1,931	2,025	2,119	2,401	2,477	2,742	3,071	3,385	3,605	4,040	4,242	5,092	4,921	5,333	5,648	5,889	6,083	6,226	6,316
3 NJ	643	663	772	751	901	1,077	973	1,181	1,226	1,314	1,373	1,597	1,738	1,941	2,059	2,202	2,463	2,591	2,578	2,822	2,959	3,199	3,048	3,090
4 DE, PA	885	961	965	1,065	1,216	1,366	1,561	1,777	1,860	1,910	2,127	2,382	2,753	2,895	3,148	3,033	3,797	3,740	4,150	4,320	4,408	4,628	4,703	4,627
5 MD, DC, VA, WV	905	991	1,052	1,154	1,354	1,556	1,650	1,739	1,778	2,096	2,244	2,597	2,800	3,324	3,556	3,615	3,761	4,593	4,884	5,198	5,407	5,580	5,561	5,777
6 NC, SC, GA	1,031	1,181	1,254	1,459	1,604	1,896	1,954	2,231	2,423	2,691	3,001	3,518	3,727	4,308	4,740	4,897	5,690	5,639	6,281	6,564	7,016	7,332	7,675	7,864
7 FL	765	953	1,075	1,192	1,288	1,457	1,627	1,747	2,021	2,275	2,391	2,753	2,926	3,303	3,672	3,687	3,983	4,291	4,929	4,918	5,137	5,483	5,642	5,781
8 AL, MS, TN	680	859	865	918	1,053	1,393	1,302	1,463	1,535	1,824	2,008	2,407	2,453	2,854	3,102	3,081	3,684	3,780	4,052	4,426	4,474	4,849	4,779	4,820
9 IN, KY, OH	1,035	1,170	1,272	1,452	1,656	1,893	1,974	2,219	2,351	2,626	3,004	3,233	3,487	3,840	4,375	4,531	4,458	5,761	5,847	5,969	6,633	6,956	7,294	7,221
10 IL	725	725	809	957	1,094	1,232	1,277	1,480	1,594	1,701	1,772	1,962	2,298	2,681	2,746	3,089	3,468	3,474	3,628	3,736	4,007	4,283	4,241	4,214
11 MI, MN, ND, SD, WI	1,056	1,170	1,230	1,360	1,566	1,693	1,960	2,024	2,215	2,454	2,804	3,173	3,327	3,635	4,076	4,197	4,838	4,808	5,351	5,459	5,862	5,929	6,163	6,565
12 IA, KS, MO, NE	542	610	694	792	941	1,012	1,100	1,230	1,366	1,465	1,610	1,810	2,052	2,223	2,419	2,448	2,810	2,796	3,015	3,258	3,522	3,772	3,785	3,838
13 AR, LA, OK	508	646	643	771	837	980	1,106	1,164	1,306	1,507	1,719	1,880	2,030	2,232	2,504	2,579	2,922	3,130	3,147	3,583	3,792	4,005	3,934	4,195
14 TX	874	1,009	1,053	1,262	1,510	1,724	1,699	1,923	2,126	2,355	2,684	3,113	3,561	3,902	4,372	4,429	4,674	4,839	5,268	5,629	6,086	6,577	6,724	6,976
15 AZ, CO, NV, NM, UT, WY	500	555	659	684	776	931	989	1,128	1,271	1,367	1,556	1,739	1,797	2,126	2,336	2,499	2,679	2,870	3,100	3,250	3,594	3,897	3,927	4,112
16 AK, ID, MT, OR, WA	367	376	435	499	566	691	735	802	942	975	1,080	1,338	1,376	1,583	1,544	1,658	1,911	1,929	2,025	2,124	2,188	2,465	2,574	2,678
17 N. CA, HI	504	691	730	757	941	1,122	1,196	1,324	1,473	1,635	1,902	2,064	2,359	2,514	2,569	2,726	3,108	3,176	3,288	3,562	3,899	4,166	4,291	4,294
18 S. CA	972	997	1,007	1,442	1,552	1,813	1,835	2,072	2,355	2,447	2,592	3,064	3,387	3,746	3,840	4,066	4,830	4,901	5,192	5,534	6,230	6,509	6,773	7,228
All	13,944	15,616	16,720	18,849	21,545	25,029	26,217	29,028	31,633	34,644	38,277	43,581	47,500	52,997	57,541	59,489	67,158	70,201	75,184	79,304	84,521	88,886	90,990	93,068
<b>DIABETIC</b>																								
1 CT, MA, ME, NH, RI, VT	107	107	115	180	215	247	292	353	358	413	437	564	637	743	820	793	1,058	1,114	1,205	1,331	1,346	1,204	1,406	1,413
2 NY	93	118	186	274	378	438	512	530	683	708	833	917	1,102	1,205	1,351	1,333	1,631	1,792	2,131	2,245	2,328	2,421	2,532	2,654
3 NJ	51	52	87	138	199	240	249	308	353	348	403	469	602	657	655	702	877	1,037	1,054	1,144	1,266	1,302	1,279	1,245
4 DE, PA	103	131	176	199	274	322	445	465	538	578	661	753	924	1,024	1,111	998	1,342	1,517	1,650	1,726	1,824	1,920	2,009	2,013
5 MD, DC, VA, WV	74	101	122	193	291	370	423	475	518	575	633	792	921	1,090	1,253	1,180	1,306	1,549	1,939	2,188	2,243	2,326	2,331	2,487
6 NC, SC, GA	100	130	156	248	355	384	490	618	659	826	823	1,065	1,241	1,460	1,645	1,671	2,089	2,241	2,699	2,773	3,117	3,137	3,354	3,397
7 FL	23	42	92	187	260	283	358	419	555	607	624	748	867	978	1,127	1,089	1,276	1,331	1,809	1,870	1,934	2,152	2,270	2,370
8 AL, MS, TN	52	57	78	122	179	231	294	323	362	473	514	682	613	891	1,068	1,020	1,301	1,494	1,659	1,839	1,862	2,073	2,091	2,146
9 IN, KY, OH	145	178	218	323	385	484	568	642	702	875	951	1,028	1,195	1,314	1,551	1,535	1,511	2,231	2,544	2,612	2,996	3,141	3,281	3,305
10 IL	89	70	135	188	253	293	327	439	455	492	493	595	673	845	828	878	1,174	1,310	1,422	1,418	1,525	1,761	1,707	1,676
11 MI, MN, ND, SD, WI	141	151	166	290	392	484	585	606	737	782	924	1,141	1,252	1,417	1,592	1,523	1,836	1,987	2,284	2,364	2,512	2,471	2,594	2,781
12 IA, KS, MO, NE	48	59	79	181	254	256	301	365	383	412	499	584	661	778	870	920	1,057	1,159	1,287	1,404	1,547	1,623	1,659	1,644
13 AR, LA, OK	46	45	59	118	168	205	275	291	379	442	558	626	695	863	981	912	1,106	1,284	1,396	1,558	1,740	1,819	1,764	1,876
14 TX	94	110	137	250	393	415	539	621	658	780	951	1,262	1,443	1,563	1,740	1,878	2,103	2,316	2,622	2,925	3,105	3,314	3,565	3,630
15 AZ, CO, NV, NM, UT, WY	74	71	109	126	212	294	325	357	495	523	625	729	717	951	1,050	1,152	1,185	1,474	1,533	1,639	1,819	1,967	2,067	2,122
16 AK, ID, MT, OR, WA	34	38	75	87	142	162	197	246	262	301	385	480	495	563	633	618	727	796	830	917	920	1,068	1,103	1,144
17 N. CA, HI	16	32	53	148	215	243	277	398	425	537	603	776	887	928	995	1,056	1,296	1,391	1,494	1,675	1,812	1,897	2,043	2,006
18 S. CA	65	85	118	284	395	492	542	668	810	764	837	1,127	1,242	1,498	1,492	1,484	1,915	2,068	2,247	2,590	2,887	3,098	3,294	3,403
All	1,355	1,577	2,161	3,536	4,960	5,843	6,999	8,124	9,332	10,436	11,754	14,338	16,167	18,768	20,762	20,742	24,790	28,091	31,805	34,218	36,783	38,694	40,349	41,312
<b>NON-DIABETIC</b>																								
1 CT, MA, ME, NH, RI, VT	599	637	699	656	770	1,015	962	1,052	1,032	1,112	1,231	1,316	1,407	1,542	1,623	1,717	1,932	1,848	1,911	1,973	2,072	1,969	2,244	2,059
2 NY	1,153	1,197	1,205	1,224	1,327	1,493	1,513	1,589	1,718	1,769	1,909	2,154	2,283	2,400	2,689	2,909	3,461	3,129	3,202	3,403	3,561	3,662	3,694	3,662
3 NJ	592	611	685	613	702	837	724	873	966	970	1,128	1,136	1,284	1,404	1,500	1,586	1,554	1,524	1,678	1,693	1,897	1,769	1,845	1,845
4 DE, PA	782	830	789	866	942	1,044	1,116	1,312	1,322	1,332	1,466	1,629	1,829	1,871	2,037	2,035	2,455	2,223	2,500	2,594	2,584	2,708	2,694	2,614
5 MD, DC, VA, WV	831	890	930	961	1,063	1,186	1,227	1,264	1,260	1,521	1,611	1,805	1,879	2,234	2,303	2,435	2,455	3,044	2,945	3,010	3,164	3,254	3,230	3,290
6 NC, SC, GA	931	1,051	1,098	1,211	1,249	1,512	1,464	1,613	1,764	1,865	2,178	2,453	2,486	2,848	3,095	3,226	3,601	3,398	3,582	3,791	3,899	4,195	4,321	4,467
7 FL	742	911	983	1,005	1,028	1,174	1,269	1,328	1,466	1,668	1,767	2,005	2,059	2,325	2,545	2,598	2,707	2,960	3,120	3,048	3,203	3,331	3,372	3,411
8 AL, MS, TN	628	802	787	796	874	1,162	1,008	1,140	1,173	1,351	1,494	1,725	1,840	1,963	2,034	2,061	2,383	2,286	2,393	2,587	2,612	2,776	2,688	2,674
9 IN, KY, OH	890	992	1,054	1,129	1,271	1,409	1,406	1,577	1,649	1,751	2,053	2,292	2,526	2,824	2,996	2,947	3,530	3,303	3,357	3,637	3,815	4,013	3,916	3,916
10 IL	636	655	674	769	841	939	950	1,041	1,139	1,209	1,279	1,367	1,625	1										

Table A.21

**Incident Rates of Reported ESRD, by Diabetic Status & ESRD Network, Adjusted***per million population*

<b>ALL</b>	<b>1990</b>	<b>1991</b>	<b>1992</b>	<b>1993</b>	<b>1994</b>	<b>1995</b>	<b>1996</b>	<b>1997</b>	<b>1998</b>	<b>1999</b>	<b>2000</b>	<b>2001</b>
1 CT, MA, ME, NH, RI, VT	188	210	227	222	277	273	280	284	295	266	300	282
2 NY	181	193	212	220	261	252	272	287	295	302	304	306
3 NJ	224	245	257	270	300	312	307	330	340	364	343	345
4 DE, PA	226	231	250	237	298	287	316	324	329	344	345	337
5 MD, DC, VA, WV	186	218	231	229	235	281	296	313	321	331	323	332
6 NC, SC, GA	185	215	230	232	264	306	336	289	300	308	318	322
7 FL	205	225	245	243	250	266	306	283	293	303	306	307
8 AL, MS, TN	182	215	229	216	261	266	281	297	301	319	315	309
9 IN, KY, OH	191	207	237	240	230	300	303	301	330	345	355	348
10 IL	204	236	257	266	295	292	303	308	327	348	342	337
11 MI, MN, ND, SD, WI	196	209	233	239	277	270	290	292	312	311	320	337
12 IA, KS, MO, NE	205	218	232	241	273	264	292	295	324	337	333	335
13 AR, LA, OK	195	213	231	237	261	279	271	312	320	340	329	346
14 TX	247	269	292	288	298	300	321	333	365	371	370	376
15 AZ, CO, NV, NM, UT, WY	186	219	230	234	250	257	260	268	286	300	294	302
16 AK, ID, MT, OR, WA	181	214	206	223	238	227	242	239	253	259	277	276
17 N. CA, HI	225	237	233	242	265	264	270	291	307	304	321	318
18 S. CA	231	249	249	256	303	305	316	328	364	367	375	394
All	203	223	238	242	269	278	293	303	318	328	331	333
<b>DIABETIC</b>	<b>1990</b>	<b>1991</b>	<b>1992</b>	<b>1993</b>	<b>1994</b>	<b>1995</b>	<b>1996</b>	<b>1997</b>	<b>1998</b>	<b>1999</b>	<b>2000</b>	<b>2001</b>
1 CT, MA, ME, NH, RI, VT	62	71	79	70	103	105	112	119	124	106	119	119
2 NY	59	64	70	69	84	92	108	114	117	120	123	128
3 NJ	78	82	81	85	107	125	125	134	145	148	143	139
4 DE, PA	72	81	88	76	104	116	125	128	136	141	146	147
5 MD, DC, VA, WV	59	69	81	74	82	95	116	131	132	138	137	142
6 NC, SC, GA	63	74	79	78	97	118	140	120	129	130	136	136
7 FL	64	69	79	75	83	85	115	110	114	120	124	127
8 AL, MS, TN	45	68	81	71	93	105	114	123	121	136	137	136
9 IN, KY, OH	65	70	84	83	77	113	130	132	148	154	158	158
10 IL	60	74	76	75	100	110	119	117	124	144	139	134
11 MI, MN, ND, SD, WI	72	80	89	86	101	109	124	127	134	131	134	143
12 IA, KS, MO, NE	66	78	87	90	103	113	125	131	145	147	150	145
13 AR, LA, OK	67	79	88	83	95	110	117	130	142	152	141	150
14 TX	101	107	116	122	134	145	160	173	186	187	196	195
15 AZ, CO, NV, NM, UT, WY	67	89	96	98	101	126	120	128	137	144	146	147
16 AK, ID, MT, OR, WA	70	80	90	91	87	98	101	110	105	112	119	124
17 N. CA, HI	84	84	88	91	106	111	117	134	140	132	146	143
18 S. CA	85	100	96	93	121	130	139	156	169	176	184	187
All	69	79	86	84	99	111	124	131	138	143	147	148
<b>NON-DIABETIC</b>	<b>1990</b>	<b>1991</b>	<b>1992</b>	<b>1993</b>	<b>1994</b>	<b>1995</b>	<b>1996</b>	<b>1997</b>	<b>1998</b>	<b>1999</b>	<b>2000</b>	<b>2001</b>
1 CT, MA, ME, NH, RI, VT	126	139	148	152	174	168	168	165	171	160	182	163
2 NY	122	129	142	151	177	159	164	173	178	182	182	178
3 NJ	146	163	176	184	193	187	181	196	195	216	199	206
4 DE, PA	154	150	162	161	195	171	191	196	193	203	200	190
5 MD, DC, VA, WV	127	149	150	155	153	186	180	183	189	193	186	189
6 NC, SC, GA	122	141	151	154	167	188	196	169	171	178	183	187
7 FL	141	156	166	168	167	180	191	173	179	183	182	180
8 AL, MS, TN	137	146	148	145	168	161	167	174	180	183	178	172
9 IN, KY, OH	126	138	153	157	152	186	173	169	182	190	197	190
10 IL	144	162	181	191	195	182	184	191	203	204	204	203
11 MI, MN, ND, SD, WI	124	129	143	154	176	160	166	166	178	180	186	194
12 IA, KS, MO, NE	139	139	145	151	170	151	167	164	179	189	183	190
13 AR, LA, OK	128	134	143	154	166	169	154	182	178	188	189	196
14 TX	146	162	176	166	165	156	160	160	179	185	174	181
15 AZ, CO, NV, NM, UT, WY	119	131	134	136	149	131	141	140	149	156	149	155
16 AK, ID, MT, OR, WA	111	134	116	132	151	129	140	129	149	147	158	152
17 N. CA, HI	141	153	144	150	159	153	153	158	167	172	175	175
18 S. CA	146	150	153	163	182	175	177	173	195	191	191	207
All	134	144	152	158	170	166	168	172	179	185	184	185

Rates are adjusted by age, race, &amp; gender.

The incident cohorts are determined at the time of ESRD initiation without applying the 60-day stable modality rule.

U.S. only; patients of unknown age or gender, or of other or unknown race, are excluded so that rates can be calculated properly.